<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Biomed</journal-id><journal-id journal-id-type="iso-abbrev">Mol Biomed</journal-id><journal-id journal-id-type="pmc-domain-id">4128</journal-id><journal-id journal-id-type="pmc-domain">molbio</journal-id><journal-title-group><journal-title>Molecular Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2662-8651</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11554974</article-id><article-id pub-id-type="pmcid-ver">PMC11554974.1</article-id><article-id pub-id-type="pmcaid">11554974</article-id><article-id pub-id-type="pmcaiid">11554974</article-id><article-id pub-id-type="pmid">39527305</article-id><article-id pub-id-type="doi">10.1186/s43556-024-00222-x</article-id><article-id pub-id-type="publisher-id">222</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Prophylactic and therapeutic vaccine development: advancements and challenges</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0007-6996-8270</contrib-id><name name-style="western"><surname>Weerarathna</surname><given-names initials="IN">Induni Nayodhara</given-names></name><address><email>induni.weerarathna@dmiher.edu.in</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doelakeh</surname><given-names initials="ES">Elijah Skarlus</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kiwanuka</surname><given-names initials="L">Lydia</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kumar</surname><given-names initials="P">Praveen</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arora</surname><given-names initials="S">Sanvi</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k949197</institution-id><institution-id institution-id-type="GRID">grid.449504.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1766 2457</institution-id><institution>Department of Biomedical Sciences, School of Allied Health Sciences, </institution><institution>Datta Meghe Institute of Higher Education and Research (Deemed to Be University), </institution></institution-wrap>Wardha, Maharashtra 442001 India </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k949197</institution-id><institution-id institution-id-type="GRID">grid.449504.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1766 2457</institution-id><institution>Department of Anesthesia, </institution><institution>School of Allied Health Sciences, Datta Meghe Institute of Higher Education and Research (Deemed to Be University), </institution></institution-wrap>Wardha, Maharashtra 442001 India </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k949197</institution-id><institution-id institution-id-type="GRID">grid.449504.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1766 2457</institution-id><institution>Department of Medical Radiology and Imaging Technology, School of Allied Health Sciences, </institution><institution>Datta Meghe Institute of Higher Education and Research (Deemed to Be University), </institution></institution-wrap>Wardha, Maharashtra 442001 India </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02k949197</institution-id><institution-id institution-id-type="GRID">grid.449504.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1766 2457</institution-id><institution>Department of Computer Science and Medical Engineering, FEAT, </institution><institution>Datta Meghe Institute of Higher Education and Research (Deemed to Be University), </institution></institution-wrap>Wardha, Maharashtra 442001 India </aff><aff id="Aff5"><label>5</label>Faculty of Medicine, Jawaharlal Medical College, Datta Meghe Institute of Higher Education and Research (Deemed to Be University), Wardha, Maharashtra 442001 India </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>5</volume><issue-id pub-id-type="pmc-issue-id">451984</issue-id><elocation-id>57</elocation-id><history><date date-type="received"><day>16</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>24</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>12</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-15 12:25:16.527"><day>15</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="43556_2024_Article_222.pdf"/><abstract id="Abs1"><p id="Par1">Biomedical research is fundamental in developing preventive and therapeutic vaccines, serving as a cornerstone of global public health. This review explores the key concepts, methodologies, tools, and challenges in the vaccine development landscape, focusing on transitioning from basic biomedical sciences to clinical applications. Foundational disciplines such as virology, immunology, and molecular biology lay the groundwork for vaccine creation, while recent innovations like messenger RNA (mRNA) technology and reverse vaccinology have transformed the field. Additionally, it highlights the role of pharmaceutical advancements in translating lab discoveries into clinical solutions. Techniques like CRISPR-Cas9, genome sequencing, monoclonal antibodies, and computational modeling have significantly enhanced vaccine precision and efficacy, expediting the development of vaccines against infectious diseases. The review also discusses challenges that continue to hinder progress, including stringent regulatory pathways, vaccine hesitancy, and the rapid emergence of new pathogens. These obstacles underscore the need for interdisciplinary collaboration and the adoption of innovative strategies. Integrating personalized medicine, nanotechnology, and artificial intelligence is expected to revolutionize vaccine science further. By embracing these advancements, biomedical research has the potential to overcome existing challenges and usher in a new era of therapeutic and prophylactic vaccines, ultimately improving global health outcomes. This review emphasizes the critical role of vaccines in combating current and future health threats, advocating for continued investment in biomedical science and technology.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Prophylactic</kwd><kwd>Therapeutic</kwd><kwd>Vaccines</kwd><kwd>Vaccine development</kwd><kwd>Biomedical technologies</kwd><kwd>Advancements</kwd><kwd>Challenges</kwd><kwd>Ethical considerations</kwd></kwd-group><funding-group><award-group><funding-source><institution>Datta Meghe Institute of Higher Education and Research</institution></funding-source></award-group><open-access><p>Open access funding provided by Datta Meghe Institute of Higher Education and Research.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Sichuan International Medical Exchange &amp; Promotion Association 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par42">Biomedical science encompasses fields such as biology, chemistry, physics, and engineering. It enhances our understanding of diseases, formulates remedies, and prevents pandemics [<xref ref-type="bibr" rid="CR1">1</xref>]. A pandemic is an epidemic affecting large areas, multiple countries, or the entire world, causing more havoc than smaller, seasonal outbreaks. They tend to cause more havoc than smaller seasonal outbreaks or epidemics [<xref ref-type="bibr" rid="CR2">2</xref>]. There is a strong association between using biomedical science to interpret the pandemics. Biomedical science is critical in interpreting pandemics by studying pathogens and their effects and developing diagnostic tools. For example, during the COVID-19 pandemic, biomedical scientists researched virus transmission, provided health guidelines, and developed surveillance techniques to curb the outbreak. This underscores the importance of integrating biomedical science into medical education. It also helps study the pandemic, the pathogen, and its effects [<xref ref-type="bibr" rid="CR3">3</xref>]. One of the new budding applications in biomedical science to put a stop to the pandemic is diagnostic tool development. A recent case can be seen with the example of COVID-19 [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Biomedical scientists have put their time into researching the transmission of the viruses. This gives valuable knowledge to develop health-related guidelines for the public to curb the virus's transmission and halt the outbreak. Researchers have also focused on looking into ways to detect the transmission of the virus. This involves various surveillance techniques that again help stop the outbreak before it gets widespread [<xref ref-type="bibr" rid="CR6">6</xref>]. The rapid development of COVID-19 vaccines, particularly the mRNA-based vaccines, highlights the potential to apply similar strategies to other serious diseases. However, market uncertainty and lack of awareness can complicate the vaccine development. Understanding vaccination, introducing non-active disease-causing organisms, and the historical advancements in vaccine development are crucial for future progress [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par43">The vaccine development process for COVID-19 showed the speed of development and has led us to focus on similar strategies for other serious diseases [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref>]. The path to vaccine development can be simple or highly complex. However, the factors that may complicate the entire process are market uncertainty or lack of awareness of the path for vaccine development [<xref ref-type="bibr" rid="CR11">11</xref>]. As to what vaccination is, it is the provision of a non-active disease-causing organism to the living body. Vaccination, especially the one with the traditional development process, did not garner much attention in comparison with the vaccines developed by newer mRNA-based technology [<xref ref-type="bibr" rid="CR10">10</xref>]. Vaccination helps in the induction of the antibodies and the T cell response. This helps keep the person safe against a variety of disease-causing organisms. These vaccines can be prophylactic or therapeutic. Prophylactic vaccines are preventive, while therapeutic vaccines are used post-infection [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par44">Experience and observation to practice 'variolation' were used by people in the twelfth and fifteenth centuries [<xref ref-type="bibr" rid="CR13">13</xref>], and the practice of variolation was the first known form of immunization of humans. Fluid or powdered scabs from the blisters of a smallpox patient were transferred into the recipient's skin via minor scratches on the surface. This technique was employed in diverse formats across China, the Middle East, and Africa before it was eventually transmitted to Europe in the seventeenth century. Edward Jenner inaugurated the seminal scientific investigation in 1796, using smallpox scabs and viruses from cowpox instead of mystery materials and performing human experiments based on Enlightenment principles. The vaccination process also got its name from Jenner; this marks the dawn of vaccinology [<xref ref-type="bibr" rid="CR14">14</xref>]. Creating a vaccine usually involves a decade to fifteen years of research conducted predominantly within commercial entities' laboratories, often necessitating collaborations with university-based researchers.</p><p id="Par45">The concept of vaccination came up in Europe in the eighteenth and nineteenth centuries, and significant advancements were made in the twentieth century due to developments in molecular biology and biotechnology [<xref ref-type="bibr" rid="CR5">5</xref>]. Computational technology has also added to the development of vaccines. Programs and algorithms (Vaxign, Bowman-Heinson, VacSol, NERVE) are built around bacterial and prokaryotic systems that aid the process [<xref ref-type="bibr" rid="CR15">15</xref>]. The ultimate aim is to target diseases like the Human Immunodeficiency Virus, Ebola, Zika virus, severe acute respiratory syndrome, dengue, chikungunya, and all cancer types: hepatitis and tuberculosis. However, on the downside, this has thrown light on the need for growth in the vaccine development market in the past 40&#160;years [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par46">This review highlights the development of prophylactic and therapeutic vaccine processes with advancements and challenges. This article aims to provide a comprehensive overview of the latest advancements and challenges in developing prophylactic and therapeutic vaccines. It explores innovative vaccine technologies, such as mRNA and viral vectors, while addressing critical scientific, regulatory, and societal challenges. The article also highlights the ethical considerations and public perception issues that impact vaccine development and deployment, emphasizing the critical role of vaccines in modern medicine and public health.</p></sec><sec id="Sec2"><title>Fundamental concepts of prophylactic and therapeutic vaccine</title><p id="Par47">Immunity is the body's ability to protect itself and withstand against damaging foreign bodies. It can be innate immunity or acquired immunity. The underlying principles of preventive and therapeutic vaccinations stem from the body's immune response, which can be classified into innate immunity and adaptive immunity. Innate immunity is the body's first shield against foreign constituents. It has a similar response to germs and foreign bodies. It is also called as "non-specific" immunity [<xref ref-type="bibr" rid="CR17">17</xref>]. It is not because of a vaccine or an infection. This can be via physical barriers or internal defenses, namely skin, hair, cilia, mucus membranes, stomach acid, digestive enzymes in the mouth, and so on [<xref ref-type="bibr" rid="CR18">18</xref>]. In the case of vaccinations, this initial reaction is crucial because it aids in stimulating the immune system as a whole, laying the groundwork for the longer-lasting and more focused adaptive immune response. For vaccines to effectively mount a defense against infections or diseases, they must activate the immune system during this early stage, both preventive and therapeutic [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par48">The adaptive immune system is the system that provides a specific type of immunity and is based on memory. Typical features include specificity, heterogeneity, and memory [<xref ref-type="bibr" rid="CR20">20</xref>]. The success of vaccinations is primarily dependent on the adaptive immune system, which provides long-term protection and is very specialized. The two primary components of a focused immune response that the body mounts in response to a pathogen or vaccine antigen are B cells, which generate antibodies, and T cells, which either directly attack diseased or infected cells or work together to coordinate the immune response. T cells are made in the bone marrow and use chemical messengers to activate other immune system cells. B cells are made in bone marrow but are activated by T cells. They turn into memory cells and help with the memory component of adaptive immunity [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par49">Establishing immunological memory is a critical component of adaptive immunity, enabling the immune system to react to disease more quickly and efficiently the next time. This idea is essential to the goal of preventive vaccinations, designed to create memory B and T cells that remain in the body to create long-lasting protection. This is a function of specificity and longevity [<xref ref-type="bibr" rid="CR21">21</xref>]. The Greeks first recorded this, and it has now become a vaccine. The memory is maintained by long-lived antigen-specific lymphocytes brought in by the first exposure and continues until a second interaction with the pathogen. This memory can be measured as adoptive transfer assays of lymphocytes. The entire process comprises an initial response by a primary antibody and then a secondary antibody, which comes in later. The production of IgM, IgG, IgA, and IgE marks the secondary antibody response. A secondary immune response will come into play upon a second interaction with the same antigen [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par50">These memory cells can quickly create a defense to stop the sickness from spreading when they come into contact with the same infection again. Though they frequently aim to elicit a more rapid and robust immune response, mainly when the disease is already established, like in chronic infections or cancer, therapeutic vaccines also use immunological memory. Depending on the vaccination's intended use, the ultimate objective in each scenario is to teach the immune system how to react to particular antigens more successfully, either for preventive or therapeutic purposes. A thorough understanding of the molecular mechanisms behind immune activation and the biological mechanisms of infections is crucial for creating preventive and therapeutic vaccines. The development of vaccines depends on figuring out the distinct features of pathogens, like viruses or bacteria, that can be attacked to trigger a potent and successful immune response. Scholars in virology, pathogen biology, and molecular biology can identify particular antigens that elicit the immune system to identify, combat, and retain the infection. This knowledge helps develop therapeutic vaccinations that strengthen the immune system's capacity to combat pre-existing illnesses, including cancer and chronic infections, and vaccines that prevent infection [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par51">Virology refers to the study of viruses and infections caused by them. They can infect all life forms (bacteria, plants, protozoa, fungi, insects, fish, reptiles, birds, and mammals). They are small, subcellular agents that cannot multiply out of a host cell. Thus, they are intracellular and obligate parasites. They can either have a viral Deoxyribonucleic Acid (DNA) or Ribonucleic Acid (RNA) and cause a variety of diseases like HIV (Human Immunodeficiency Virus), ebola, herpes, chicken pox and so on [<xref ref-type="bibr" rid="CR23">23</xref>]. Pathogens, unlike general thinking, are not limited to hostility. It lives at the expense of the host [<xref ref-type="bibr" rid="CR24">24</xref>]. In scientific terms, it is defined as an organism causing disease to its host, with the severity of the disease symptoms referred to as virulence [<xref ref-type="bibr" rid="CR25">25</xref>]. They can be facultative or obligate. Obligate pathogens need a host to complete their life cycle; this can be one host or multiple. Facultative pathogens are mainly environmental bacteria or fungi, requiring a host only as a niche. Furthermore, knowing a pathogen's virulence, or the degree of the disease it causes, aids in developing vaccinations that either weaken the pathogen or expose the immune system to a safe form of its antigen [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par52">Molecular biology is an essential field in vaccine development that studies the interactions between proteins, RNA, and DNA [<xref ref-type="bibr" rid="CR27">27</xref>].&#160;Nucleic acids are simpler than proteins since they comprise only four main types of bases joined via a chain of sugars and phosphates. The sequence of these bases in the DNA of any organism forms its genetic information. This sequence makes all of the proteins an organism can produce, all of the chemical reactions it can carry out, and all of the behavior the organism can showcase as an answer to its environment [<xref ref-type="bibr" rid="CR28">28</xref>]. Researchers have also quickly found new antigens and enhanced vaccine formulation because of developments in molecular biology, such as genome sequencing [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par53">Vaccines, whether preventive or curative, utilize the body's natural defenses against infections and illnesses, both innate and adaptive. The body's first line of defense is the innate immune response, while memory cells produced by the adaptive immune system give the body specialized, long-lasting protection [<xref ref-type="bibr" rid="CR30">30</xref>]. Whether creating vaccines to prevent infections or cure pre-existing diseases like cancer and chronic infections, a thorough grasp of virology, pathogen biology, and molecular pathways is crucial. By making it possible to identify antigens and improve vaccine composition precisely, recent developments in molecular biology have sped up the research on vaccinations and held out hope for the day when vaccines may be customized for both therapeutic and preventive uses [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec3"><title>Vaccine development process</title><p id="Par54">Vaccines serve an essential role in world health. They contribute to longer, healthier lives and higher quality of life. Vaccination is an effective means to avoid several dangerous and contagious diseases. It has been identified as one of the most essential approaches to combat a pandemic [<xref ref-type="bibr" rid="CR32">32</xref>]. Its applications include smallpox and polio eradication [<xref ref-type="bibr" rid="CR33">33</xref>]. Vaccination has substantially decreased the prevalence of many pediatric illnesses, including measles and polio [<xref ref-type="bibr" rid="CR34">34</xref>]. Influenza vaccination is routinely used yearly to guarantee influenza prevention during the season [<xref ref-type="bibr" rid="CR35">35</xref>]. As a result, many scientific studies have recognized vaccination as one of the most efficacious disease transmission prevention measures through stopping disease transmission. Infectious diseases as human health problems are one of the biggest concerns in healthcare [<xref ref-type="bibr" rid="CR36">36</xref>]. Terrifying are the diseases that spread around, especially those that kill many victims. Traditionally, viral infections were considered among the misfortunes or the expressions of a deity's wrath from the earliest times of humanity [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par55">Advancements in the etiological study of diseases caused by viruses, knowledge of microbiology, and the discovery of different vaccines have prevented humanity from its unreasonable fear of death. The invention of vaccines and their development is regarded as one of the most outstanding achievements in medical history. Millions of lives have been saved because of vaccination, and its value is only expanding. Despite extensive efforts that have been made to develop&#160;competent and productive vaccines, there are inadequate obstacles to protecting people from diseases that could produce outbreaks or widespread diseases affecting a large number of people [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Therefore, researchers are attempting to extend the number of illnesses that vaccinations can stop, thereby broadening the target populations who will benefit from vaccination in the future. Moreover, the techniques of developing vaccines are customized to meet individual countries' distinct wellness and financial needs. Before introducing a vaccine to the community, some initial stages should be gone through, such as proof of concept, vaccine testing, and the final vaccine manufacturing process.</p><sec id="Sec4"><title>Proof of concept of vaccine development</title><p id="Par56">As with other forms of prevention, health organizations must conduct relentless, post-licensure safety testing by active and passive methods of the vaccines distributed worldwide. Academia should investigate vaccine safety and concentrate chiefly on manufacturing vaccines and letting vaccine manufacturing be the production of the vaccines. Above all, how people see vaccine-making can affect their faith in and usage of approved vaccines [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. However, this priority should not be confused with the notion that strict quality control practices must also characterize the vaccine production process. The general public's perspective on vaccine manufacturing can either make people take up the vaccination or lose faith in these vaccines entirely [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. For example, improved knowledge of the conditions and potential complications in the case of lack of vaccine, such as the flu or human papillomavirus (HPV), and the mechanism of vaccine are likely to shape public opinion and stimulate public responsiveness to vaccination programs [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par57">The manufacturing of vaccines, as with any other medical product, must pass good manufacturing practices, but it has several quality control stages more than any other pharmaceutical [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Vaccines are produced within 6&#8211;24&#160;months. At the same time, the whole process, including all of the developmental stages, usually lasts many years, mainly because its quality control and testing procedures are very demanding [<xref ref-type="bibr" rid="CR48">48</xref>]. The company must ensure that it has established and practiced quality tests, including the purity of the cell substrate, in every production phase. Assessments such as testing the quality of the organism harvest, ensuring the whole manufacturing process is practical, and making sure the suitability when it is taken into large containers are included [<xref ref-type="bibr" rid="CR49">49</xref>]. The pharmaceutical industry must follow this strict guideline, placing the primary legal responsibility on the manufacturer to ensure their product's safety, quality, and efficacy [<xref ref-type="bibr" rid="CR50">50</xref>]. If the vaccine demonstrates promising results, it will advance to clinical trials involving human subjects.</p></sec><sec id="Sec5"><title>Vaccine testing</title><p id="Par58">The vaccine progresses to the clinical testing stage, often called a clinical trial. The process starts early here when the company presents an IND (Investigational New Drug) application to the FDA (Food and Drug Administration); this application contains the data gathered from animal studies, the manufacturing process, and research details about the vaccine quality. The quality assurance of vaccines plays a role of primary importance as it heavily influences the vaccine's effectiveness during both short- and long-term periods of disease prevention. The clinical trial process is a three-stage puzzle set, and an additional fourth phase of the FDA will be considered if the agency approves the vaccine [<xref ref-type="bibr" rid="CR51">51</xref>]. These days, biological systems are handled and analyzed using newly developed technologies that are revolutionizing information technology and biotechnology and generating enormous volumes of data.</p><p id="Par59">Integrating this data is necessary to expedite the process of knowledge discovery and facilitate the study of biological systems at different levels. <italic toggle="yes">Modeling</italic> is how humans represent, manipulate, and communicate everyday items seen in the real world. Increasingly, high-throughput genomics and proteomics efforts generate biomedical data that can be deduced using mathematical and computer models. Using sophisticated computer models that simulate intricate biological processes results in the formulation of theories and the suggestion of investigations. Computational models are prepared to use text mining and knowledge discovery techniques to exploit the abundance of data on biomedical databases.</p><p id="Par60">The 1980s saw the development of the first immunoinformatics tools for vaccine creation by DeLisi, Berzofsky, and others. Epitope-mapping algorithms are the most critical informatics tool for vaccine design [<xref ref-type="bibr" rid="CR52">52</xref>]. Accompanying the progress in molecular biology and sequencing technologies, in silico identification of vaccination targets has been made possible by bioinformatics analysis of microbial genome data. Hundreds of new vaccine design algorithms have been developed due to further developments in immunoinformatics. This new method of vaccine development is known as immunome-derived vaccine design or reverse vaccinology [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].</p><p id="Par61">Several computational modeling techniques, such as higher-order systems, agent-based models, and mathematical models, are applied to vaccinology science. Understanding biological systems requires the use of computational models. These models can forecast or improve therapy outcomes at the organism level. Agent-based modeling (ABM) can be used to conduct in silico experiments that result in the formulation and validation of biological hypotheses and provide helpful guidance for designing the best possible treatment plans.</p><p id="Par62">SimTriplex is a specialized cellular automata successfully used in computational vaccinology to model the Triplex vaccine, mammary cancer, and immune system competition [<xref ref-type="bibr" rid="CR55">55</xref>]. Triplex is an immune-preventive HER-2/neu breast cancer vaccine comprising two non-antigen specific adjuvants (IL-12 and allogeneic major histocompatibility complex (MHC) class I molecules) in addition to the specific target antigen, p185 (HER-2/neu). HER-2/neu transgenic mice were used to evaluate four different vaccine administration schedules: early, late, very late, and chronic. The results indicated that the chronic schedule only offers complete, long-term protection against mammary cancer [<xref ref-type="bibr" rid="CR56">56</xref>]. Before manufacturing the vaccine, there are three clinical phases: phase one, phase two, and phase three.</p><sec id="Sec6"><title>Phase 1</title><p id="Par63">In this trial stage, small samples of the participatory group serve as subjects (a variety of 20 to 100), and the first group will be vaccinated. This is the research phase where the investigators will examine the vaccine&#8217;s possible complications with the use of human subjects and find out if it can prompt immune responses [<xref ref-type="bibr" rid="CR57">57</xref>].</p></sec><sec id="Sec7"><title>Phase 2</title><p id="Par64">The trial is extended from a single-digit triad to a three-digit care group with the selection of the samples that will be vaccinated once the trial is successful. This is based on other factors like age and physical condition. It also aims to include people from different backgrounds to ensure that all communities are represented. This testing stage aims to get further safety information related to potential side effects and dangers and to evaluate the immunogenicity of a vaccine [<xref ref-type="bibr" rid="CR58">58</xref>].</p></sec><sec id="Sec8"><title>Phase 3</title><p id="Par65">The clinical trial is expanded to include a group of thousands of patients, ranging between 1,000 and 3,000. In this stage, scientists verify the efficiency of the vaccine, evaluate its common and rare side effects, and collect data that supports it as an approved human application. This is referred to as Phase Four after FDA approval has been granted. As soon as the FDA approves (also known as "licensing") the use of vaccines for the general population, it may move on to another phase of clinical trials with many participants involved. Phase four is designed as a structured continuous study that assesses the safety and effectiveness of new vaccines over long periods [<xref ref-type="bibr" rid="CR59">59</xref>].</p></sec></sec><sec id="Sec9"><title>The vaccine manufacturing process</title><p id="Par66">The FDA tries to see if the process of manufacturing the vaccine developer&#8217;s choice is up to standard in the last Phase 3 clinical trial. Besides this, the FDA audits/inspects the vaccine manufacturing facility to ensure a consistently dependable production of large quantities. The manufacturer produces lots, which, in turn, the approval authorities purposefully compare between each lot to verify uniformity. The FDA requires a firm to submit the data following the pre-clearance to exercise control over implementing a proven and efficacious production sequence [<xref ref-type="bibr" rid="CR60">60</xref>]. Developing a vaccination can take ten to fifteen years, from beginning to end <bold>(</bold>Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref><bold>)</bold>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Schematic represents the vaccine development process</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="43556_2024_222_Fig1_HTML.jpg"/></fig></p></sec></sec><sec id="Sec10"><title>Therapeutic vaccine development process</title><p id="Par67">Immunotherapy through therapeutic vaccines is a viable and efficient approach for tackling new illnesses, chronic diseases, and existing epidemic and endemic diseases. They have safety, precision, in and out, and tumor enlargement can respond, so it is most effective. However, most therapeutic vaccines are still being tested in clinical trials to ensure they offer effective results. Nevertheless, better comprehension of the flow of immune reactions associated with the vaccines and burning immunomodulatory approaches could enhance the clinical applicability and efficacy of the vaccines [<xref ref-type="bibr" rid="CR61">61</xref>]. Efforts to progress therapeutic vaccines should focus on three key areas: choosing an antigen, testing for an antigen, and deciding on the delivery method of antigens therapeutically or otherwise, which come in handy. It is also important to point out that searching for stable antigens associated with differing pathophysiologic events often requires a better understanding of pathophysiologic processes. For example, a better understanding of tumor-associated antigens, neoantigens, and natural immune responses has improved vaccine design in tumor immunology [<xref ref-type="bibr" rid="CR62">62</xref>]. Regarding optimal results, the quality of neoepitopes should be improved more.</p><p id="Par68">Antigen delivery is heavily influenced by the adjuvant used and the route of administration. Each form of therapeutic vaccination has distinct advantages and disadvantages. Protein/peptide vaccines are easy to produce but have limited immunogenicity. Vector-based vaccinations often deliver antigens with excellent effectiveness but raise safety issues. DNA vaccines lack a robust immunological response [<xref ref-type="bibr" rid="CR63">63</xref>]. Activating adjuvants can boost the innate immune system's cellular and molecular components, thereby augmenting the efficacy of protein/peptide and DNA vaccines.</p><p id="Par69">Moreover, emerging carrier systems such as lipoplex, liposomes, and self-assembling nanoparticles are anticipated to significantly contribute to developing protein/peptide vaccine platforms. Further, installing other/novel therapies like immune checkpoint inhibitors, CAR-T cell therapy, and TCR-T therapy shall also improve therapeutic vaccines. It has been found that therapeutic interfaces are enhanced when neoantigen vaccines are administered in combination with other immunotherapies. This is because, in chronic viral infections, the virus-specific T cells are gagged, letting them be exhausted quickly [<xref ref-type="bibr" rid="CR64">64</xref>]. In vivo, inhibition of the PD-1/PD-L1 pathway positively impacted the efficacy of the therapeutic HBV (Hepatitis B virus) vaccine in the LCMV mouse model [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par70">Chronic non-communicable diseases are a leading contributor to illness and death on a global scale, responsible for 71% of all fatalities and exerting a considerable impact on the global economic burden [<xref ref-type="bibr" rid="CR66">66</xref>]. Chronic non-communicable diseases encompass conditions such as cardiovascular disease, cancer, respiratory illnesses, diabetes, hypertension, Alzheimer's disease, dyslipidemia, asthma, and chronic obstructive pulmonary disease [<xref ref-type="bibr" rid="CR67">67</xref>]. Over 80% of fatalities stem from the leading quartet of chronic non-communicable illnesses, comprising cardiovascular diseases, cancer, respiratory ailments, and diabetes [<xref ref-type="bibr" rid="CR6">6</xref>]. Thus, therapeutic vaccine development is desirable for an established disease that can go around the body's immune system to achieve a targeted immune response and constant destruction of the known disease. These vaccines provoke antigen-specific immune responses to prevent infected cells from escaping elimination [<xref ref-type="bibr" rid="CR68">68</xref>]. In 1890, Koch developed the therapeutic vaccine for Tuberculosis (TB) known as Tuberculin, which consists of Tuberculin suspended in glycerol to create a preparation. This marked a significant advancement in distinguishing vaccines' preventive and healing capabilities [<xref ref-type="bibr" rid="CR69">69</xref>]. Following Almroth Wright's depiction of employing a comparable antibacterial immunization for addressing prolonged regional bacterial infections in 1897, therapeutic vaccines underwent swift advancement yet simultaneously provoked considerable controversy due to misuse [<xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par71">The different compounds and antibiotics have affected the researchers' challenge of therapeutic vaccines. Since HIV was first discovered in early 1981, antiviral immunology has been rapidly advancing. Healthcare reforms, changes in disease nature and patterns, particularly of chronic diseases, and the growing prevalence of antibiotic-resistant bacteria have influenced therapeutic vaccine development again intensively after the approval of Sipuleucel-T in 2010 [<xref ref-type="bibr" rid="CR71">71</xref>], The development of therapeutic vaccines gained momentum, with numerous studies demonstrating their beneficial clinical role in treating tumors and infectious diseases [<xref ref-type="bibr" rid="CR72">72</xref>]. Based on fundamental research, they have begun moving towards the stage of clinical trials, and this reflects the scholarly literature foundations. Currently, many therapeutic vaccines are under clinical trials for therapeutic uses in both communicable and non-communicable illnesses, infective and non-infective, such as viral diseases, cancer, hypertension, Alzheimer's disease, diabetes, and dyslipidemia [<xref ref-type="bibr" rid="CR73">73</xref>]. Therapeutic vaccinations offer numerous advantages compared to contemporary chemical or biological treatments. These include precise targeting, minimal adverse effects, enduring efficacy, and immunity to drug resistance. They present a promising avenue for combating infectious diseases and chronic non-communicable conditions, offering renewed optimism for treatment&#160;[<xref ref-type="bibr" rid="CR74">74</xref>]. Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> shows the precision vaccinology approach.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>The precision-vaccinology strategy for responding to and preparing for epidemics or pandemics involves: Includes: <bold>A</bold> particular selection of strong adjuvants fitting the target population, <bold>B</bold>&#160;modification of the chemical structure of certain adjuvants for specific functions, <bold>C</bold>&#160;optimization of the use of mixtures of antigens and adjuvants combined with appropriate formulation, <bold>D</bold>&#160;identification of the right pathway of administration capable of adequately targeting protective correlates</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="43556_2024_222_Fig2_HTML.jpg"/></fig></p><sec id="Sec11"><title>Clinical trials</title><p id="Par72">It is crucial to have clinical trials in the development of vaccines. They provide safety and efficacy for regulatory purposes and health management, supporting the NITAG (National Immunization Technical Advisory Group). The design of the vaccine clinical program and specific trials that make up this program is a process that can only be conceptualized and mapped out in advance in many cases. This includes preclinical data, epidemiological information, other vaccines and medical treatments intended for the targeted product profile, and new clinical data as they become available. Further characteristics of vaccine clinical trials involve assessing tolerance and side effects to assess safety; utilizing serologic or immunologic changes as markers of biological effect; targeting mainly to avoid naturally occurring infective illnesses as the significant test of effectiveness; incorporating indicative effectiveness pointers short of prevention of the disease; and utilizing clinical records to ensure drug quality and consistency [<xref ref-type="bibr" rid="CR75">75</xref>].</p></sec><sec id="Sec12"><title>Therapeutic vaccine</title><p id="Par73">Therapeutic vaccines are categorized into three types, suitable for preclinical and clinical trials: molecular-based vaccines, vaccines delivered with the help of vectors, and vaccines created with the help of living cells [<xref ref-type="bibr" rid="CR76">76</xref>]. Molecular-based immunizations include peptide/ protein vaccines, which contain entire proteins or protein portions of an illness-causing agent; DNA vaccines, which use the tiny genetic material of the pathogen; and mRNA vaccines [<xref ref-type="bibr" rid="CR77">77</xref>]. These notable immunizations employ neoantigens, pure peptides/proteins, or genes encoding the proteins-DNA/mRNA in combination with adjuvants to generate immune responses [<xref ref-type="bibr" rid="CR78">78</xref>]. Vector-based vaccines utilize naturally existing or genetically engineered bacteria, viruses, and yeast as effective transporters of antigen transgenes [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. Dendritic cell vaccines and genetically modified cell vaccines are two types of cell-based vaccinations that express or transport antigens using dendritic cells or cells that have been genetically modified [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Immunomodulating vaccines administer antigens intravenously or extraneously with adjuvants to prime dendritic cells (DCs). These vaccinations effectively target existing antigens by improving the appearance of epitope-specific T cells to get to the site of infection and lesions to halt the infection. Also, they activate specific B cells in the body to secrete antibodies specific to the virus, which it has to neutralize&#160;[<xref ref-type="bibr" rid="CR83">83</xref>]. Table <xref rid="Tab1" ref-type="table">1</xref> describes the types of therapeutic vaccines and their sources and applications.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Overview of current therapeutic vaccines: sources, applications</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"><bold>Serial No</bold></th><th align="left" colspan="1" rowspan="1"><bold>Vaccines</bold></th><th align="left" colspan="1" rowspan="1"><bold>Sources</bold></th><th align="left" colspan="1" rowspan="1"><bold>Application</bold></th><th align="left" colspan="1" rowspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Provenge (sipuleucel-T)</td><td align="left" colspan="1" rowspan="1">It is a therapeutic cancer vaccine developed by Dendreon Corporation</td><td align="left" colspan="1" rowspan="1">This treatment is uniquely crafted to combat prostate cancer by activating the patient's immune system to identify and eliminate prostate cancer cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR84">84</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Talimogene laherparepvec (T-VEC)</td><td align="left" colspan="1" rowspan="1">It is is an oncolytic viral therapy derived from the herpes simplex virus type 1 (HSV-1)</td><td align="left" colspan="1" rowspan="1">This genetically engineered organism is designed to replicate specifically within tumors and generate the immune-boosting protein granulocyte&#8211;macrophage colony-stimulating factor (GM-CSF), aiding in the eradication of cancerous cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR85">85</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Cervarix</td><td align="left" colspan="1" rowspan="1">It is a vaccine developed by GlaxoSmithKline (GSK)</td><td align="left" colspan="1" rowspan="1">is a vaccine developed by GSK. It is primarily used to protect against HPV types 16 and 18, which are associated with a significant risk of cervical cancer and has been research into its therapeutic potential in treating existing HPV-related conditions</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">BCG vaccine (Bacillus Calmette-Guerin)</td><td align="left" colspan="1" rowspan="1">It is derived from a strain of Mycobacterium bovis, which is a relative of Mycobacterium tuberculosis, the bacterium that causes tuberculosis</td><td align="left" colspan="1" rowspan="1">The BCG vaccine is primarily used to prevent TB and is also employed in the treatment of bladder cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR87">87</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">VGX-3100</td><td align="left" colspan="1" rowspan="1">is a therapeutic DNA vaccine developed by Inovio Pharmaceuticals</td><td align="left" colspan="1" rowspan="1">designed to treat precancerous lesions caused by HPV types 16 and 18. It targets the E6 and E7 oncoproteins of HPV, which are crucial for the virus's role in causing cervical intraepithelial neoplasia (CIN) 2/3 lesions</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">HIV therapeutic vaccines</td><td align="left" colspan="1" rowspan="1"><p>ACTG's A5374 Study</p><p>AELIX-002 Study</p><p>NIAID Research</p></td><td align="left" colspan="1" rowspan="1">Help to manage the virus without the need for continuous antiretroviral therapy (ART)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR89">89</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Hepatitis B therapeutic vaccines</td><td align="left" colspan="1" rowspan="1"><p>INOVIO Pharmaceuticals</p><p>Dynavax Technologies</p></td><td align="left" colspan="1" rowspan="1">designed to treat individuals already infected with the HBV, aiming to enhance the body's immune response to control or eliminate the virus</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR90">90</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">CIMAvax-EGF</td><td align="left" colspan="1" rowspan="1">It is a therapeutic cancer vaccine developed by the Center of Molecular Immunology (CIM) in Havana, Cuba</td><td align="left" colspan="1" rowspan="1">It is designed to treat non-small cell lung cancer by targeting the epidermal growth factor (EGF), which is involved in the growth and proliferation of cancer cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR91">91</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec13"><title>Immune response induced by therapeutic vaccines</title><p id="Par74">Strategically administered vaccines such as bacterial and viral vectors, peptide/protein, and DNA and mRNA vaccines are delivered locally. Adjuvants in these vaccines activate local innate immune cells and appear to induce specific inflammatory mediators' chemokines [C/C] and [X/X] that attract macrophages and DCs to the injection site. The dendritic cells in the skin capture the subcutaneous antigen in the vaccine, and after being activated, the cells move to the regional lymph nodes. DC maturation results in the expression of MHCII molecules and co-stimulatory receptors &#8211; CD40, CD80, and CD86 &#8211; on their surface and the release of cytokines. In nodes of lymphatic tissue, the activated DCs then display the specificity antigens, which are presented in the form of peptide-MHC to T lymphocytes. At the same time, co-stimulatory and cytokines signals activate the CD8&#8201;+&#8201;T cells. As the center of focus, the Ag-stimulated mature B cells differentiated antibody-producing cells and CD8&#8201;+&#8201;T cells specific to the particular Ag disseminate to the focus of infection/lesion and perform their functions [<xref ref-type="bibr" rid="CR81">81</xref>]. Adjuvants are essential in vaccines because they help increase the intensity and sustainability of the immune response to antigens. The commonplace adjuvants of approved vaccines include alum, MF59, CpG 1018, AS01, AS02, AS03, and AS04; other effective adjuvants are still under study in animal models and human tests. These substances, which bear immune stimulating characteristics, can either be like the damage-associated host-derived molecules or pathogen-derived molecular patterns that engage with Pattern Recognition Receptors (PRRs) on innate immune cells [<xref ref-type="bibr" rid="CR92">92</xref>]. In clinical settings, therapeutic vaccinations are commonly given via intramuscular, subcutaneous, or intradermal routes, with intramuscular injection being the most commonly used method [<xref ref-type="bibr" rid="CR93">93</xref>]. Influence on the potency and duration of the adaptive immune response is exerted by inflammation at the localized tissue [<xref ref-type="bibr" rid="CR94">94</xref>].</p><p id="Par75">Adjuvants in the vaccines elicit an immune response that causes the activation of the local innate immune responses and release chemokines, including CCL2 and CXCL1, among others, and cytokines. These substances then recruit more innate immune cells, including neutrophils, macrophages, monocytes, and dendritic cells, to the injection site [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. DCs enter the injection site and act as the primary antigen-presenting cells (APCs), triggering a robust adaptive immune response [<xref ref-type="bibr" rid="CR93">93</xref>]. DCs at the immunization site endocytose the vaccine's antigen component. DCs stimulated at the immunization site transport vaccine components to the draining lymph nodes [<xref ref-type="bibr" rid="CR95">95</xref>]. Appropriate stimulation of the dendritic cells needs to increase the surface expression in MHCII and CD40, CD80, and CD86 molecules and cytokine synthesis. Mobiles and activated dendritic cells bear antigens in the form of peptide MHC complexes to the T lymphocytes within the lymph nodes. Classically, CD8&#8201;+&#8201;T cells are known to be activated only when they receive co-stimulatory and cytokine signals [<xref ref-type="bibr" rid="CR96">96</xref>]. B cells that antigens have activated undergo maturation and rapid proliferation. Subsequently, CD8&#8201;+&#8201;T lymphocytes, specific to the antigen, migrate to sites of infection and lesions to carry out their function<bold>.</bold> Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref> depicts the complex network of cells and mechanisms that make up the body's immune system.<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Schematic representation of vaccine efficacy and safety are governed by innate and adaptive immune responses. Host variables influence these interactions and can be guided by vaccination characteristics</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="43556_2024_222_Fig3_HTML.jpg"/></fig></p></sec></sec><sec id="Sec14"><title>Vaccine development technologies and innovations</title><p id="Par76">Many advanced technologies and advances have revolutionized the vaccine development landscape. These developments cover various approaches, such as CRISPR-cas systems, protein subunit vaccines, nanoparticle vaccines, viral vector vaccines, and nucleic acid vaccine technology. Every strategy offers distinct benefits and innovations that improve vaccine development processes' safety, effectiveness, and speed <bold>(</bold>Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref><bold>)</bold>. In this section, authors have discussed selective technologies.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Various development technologies and innovations in the vaccine development process, including nucleic acid vaccine technology, protein subunit vaccines, nanoparticle vaccines, viral vector vaccines, and the CRISPR-Cas system, highlighting the diverse approaches used to enhance vaccine efficacy and development</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="43556_2024_222_Fig4_HTML.jpg"/></fig></p><sec id="Sec15"><title>Genomic sequencing</title><p id="Par77">Determining the order of nucleic acid residues in biological samples is essential for various scientific purposes. Over the past 50&#160;years, much research has gone into developing the techniques and instruments required to sequence DNA and RNA molecules [<xref ref-type="bibr" rid="CR97">97</xref>]. Lucy van et al. study noted that genomic sequence use in the COVID-19 pandemic not only offered previously unheard-of insights into the historical demography of SARS-CoV-2 but also tracked the virus's adaptation to its new human host, providing information that informs the development of drugs and vaccines [<xref ref-type="bibr" rid="CR98">98</xref>]. Genomic data can be utilized to characterize the more evolutionarily constrained sections of a pathogen genome that should be targeted preferentially to prevent rapid drug and vaccine escape mutants and uncover pathogen genes interacting with the host [<xref ref-type="bibr" rid="CR99">99</xref>]. Furthermore, a nomenclature system can help with real-time epidemiology in an ongoing and dynamic epidemic like SARS-CoV-2 by offering globally accepted labels for circulating viruses. This helps identify the connections between outbreaks that have similar virus genomes [<xref ref-type="bibr" rid="CR100">100</xref>]. The various mutations found at each location on the genome and the mutations assumed to occur are displayed by genomic sequencing. The distribution of the segregating variant in the phylogeny and on the map can be found by choosing a site in the genome with non-zero entropy. This makes it possible to investigate genetic alterations that could be adaptive or the root cause of altered disease dynamics [<xref ref-type="bibr" rid="CR101">101</xref>].</p><p id="Par78">A study by Robert P. et al. revealed that distinct viral variants, as determined by genomic sequencing, exhibit varying receptor attachment. Specifically, the mutants exhibit a significant decrease in binding to avian-type (&#945;2&#8211;3) receptors and an increase in binding to human-type (&#945;2&#8211;6) receptors. This makes it possible for various therapeutic and vaccination biomedical researchers to develop unique strategies [<xref ref-type="bibr" rid="CR102">102</xref>]. Several full or partial Zika virus genomes, primarily from Brazil, and presenting information produced by a mobile genomics lab revealed that, According to estimates produced by combining analyses of viral genomes with ecological and epidemiological data, the Zika virus was likely already prevalent in northeast Brazil by February 2014. It had spread throughout the country and beyond before it was first discovered in the Americas. According to a study about establishing and transmitting the Zika virus in Brazil and the Americas, estimated dates for the virus's international spread from Brazil reflect the length of pre-detection cryptic transmission in recipient regions [<xref ref-type="bibr" rid="CR103">103</xref>].</p><p id="Par79">The genetic makeup of a virus can be ascertained using genome sequencing, which can also be used to create vaccinations that target particular proteins or genomic regions. The COVID-19 vaccines, which target the virus's spike protein, are developed using this technology. The genetic makeup of a virus can be determined using genome sequencing, which can also be used to create vaccines that target particular proteins or genomic areas. Furthermore, despite efforts to prevent it, SARS-CoV-2 sequencing has proven crucial in tracking mutations during the COVID-19 pandemic and understanding how the virus spreads to and from patients and healthcare workers [<xref ref-type="bibr" rid="CR104">104</xref>]. Governments utilize the genetic laboratories' data to monitor the epidemic's spread, organize public health campaigns, and ensure that patients can get drugs and vaccines. In a study by Stefan Elbe et al., this was emphasized as extremely important. They also highlighted the likelihood of a potentially disastrous human pandemic and the comparatively rapid evolution of influenza viruses [<xref ref-type="bibr" rid="CR105">105</xref>].</p><p id="Par80">The table below <bold>(</bold>Table&#160;<xref rid="Tab2" ref-type="table">2</xref><bold>)</bold> delivers different summarized descriptions of genomic sequencing technologies used to gain information about the different microorganisms like Coronavirus, Ebola virus, etc. The information acquired is used to develop different prophylactic and therapeutic vaccines against those organisms.
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Uses of genomic sequencing technologies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"><bold>Serial No</bold></th><th align="left" colspan="1" rowspan="1"><bold>Detailed use of genomic sequencing technology</bold></th><th align="left" colspan="1" rowspan="1"><bold>viruses</bold></th><th align="left" colspan="1" rowspan="1"><bold>Vaccine</bold></th><th align="left" colspan="1" rowspan="1"><bold>Reference</bold></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Tracks the virus&#8217; adaptation to its new host and gives an over view of the genome</td><td align="left" colspan="1" rowspan="1">Corona virus</td><td align="left" colspan="1" rowspan="1">Pfizer-BioNTech and Moderna vaccines</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Gives a view about the spread of the disease</td><td align="left" colspan="1" rowspan="1">Ebola virus</td><td align="left" colspan="1" rowspan="1">rVSV-ZEBOV vaccine</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Notification about the different mutations of a given virus, use of the different receptors in the body after mutation</td><td align="left" colspan="1" rowspan="1">Avian Influenza, Human H1 and H3N2 viruses</td><td align="left" colspan="1" rowspan="1">mRNAseasonal Influenza vaccine</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Identification of the origin of the virus genome before and after mutation</td><td align="left" colspan="1" rowspan="1">Zika virus</td><td align="left" colspan="1" rowspan="1">VRC5288 and VRC5283 Vaccines</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR109">109</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Genetic information about the virus spread from patients to health workers</td><td align="left" colspan="1" rowspan="1">Corona virus</td><td align="left" colspan="1" rowspan="1">NVX-CoV2373 vaccine</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Control epidemics from becoming pandemics</td><td align="left" colspan="1" rowspan="1">Influenza virus</td><td align="left" colspan="1" rowspan="1">CRISPR &#8211;Cas systems influenza vaccines</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec16"><title>Nucleic acid vaccine technology</title><p id="Par81">Nucleic acid vaccines are novel vaccinations that teach cells to generate an antigen that elicits an immune response using genetic material, either DNA or RNA. The nucleic acids are expressed after being ingested by antigen-presenting cells. They are non-infectious but imitate natural infection by producing endogenous antigens and evoking potent T and B cell responses [<xref ref-type="bibr" rid="CR106">106</xref>].</p><sec id="Sec17"><title>Messenger ribonucleic acid (mRNA) vaccine technology</title><p id="Par82">One significant scientific advance in recent decades has been the creation of mRNA treatments and vaccinations. Researchers like Katalin Karik&#243; and Drew Weissman first proposed employing mRNA as a therapeutic tool in the early 1990s when they found that synthetic mRNA might be altered to lessen its intrinsic immunogenicity [<xref ref-type="bibr" rid="CR113">113</xref>]. This was essential since unmodified mRNA could cause an undesired immune response and was easily degraded. They improved mRNA's translational efficiency and stability by introducing modified nucleosides, which set the stage for its application in vaccines and treatments. Targeting the rabies virus, the first mRNA vaccine to reach clinical trials was created in 2013, showcasing the technology's potential for use in people. However, the COVID-19 pandemic of 2020, which led to the quick creation, licensing, and widespread distribution of Moderna's mRNA-1273 and Pfizer-BioNTech's BNT162b2 vaccines, was what brought attention to the benefits of mRNA vaccines [<xref ref-type="bibr" rid="CR114">114</xref>]. These vaccines demonstrated the versatility of mRNA technology in treating newly emerging infectious diseases in addition to their speed and scalability. A new era in vaccination research has been ushered in by the success of these vaccines, which have prompted additional studies into mRNA-based treatments, including ones that target infectious diseases and cancer [<xref ref-type="bibr" rid="CR115">115</xref>].</p><p id="Par83">Katalin Karik&#243; et al. revealed that because mRNA is non-infectious and degrades naturally by cellular processes, it has been an asset in vaccine creation through research and various technologies over the years. Moreover, mRNA is much more translatable and stable [<xref ref-type="bibr" rid="CR116">116</xref>]. The production of mRNA involves in vitro reactions with recombinant enzymes, ribonucleotide triphosphates (NTPs), and a DNA template, as reported in a study by Norbert P et al. This makes mRNA production faster and more accessible than conventional protein subunits and live or inactivated vaccine production platforms [<xref ref-type="bibr" rid="CR117">117</xref>]. When a vaccine is encapsulated in lipid nanoparticles (LNPs) for optimal cellular uptake and protection, the mRNA stays in the host cell's cytoplasm [<xref ref-type="bibr" rid="CR118">118</xref>]. The antigen protein is produced by the host cell's machinery using genetic instructions. On the cell surface, the antigen is shown, triggering the humoral and cellular immune responses and forming memory cells, which offer long-term immunity [<xref ref-type="bibr" rid="CR119">119</xref>].</p><p id="Par84">Multiple vaccine candidates against COVID-19 are included in the promising class of mRNA-based vaccines. A nucleoside-modified mRNA-lipid nanoparticle (mRNA-LNP) vaccine that encodes the receptor-binding domain of the spike protein as a monomer or the whole SARS-CoV-2 spike glycoprotein [<xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR121">121</xref>]. Because of its safety, uncomplicated design, and ease of manufacture, mRNA research has continued. Finally, tenacity paid off, as proven by the discovery of highly effective COVID-19 mRNA vaccines, which have played a critical role in continuing pandemic control efforts [<xref ref-type="bibr" rid="CR122">122</xref>]. The mRNA vaccines used currently are mRNA-1273, developed by Moderna, and BNT162b2, developed by Pfizer-BioNTech [<xref ref-type="bibr" rid="CR106">106</xref>]. Monslow et al. tested the efficacy of an LNP-enclosed mRNA vaccine encoding the varicella-zoster virus (VZV)gE antigen against two other approved vaccines. The results showed that the VZV gE mRNA/LNP platform can elicit a robust immune response [<xref ref-type="bibr" rid="CR123">123</xref>].</p><p id="Par85">A study by Justin M. et al. revealed that since there is now no medication to combat the Zika virus, immunization is the only way to avoid the risks of infection. mRNA vaccines against the Zika virus commonly use membrane and envelope proteins as antigens [<xref ref-type="bibr" rid="CR124">124</xref>]. Influenza viruses are of four strains: A, B, C, and D; however, types A and B are clinically linked to human diseases. According to a study by Benjamin P. et al., an mRNA vaccine was developed against the human influenza virus; the target of the vaccine is the glycoprotein hemagglutinin (HA) on the virus's surface since it mediates the viral entry [<xref ref-type="bibr" rid="CR125">125</xref>]. A paper published by Kai Wu et al. described in detail the immunological responses that both seropositive and seronegative healthy volunteers from a phase 1 randomized, first-in-human clinical trial had in response to the investigational cytomegalovirus (CMV) vaccine, mRNA-1647. The results of the investigation showed that both fibroblasts and epithelial cells responded strongly and broadly to three dosages of mRNA-1647 (180&#160;&#956;g) when it came to CMV infection [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR127">127</xref>]. Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref> shows the techniques for treatment and prevention against SARS-Cov-2.<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Schematic representation of techniques for Treatment and Prevention against SARS-Cov-2. Techniques for Treatment and Prevention Against SARS-Cov-2.a), Vaccine targets and vaccine platforms against SArS-coV-2. b, examples of viral targets and of potential antiviral drugs against SArS-coV-2. OrF, open reading frame; rdrp, rNA-dependent rNA polymerase; PLpro, papain-like protease; Ace 2, angiotensin-converting enzyme 2; TmPrSS 2, transmembrane protease, serine 2; er, endoplasmic reticulum; erGIc, endoplasmic-reticulum&#8211;Golgi intermediate compartment; IL-6r, interleukin-6 recseptor</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="43556_2024_222_Fig5_HTML.jpg"/></fig></p><p id="Par86">According to findings from a study by Mia et al., cellular immune responses to the rabies mRNA vaccine RV021 at 5&#160;&#956;g may be more powerful than those to Inactivated Rabies Vaccines (IRVs). The cellular immune response was significantly improved by switching from one dose of RV021 to two doses, as opposed to increasing the single dose from 1&#160;&#956;g to 5&#160;&#956;g [<xref ref-type="bibr" rid="CR128">128</xref>]. For many years, there have been unsuccessful attempts to create effective anti-HIV vaccinations. The new mRNA vaccine technique has made great strides recently in terms of adoption as an anti-HIV strategy. Several mRNA-based HIV vaccines are being tested in clinical settings to determine their efficacy and safety [<xref ref-type="bibr" rid="CR129">129</xref>].</p><p id="Par87">A revolutionary development in immunization, mRNA vaccine technology has several distinct benefits over conventional vaccination platforms. Instead of growing live viruses, these vaccines can elicit a potent immune response by using synthetic mRNA to tell cells to make viral proteins. This creative method has sped up the production and distribution of vaccines, as the COVID-19 pandemic has shown. Nevertheless, mRNA vaccines have their own set of difficulties and restrictions, much like any new technology, particularly in contrast to the more well-established conventional vaccinations. Table <xref rid="Tab3" ref-type="table">3</xref> offers each platform's benefits and drawbacks by comparing mRNA vaccines and conventional vaccinations in several areas.
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>The advantages and disadvantages of each platform, including mRNA vaccines and traditional vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"><bold>Sr.No</bold></th><th align="left" rowspan="2" colspan="1"><bold>Aspects</bold></th><th align="left" colspan="2" rowspan="1"><bold>Advantages</bold></th><th align="left" colspan="2" rowspan="1"><bold>Disadvantages</bold></th><th align="left" rowspan="2" colspan="1"><bold>References</bold></th></tr><tr><th align="left" colspan="1" rowspan="1"><bold>mRNA Vaccines</bold></th><th align="left" colspan="1" rowspan="1"><bold>Traditional Vaccines</bold></th><th align="left" colspan="1" rowspan="1"><bold>mRNA Vaccines</bold></th><th align="left" colspan="1" rowspan="1"><bold>Traditional Vaccines</bold></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Development Speed</td><td align="left" colspan="1" rowspan="1">Rapid design and production do not require virus cultivation</td><td align="left" colspan="1" rowspan="1">Established processes with predictable timelines</td><td align="left" colspan="1" rowspan="1">Limited long-term data on safety and efficacy</td><td align="left" colspan="1" rowspan="1">Requires the cultivation of live viruses or proteins, which takes more time</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR130">130</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Flexibility</td><td align="left" colspan="1" rowspan="1">Easily updated for new variants by modifying the mRNA sequence</td><td align="left" colspan="1" rowspan="1">Can be updated for new strains</td><td align="left" colspan="1" rowspan="1">Requires ultra-cold storage, complicating distribution</td><td align="left" colspan="1" rowspan="1">Slower adaptation to rapidly mutating pathogens</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR131">131</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Immune Response</td><td align="left" colspan="1" rowspan="1">Induces robust antibody and T-cell responses</td><td align="left" colspan="1" rowspan="1">Provide long-lasting immunity with a single dose or a few doses</td><td align="left" colspan="1" rowspan="1">The durability of immunity is still under study</td><td align="left" colspan="1" rowspan="1">May require multiple doses or boosters to maintain immunity</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Storage and Stability</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">Generally stored at 2&#8211;8&#160;&#176;C, suitable for global distribution</td><td align="left" colspan="1" rowspan="1">Ultra-cold storage (-70&#160;&#176;C) is required for some, limiting use in low-resource settings</td><td align="left" colspan="1" rowspan="1">Live-attenuated vaccines need precise storage to maintain potency</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR133">133</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Delivery Mechanism</td><td align="left" colspan="1" rowspan="1">LNPs effectively deliver mRNA into cells for protein production</td><td align="left" colspan="1" rowspan="1">Includes injections, oral vaccines, nasal sprays, etc</td><td align="left" colspan="1" rowspan="1">NPs can cause mild side effects</td><td align="left" colspan="1" rowspan="1">Live-attenuated vaccines may cause more pronounced side effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Long-Term Data</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">The long history of use</td><td align="left" colspan="1" rowspan="1">Ongoing collection of long-term safety and efficacy data</td><td align="left" colspan="1" rowspan="1">May not be as effective against new or rapidly mutating pathogens</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Production Scalability</td><td align="left" colspan="1" rowspan="1">High scalability</td><td align="left" colspan="1" rowspan="1">Scalable</td><td align="left" colspan="1" rowspan="1">Requires advanced manufacturing facilities and strict quality control</td><td align="left" colspan="1" rowspan="1">Requires specialized facilities for the growth and inactivation of pathogens</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR131">131</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Global Accessibility</td><td align="left" colspan="1" rowspan="1">Potentially high</td><td align="left" colspan="1" rowspan="1">Widely accessible</td><td align="left" colspan="1" rowspan="1">Logistically challenging</td><td align="left" colspan="1" rowspan="1">Variable</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR117">117</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Regulatory Approval</td><td align="left" colspan="1" rowspan="1">Accelerated approval</td><td align="left" colspan="1" rowspan="1">Established pathways</td><td align="left" colspan="1" rowspan="1">Rigorous oversight</td><td align="left" colspan="1" rowspan="1">Time consuming</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Public Perception</td><td align="left" colspan="1" rowspan="1">Innovative</td><td align="left" colspan="1" rowspan="1">Trusted</td><td align="left" colspan="1" rowspan="1">Skepticism</td><td align="left" colspan="1" rowspan="1">Vaccine hesitancy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">Customizability</td><td align="left" colspan="1" rowspan="1">Highly customizable</td><td align="left" colspan="1" rowspan="1">Established methods</td><td align="left" colspan="1" rowspan="1">Complex design</td><td align="left" colspan="1" rowspan="1">Limited flexibility</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR137">137</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">Efficacy Across Populations</td><td align="left" colspan="1" rowspan="1">Consistent efficacy</td><td align="left" colspan="1" rowspan="1">Proven efficacy</td><td align="left" colspan="1" rowspan="1">Uncertain long-term efficacy</td><td align="left" colspan="1" rowspan="1">Variable response</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">Side Effects and Tolerability</td><td align="left" colspan="1" rowspan="1">Mild side effects</td><td align="left" colspan="1" rowspan="1">Well-known profile</td><td align="left" colspan="1" rowspan="1">Unknown rare effects</td><td align="left" colspan="1" rowspan="1">More severe side effects</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR138">138</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Targeted Delivery</td><td align="left" colspan="1" rowspan="1">Precision targeting</td><td align="left" colspan="1" rowspan="1">General efficacy</td><td align="left" colspan="1" rowspan="1">Delivery challenges</td><td align="left" colspan="1" rowspan="1">Less specific</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR139">139</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">Pandemic Preparedness</td><td align="left" colspan="1" rowspan="1">Rapid deployment</td><td align="left" colspan="1" rowspan="1">Historical success</td><td align="left" colspan="1" rowspan="1">Dependent on advanced infrastructure</td><td align="left" colspan="1" rowspan="1">Slower response</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR140">140</xref>]</td></tr></tbody></table></table-wrap></p><sec id="FPar1"><title>Therapeutic mRNA vaccines</title><p id="Par88">In contrast to a preventative strategy for infectious diseases, mRNA vaccines are typically used therapeutically to treat cancer [<xref ref-type="bibr" rid="CR141">141</xref>]. Its usual purpose is to encrypt neoantigens or tumor-associated antigens (TAAs) in order to trigger antitumor immune responses as used in cancers such as melanoma, brain, ovarian, prostate, blood system, digestive system, and breast cancers, as well as non-small cell lung cancer [<xref ref-type="bibr" rid="CR116">116</xref>]. The malignant transformation of melanocytes, which are found throughout the body, including the skin, mucosa, uvea, inner ear, and rectum, is the cause of melanoma. The primary use for DC-based mRNA vaccines is against melanoma, which induces a broad spectrum of T-cell responses when injected [<xref ref-type="bibr" rid="CR142">142</xref>].</p><p>Additionally, a study by Yanina&#160;J et al. revealed that in patients with metastatic melanoma, autologous monocyte-derived mRNA co-electroporated dendritic cells expressing mRNA encoding CD40 ligand (CD40L), CD70, and constitutively activated TLR4 (caTLR4) exhibit antitumor efficacy. These cells are known as TriMixDC-MEL. Adjuvant therapy with TriMixDC-MEL id/iv is acceptable and can potentially increase the 1-year disease-free survival rate [<xref ref-type="bibr" rid="CR143">143</xref>]. The most prevalent primary brain tumor in adults, glioblastoma (GBM), has a median survival of fewer than two years when treated with standard care [<xref ref-type="bibr" rid="CR144">144</xref>]. It is always fatal. Immunotherapies based on RNA offer a significant chance of establishing a long-lasting therapeutic response for GBM and other malignant brain tumors. Although RNA has apparent benefits over antigen-focused strategies, its biological instability frequently prevents it from being delivered directly, so it is usually used in RNA dendritic cell vaccinations and RNA nanoparticle treatments [<xref ref-type="bibr" rid="CR145">145</xref>].</p><p>Globally, lung cancer is the primary cause of cancer death and the second most common type of cancer. Non-small cell lung cancer by mRNA 85% of all lung cancers are non-small cell lung cancers (NSCLCs) [<xref ref-type="bibr" rid="CR146">146</xref>]. Two mRNA-based vaccines, CV9201 and BI1361849 (CV9202), were clinically studied in NSCLC. A study by Martin Sebastian et al. demonstrated that CV9201 is an RNActive-based cancer immunotherapy encoding five NSCLC antigens [<xref ref-type="bibr" rid="CR147">147</xref>]. Ovarian cancer is the fifth most significant cause of cancer-related deaths in women worldwide, accounting for less than 5% of all cancer-related deaths in women [<xref ref-type="bibr" rid="CR148">148</xref>]. Tetiana et al.'s study demonstrated the use of lipid nanoparticles to transfer mRNA encoding the follistatin protein. This protein inhibits activin A, a protein linked to both cachexia, a disease where patients with cancer frequently experience muscle atrophy, and aggressive ovarian cancer [<xref ref-type="bibr" rid="CR149">149</xref>].</p><p>According to Global Cancer Statistics 2020, breast cancer in women has overtaken lung cancer as the most common disease to be diagnosed. Triple-negative breast cancer (TNBC), HER2&#8201;+&#8201;, and ER&#8201;+&#8201;are the three main subtypes of breast cancer [<xref ref-type="bibr" rid="CR148">148</xref>]. Among the various subtypes of breast cancer, the mutational burden is highest in TNBC. Furthermore, increased tumor-associated antigen levels imply that immunotherapies, particularly for TNBC, are a promising therapeutic alternative [<xref ref-type="bibr" rid="CR150">150</xref>]. According to recent research, mRNA vaccines have more immunostimulatory antigens than peptide-loading DCs and vaccinations based on HER2&#8201;+&#8201;tumor cells. They thus produced the greatest cell lysis by the in vitro HER2-specific cytotoxic T cell (CTL) induction [<xref ref-type="bibr" rid="CR151">151</xref>].</p><p>There have been reports that mRNA vaccines could be used to cure a variety of uncommon illnesses. For example, cystic fibrosis is a genetic disorder affecting the lungs, pancreas, and other organs [<xref ref-type="bibr" rid="CR152">152</xref>]. Robinson et al. demonstrated a promising platform for the correction of cystic fibrosis. They found that a chemically modified mRNA encoding Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), packed in lipid nanoparticles, increased membrane-localized CFTR and preserved its function as a chloride channel in patient-derived bronchial epithelial cells. When applied topically, the modified mRNA restored CFTR-mediated chloride secretion to conductive airway epithelia in CFTR-deficient mice [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="FPar2"><title>Prophylactic mRNA vaccines</title><p id="Par93">mRNA is much more translatable and stable [<xref ref-type="bibr" rid="CR116">116</xref>]. The production of mRNA involves in vitro reactions with recombinant enzymes, ribo NTPs, and a DNA template, as reported in a study by Norbert P et al. This makes mRNA production faster and more accessible than conventional protein subunit and live or inactivated vaccine production platforms [<xref ref-type="bibr" rid="CR117">117</xref>]. When a vaccine is encapsulated in LNPs for optimal cellular uptake and protection, the mRNA stays in the host cell's cytoplasm [<xref ref-type="bibr" rid="CR118">118</xref>]. The antigen protein is produced by the host cell's machinery using genetic instructions. On the cell surface, the antigen is shown, triggering the humoral and cellular immune responses and forming memory cells, which offer long-term immunity [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR153">153</xref>].</p><p>Multiple vaccine candidates against COVID-19 are included in the promising class of mRNA-based vaccines. A nucleoside-modified mRNA-LNP vaccine that encodes the receptor-binding domain of the spike protein as a monomer or the whole SARS-CoV-2 spike glycoprotein [<xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR121">121</xref>]. Because of its safety, uncomplicated design, and ease of manufacture, mRNA research has continued. Finally, tenacity paid off, as proven by the discovery of highly effective COVID-19 mRNA vaccines, which have played a critical role in continuing pandemic control efforts [<xref ref-type="bibr" rid="CR122">122</xref>]. The mRNA vaccines used currently are mRNA-1273, developed by Moderna, and BNT162b2, developed by Pfizer-BioNTech [<xref ref-type="bibr" rid="CR106">106</xref>].</p><p>Monslow et al. tested the efficacy of an LNP-enclosed mRNA vaccine encoding the varicella-zoster virus (VZV) gE antigen against two other approved vaccines. The results showed that the VZV gE mRNA/LNP platform can elicit a robust immune response [<xref ref-type="bibr" rid="CR123">123</xref>]. A study by Justin M. et al. revealed that since there is now no medication to combat the Zika virus, immunization is the only way to avoid the risks of infection. mRNA vaccines against the Zika virus commonly use membrane and envelope proteins as antigens [<xref ref-type="bibr" rid="CR124">124</xref>]. Influenza viruses are of four strains: A, B, C, and D; however, types A and B are clinically linked to human diseases. According to a study by Benjamin P. et al., an mRNA vaccine was developed against the human influenza virus; the target of the vaccine is the glycoprotein HA on the virus's surface since it mediates the viral entry [<xref ref-type="bibr" rid="CR125">125</xref>].</p><p>A paper published by Kai Wu et al. described in detail the immunological responses of seropositive and seronegative healthy volunteers from a phase 1 randomized, first-in-human clinical trial in response to the investigational CMV vaccine, mRNA-1647. The investigation showed that both fibroblasts and epithelial cells responded strongly and broadly to three dosages of mRNA-1647 (180&#160;&#956;g) regarding CMV infection [<xref ref-type="bibr" rid="CR126">126</xref>].</p><p>By encoding for a stable prefusion F glycoprotein, which is essential for the virus to infect host cells, this experimental vaccination specifically targets the Respiratory Syncytial Virus (RSV). Results from clinical trials have been encouraging, especially for older persons. A vaccination efficacy of 83.7% against RSV-associated lower respiratory tract disease with two or more symptoms was shown in Phase 3 ConquerRSV research. The FDA has designated Moderna's mRNA-1345 as a Breakthrough Therapy [<xref ref-type="bibr" rid="CR127">127</xref>].</p></sec></sec><sec id="Sec18"><title>DNA vaccines</title><p id="Par98">Direct injections of genetically modified DNA encoding the antigen are used in DNA vaccines. The host cells take up the DNA, creating the antigen and triggering an immunological reaction. DNA vaccines have shown promise in preclinical and clinical trials while still primarily experimental [<xref ref-type="bibr" rid="CR154">154</xref>]. Using recombinant DNA technology, antigens that can be included in vaccinations are created by modifying DNA sequences. DNA vaccines differ from traditional protein or peptide vaccinations, recombinant proteins, or virus-like particles in that they typically elicit robust humoral and cellular (Th1 type CD4&#8201;+&#8201;T cells and CD8&#8201;+&#8201;cytotoxic T cells) responses upon in vivo introduction of genetic material [<xref ref-type="bibr" rid="CR155">155</xref>]. Developing a DNA vaccine starts with identifying and culture the intended target organisms. The genetic sequences that encode immunogenic peptides are then found by sequencing the DNA of these organisms. The ensuing identification of immunogenic peptide motifs depends on these sequences. Following their identification, these motifs are put into a plasmid vector, which is subsequently built to include the genetic material required for the immunological response. After purification, the plasmid DNA is ready for examination. Lastly, tests of its safety and effectiveness are conducted on animal models to confirm the DNA vaccine's ability to elicit the intended immune response <bold>(</bold>Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref><bold>).</bold><fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>The DNA vaccine development process, starting with identifying and culturing organisms, sequencing their DNA, and identifying immunogenic DNA sequences. These sequences are used to identify immunogenic peptide motifs, which are then inserted into a plasmid vector. The plasmid DNA is purified and tested as a DNA vaccine in animal models</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="43556_2024_222_Fig6_HTML.jpg"/></fig></p><sec id="FPar3"><title>Prophylactic recombinant DNA technology vaccines</title><p id="Par99">Cervical cancer and other malignant tumors are known to be primarily caused by persistent HPV infection. Surgical treatments and efficient HPV screening technologies can help diagnose and cure cervical cancer early on. As a more potent remedy, vaccinations are anticipated to avert viral infection and the ensuing illnesses during the prophylactic and curative stages [<xref ref-type="bibr" rid="CR156">156</xref>]. Global licensing has been granted for three prophylactic HPV vaccinations: quadrivalent, bivalent, and nonavalent [<xref ref-type="bibr" rid="CR157">157</xref>]. A study by Stanley et al. revealed that each vaccine consists of virus-like particles (VLPs) with an L1 main capsid protein that has been recombinant produced from a particular type of HPV. All of them focus on high-risk HPV strains 16 and 18, which account for over 71% of occurrences of cervical cancer globally [<xref ref-type="bibr" rid="CR158">158</xref>].</p><p>Furthermore, a study by Rashi Y et al. found that the most recent HPV vaccine, Gardasil-9 (a nonavalent vaccine), offers minimal cross-protection against non-vaccine HPV types and protects against seven HPV types linked to about 90% of cervical cancer cases as well as two HPV types linked to about 90% of genital wart cases [<xref ref-type="bibr" rid="CR159">159</xref>]. Hepatitis B recombinant vaccine, the noninfectious subunit hepatitis B vaccine Engerix B((R)) [Hep-B(Eng)], is recommended for the active immunization of adults, children, and newborns against hepatitis B virus infection. It comprises the hepatitis B surface antigen (HBsAg), created via recombinant DNA technology by the yeast Saccharomyces cerevisiae [<xref ref-type="bibr" rid="CR160">160</xref>].</p><p>The creation of a DNA influenza vaccine is now a more realistic objective. A single consensus H5 antigen was used to produce protective antibody titers to several clades of H5N1 in a preclinical investigation of an H5N1 influenza DNA vaccine [<xref ref-type="bibr" rid="CR161">161</xref>]. Furthermore, their preclinical model success has made the development of DNA vaccines against multiple influenza strains possible. Several DNA-based influenza vaccines, including those against potentially deadly pandemic strains like H5N1 and H1N1, are in various phase I clinical trials [<xref ref-type="bibr" rid="CR162">162</xref>]. When administered alone or in conjunction with aluminum-based adjuvants, inactivated split-virus vaccines have shown some degree of immunogenicity after two doses spaced 21&#8211;28&#160;days apart [<xref ref-type="bibr" rid="CR163">163</xref>].</p><p>Several methods are being researched to increase the immunogenicity of potential HIV-1 DNA vaccines. The expression of many antigens, safety, and ease of design make DNA vaccines advantageous. A study by Srilatha et al. did a clinical trial on the PENNVAX&#174;-GP DNA vaccine was evaluated in the HVTN 098 trial in healthy adult participants at 1-,3-, and 6-month intervals via intradermal (ID) or intramuscular (IM) electroporation (EP). The trial reported positively on safety, tolerability, and acceptability [<xref ref-type="bibr" rid="CR164">164</xref>].</p></sec><sec id="FPar4"><title>Therapeutic recombinant DNA technology vaccines</title><p id="Par103">The development of HPV vaccinations for patients with established CIN2/3 and invasive cervical cancer has been the focus of ongoing research efforts; for patients with HPV16-associated CIN2/3, a study by Alvarez et al. showed the viability, safety, and possible therapeutic efficacy of pNGVL4a-CRT/E7(detox), a new DNA vaccine made of a pNGVL4a plasmid vector harboring a mutant version of the HPV16 E7 antigen linked to calreticulin (CRT) [<xref ref-type="bibr" rid="CR165">165</xref>]. Using therapeutic DNA vaccines against mycobacterium TB is a promising strategy, according to a study by Changhong et al. IL-2 and the HSP65 fusion gene expression in DNA vaccines were investigated. It improved the HSP65-DNA vaccine's immunogenicity, therapeutic benefits, and protective qualities against tuberculosis in mice. By enhancing the Th1-type response, this was accomplished [<xref ref-type="bibr" rid="CR166">166</xref>].</p></sec></sec></sec><sec id="Sec19"><title>CRISPR-Cas systems</title><p id="Par104">Programmable endonucleases found in microbial CRISPR-associated (CRISPR-Cas) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems can be used for CRISPR-based diagnostics (CRISPRDx) [<xref ref-type="bibr" rid="CR167">167</xref>]. Gene-editing techniques called CRISPR-Cas systems have recently been modified for application in antiviral treatments, including HIV, Influenza, and SARS-CoV-2. By focusing on particular viral genes and impairing their function, CRISPR-based treatments can stop the virus from proliferating. These therapies work by concentrating on viral proteins that are conserved across all viruses [<xref ref-type="bibr" rid="CR168">168</xref>].</p><p id="Par105">Mireille Be'termier et al.'s study revealed that by causing a double-strand break (DSB) at a target genomic locus, CRISPR-Cas9 systems facilitate genome editing [<xref ref-type="bibr" rid="CR169">169</xref>]. The cell's DNA repair mechanism promptly repairs the DSB. The technique known as non-homologous end joining (NHEJ), which is highly accurate, can be used to link the ends of DNA that are created. Because of its superior simplicity, efficiency, and multiplex ability compared to other nucleases like zinc finger nucleases (ZFNs) and transcription-activator-like effector nucleases (TALENs), CRISPR-Cas9 technology has become the most widely used method for genome engineering available today [<xref ref-type="bibr" rid="CR170">170</xref>].</p><sec id="Sec20"><title>Prophylactic technology</title><p id="Par106">A study by Kaito A. et al. noted that with the ability to knock out or modify specific genes essential for viral virulence, CRISPR/Cas technology has emerged as a revolutionary tool in genetic engineering with great potential for creating influenza vaccines [<xref ref-type="bibr" rid="CR112">112</xref>]. The result is a virus that is still immunogenic but not pathogenic.HBV treatment entails inactivating HBV cDNA, which is difficult because of its placement within the nucleus. To overcome this issue, gene editing can be used with gene-silencing technologies as a potential anti-HBV therapy [<xref ref-type="bibr" rid="CR171">171</xref>].</p></sec><sec id="Sec21"><title>Therapeutic vaccines technology</title><p id="Par107">It has been demonstrated that employing multiplexed guide RNAs (gRNAs) in conjunction with CRISPR/Cas9 to cleave multiple HBV genome areas at once increases the efficiency of HBV genome ablation and elimination. Completely removing a full-length 3175&#160;bp HBV DNA from the host genome using CRISPR/Cas9 technology [<xref ref-type="bibr" rid="CR172">172</xref>]. The CRISPR/Cas9 system can precisely target and cleave conserved areas in the HBV genome, leading to potent inhibition of viral gene expression and replication, according to a study by Vyas Ramanan et al., adding that this might be a cutting-edge therapeutic strategy to manage the virus and perhaps even heal people [<xref ref-type="bibr" rid="CR173">173</xref>].</p></sec></sec><sec id="Sec22"><title>Viral vector vaccines</title><p id="Par108">Vaccines with viral vectors introduce genetic material into cells through altered viruses, inducing an immunological response. To increase safety, these vectors can be less capable of replicating. Vaccines based on viral vectors come in two varieties: replicating and non-replicating. Replication-deficient viral vectors are used in non-replicating viral vector-based vaccinations to transfer a specific antigen's genetic material to the host cell and create immunity against the target antigen [<xref ref-type="bibr" rid="CR79">79</xref>].</p><sec id="Sec23"><title>Prophylactic viral vector vaccines</title><p id="Par109">The JNJ-78435735 vaccine from Johnson and Johnson (Janssen) and Beth Israel Deaconess Medical Center, AZD1222 from Oxford-AstraZeneca, Sputnik V and Sputnik Light from Gamaleya Research Institute of Epidemiology and Microbiology, and Convidecia vaccine from CanSino Biologics are the current adenovirus vector-based vaccines being used to prevent SARS-CoV-2 infection [<xref ref-type="bibr" rid="CR174">174</xref>]. Furthermore, the FDA in the US has authorized the Janssen vaccine for use in emergencies out of the five vaccinations [<xref ref-type="bibr" rid="CR175">175</xref>]. Once injected into the host cell, the genetically altered adenovirus 26 is transformed into a vaccine absorbed by the cell [<xref ref-type="bibr" rid="CR176">176</xref>].</p><p id="Par110">The AZD1222 vaccine, formerly ChAdOx1 nCoV-19, is also called Covishield, Vaxzevria, Oxford-AstraZeneca Vaccine, and others [<xref ref-type="bibr" rid="CR174">174</xref>]. It proved effective and safe in preventing severe and symptomatic Covid-19 in various demographics, including senior citizens. According to the phase 3 study, the vaccine had a 76% efficacy rate in avoiding symptomatic COVID-19 infection and a 100% efficacy rate in preventing hospitalizations and severe or critical illness [<xref ref-type="bibr" rid="CR177">177</xref>].Gam-COVID-Vac trade-named Sputnik V, so named after the first artificial satellite. It is an adenoviral vector-based COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. The vaccine was designed with two recombinant adenovirus vectors and was developed as two formulations (frozen [Gam-COVID-Vac] and lyophilized [Gam-COVID-Vac-Lyo [<xref ref-type="bibr" rid="CR178">178</xref>]. Random mutations and deletions brought about by the passage of parental VACA contributed to VACV's decreased pathogenicity. Listeria clone 16m8 (LC16m8), Dairen I strain (Dis), M65, M101, modified vaccinia virus Ankara (MVA), and many attenuated fowl pox viruses are among the vectors of the third generation of poxviruses [<xref ref-type="bibr" rid="CR179">179</xref>].</p></sec><sec id="Sec24"><title>Therapeutic viral vector vaccines</title><p id="Par111">Vaccines with viral vectors are utilized more often to treat cancer because of their potent immune-stimulating effects. These vaccinations encourage the immune system to recognize and eliminate cancer cells [<xref ref-type="bibr" rid="CR180">180</xref>]. A study by Jei Wang et al. revealed that an Oncolytic adenovirus is a novel form of viral preparation with low cytotoxicity and good selectivity for treating castration-resistant prostate cancer&#160;(CRPC) [<xref ref-type="bibr" rid="CR181">181</xref>]. Prostate cancer cells can undergo apoptosis when exposed to the oncolytic mutant Ad deleted without E1B19K and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="E1ACR2">E1ACR2</ext-link> [<xref ref-type="bibr" rid="CR182">182</xref>].</p><p id="Par112">Furthermore, the recombinant vaccinia virus, which can trigger the first immune response, and the fowl pox virus, which is utilized to boost the immune response, are the two components of Prostvac, a tumor vaccine based on recombinant poxvirus vector [<xref ref-type="bibr" rid="CR183">183</xref>]. Viral vector vaccines are employed in gene therapy to replace damaged genes with functional ones, hence treating genetic diseases. The most well-known viral-based vectors for gene delivery are lentivirus, adenovirus, and adeno-associated virus (AAV) [<xref ref-type="bibr" rid="CR184">184</xref>]. A study by Prado et al. revealed that The FDA has approved Luxturna as a gene therapy for Leber's congenital amaurosis, a hereditary condition that results in blindness. The RPE65 gene is functionally delivered to retinal cells via an AAV vector. The therapy restores vision for those suffering from this uncommon hereditary condition [<xref ref-type="bibr" rid="CR185">185</xref>].</p></sec></sec><sec id="Sec25"><title>Protein subunit vaccines</title><p id="Par113">The biotechnology field is expanding quickly, allowing for further advancements in the investigation of antigen suitability as potential vaccination candidates. Protein subunit vaccinations expose the immune system to one or more antigens, often presented as isolated or purified proteins, polysaccharides, nucleic acids, or specific portions of proteins that have been shown to have immunogenic qualities [<xref ref-type="bibr" rid="CR186">186</xref>].</p><p id="Par114">The conjugate vaccine for Haemophilus influenzae type b (Hib), which consists of a polysaccharide-protein conjugate, is an example of a successful subunit vaccination. According to research by Muganga et al. conducted in Rwanda, this vaccination has eradicated or significantly decreased this disease in children in regions of Africa [<xref ref-type="bibr" rid="CR187">187</xref>]. The European Medicines Agency (EMA) has given its reasonable scientific opinion to RTS, S/AS01, the first and only malaria vaccine. In order to boost the immune response, it targets the circumsporozoite protein (CSP) of Plasmodium falciparum in conjunction with the adjuvant AS01. With roughly 39% efficacy in preventing malaria in young children and 29% efficacy in babies, the vaccination offers only modest protection against the disease [<xref ref-type="bibr" rid="CR188">188</xref>].</p><p id="Par115">According to a study by Koupaei M, immunological responses are elicited by protein subunits that contain a particular viral product rather than the entire viral particle. Structural and non-structural proteins are present in SARS-CoV-2 in addition to accessory proteins. The primary SARS-CoV-2 structural proteins are membrane (M), envelope (E), and (S) proteins [<xref ref-type="bibr" rid="CR189">189</xref>].</p></sec><sec id="Sec26"><title>Nanoparticle vaccines</title><p id="Par116">The use of nanoparticle-based vaccinations has drawn much attention in recent years to enhance immunization tactics, vaccine efficacy, and targeted delivery to produce the intended immune responses at the cellular level [<xref ref-type="bibr" rid="CR149">149</xref>]. When developing vaccines, NPs can also be designed to make it easier for antigens to be included. NPs can include antigens through encapsulation (physical trapping) or conjugation (covalent functionalization). Because antigenic material is encapsulated in NPs, antigens that would otherwise rapidly degrade or elicit a localized immune response can be administered [<xref ref-type="bibr" rid="CR190">190</xref>]. The effectiveness of the COVID-19 mRNA vaccines demonstrates the potential of nanoscale platforms as safe and efficient vaccine delivery systems. Additionally, native pathogen-associated molecular patterns (PAMPs) found in biologically generated nanoparticles can lessen the requirement for synthetic adjuvants [<xref ref-type="bibr" rid="CR191">191</xref>].</p><p id="Par117"><italic toggle="yes">Gardasil</italic> is a four-component vaccination that targets HPV specifically and is based on VLPs. It is given with an aluminum adjuvant and contains the L1 main capsid protein of HPV types 6, 11, 16, and 18. The HPV combination vaccine was 100% effective in preventing clinical illness and was immunogenic, producing long-lasting antibodies, as noted in a study by Villa et al. [<xref ref-type="bibr" rid="CR192">192</xref>]. Three trials have used the Respiratory Syncytial Virus Fusion (RSVF) nanoparticle vaccination with aluminum in phases two and three to prevent RSV infections. The RSVF Dose-Ranging Study in Women was the first clinical study of RSV, lasting from October 2013 to May 2016. According to the study, no significant adverse effects were associated with the medication, and all formulations were well tolerated [<xref ref-type="bibr" rid="CR193">193</xref>]. Figure&#160;<xref rid="Fig7" ref-type="fig">7</xref> presented the development of gold nanoparticle-based vaccines, where gold nanoparticles target APCs to enhance the immune response.<fig id="Fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>Vaccine development process using gold nanoparticles</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="43556_2024_222_Fig7_HTML.jpg"/></fig></p><p id="Par118">Ferritin-backed self-assembling nanoparticle vaccine candidates may be produced practically and safely, and this platform offers unique benefits in terms of flexible assembly and comparatively easy scale-up. Heng Li et colleagues. used rhesus monkeys to explore the immune responses and protective impact of Receptor-Binding Domain (RBD) ferritin nanoparticles and to develop a SARS-CoV-2 vaccination platform with strong immunogenicity, high protection efficiency, broad range, and good safety [<xref ref-type="bibr" rid="CR194">194</xref>]. Table <xref rid="Tab4" ref-type="table">4</xref> shows the various biomedical technologies and innovations that have contributed to the development of vaccines, with examples.
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Various biomedical technologies and innovations that have contributed to the development of vaccines with examples</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"><bold>S/N</bold></th><th align="left" colspan="1" rowspan="1"><bold>Technology</bold></th><th align="left" colspan="1" rowspan="1"><bold>Use</bold></th><th align="left" colspan="1" rowspan="1"><bold>Example</bold></th><th align="left" colspan="1" rowspan="1"><bold>Reference</bold></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">1273 (Moderna), BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">prophylactic</td><td align="left" colspan="1" rowspan="1">Varicella zoster vaccine (vzvgE)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR123">123</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Zika virus vaccine</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR195">195</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Influenza Vaccine</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR125">125</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Cytomegalo virus vaccine</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">RSV</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR127">127</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Rabies virus vaccine</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR128">128</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Prophylactic (clinical trials)</td><td align="left" colspan="1" rowspan="1">HIV vaccine</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR129">129</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Therapeutic</td><td align="left" colspan="1" rowspan="1">Melanoma vaccines</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR196">196</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Therapeutic</td><td align="left" colspan="1" rowspan="1">Glioblastoma vaccines</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR145">145</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Therapeutics</td><td align="left" colspan="1" rowspan="1">NSCLC</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR147">147</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Therapeutics</td><td align="left" colspan="1" rowspan="1">Ovarian cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR149">149</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Therapeutics</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR151">151</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">Therapeutics</td><td align="left" colspan="1" rowspan="1">Cystic fibrosis</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR152">152</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">Recombinant DNA</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Cervical cancer (HPV)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">Recombinant DNA</td><td align="left" colspan="1" rowspan="1">Therapeutic</td><td align="left" colspan="1" rowspan="1">Cervical cancer (HPV)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR165">165</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">Recombinant DNA</td><td align="left" colspan="1" rowspan="1">Therapeutic</td><td align="left" colspan="1" rowspan="1">Tuberculosis (MTB)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR166">166</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">Recombinant DNA</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Avian influenza</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR163">163</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">Recombinant DNA</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">HIV</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR164">164</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">Recombinant DNA</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Hip B</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR160">160</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">CRISPR &#8211;Cas systems</td><td align="left" colspan="1" rowspan="1">Therapeutics</td><td align="left" colspan="1" rowspan="1">HBV</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR173">173</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1">CRISPR &#8211;Cas systems</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Influenza</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR112">112</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1"><p>SARS-COV-2 (Janssen vaccine</p><p>Sputnik vaccine, Covishield)</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR174">174</xref>, <xref ref-type="bibr" rid="CR175">175</xref>, <xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR178">178</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">Viral vector</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Pox virus</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR179">179</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Haemophilus influenza type B (HiB)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR187">187</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Malaria</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR188">188</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">Protein subunit</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">SARS-CoV-2</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR189">189</xref>],</td></tr><tr><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">Nano particles</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">Covid-19</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR190">190</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">Nano particles</td><td align="left" colspan="1" rowspan="1">Prophylactic</td><td align="left" colspan="1" rowspan="1">HPV</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR192">192</xref>]</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec27"><title>Key challenges in vaccine development and deployment</title><p id="Par119">Developing effective vaccines involves overcoming numerous challenges. This highlights a few challenges, including delivery methods, antigen identification, and transportation and storage logistics. These challenges are critical to ensuring the success of vaccination campaigns and improving public health outcomes.</p><sec id="Sec28"><title>Vaccine delivery and administration</title><p id="Par120">They create efficient delivery methods that guarantee the vaccine's durability, bioavailability, and appropriate immunological presentation. This may use viral vectors, liposomes, or nanoparticles [<xref ref-type="bibr" rid="CR117">117</xref>]. The obstacles associated with manufacturing, stability, and immune response modification are unique to each delivery strategy [<xref ref-type="bibr" rid="CR197">197</xref>]; according to a study by Rashmirekha P et al., there has been much focus on using vaccines based on nanoparticles to enhance vaccination efficacy, immunization tactics, and targeted delivery to produce the intended immune responses at the cellular level. These nanocarriers must prevent premature proteolytic destruction of the antigens, aid in antigen absorption and processing by antigen-presenting cells, regulate release, and be safe for human usage to increase vaccine efficacy [<xref ref-type="bibr" rid="CR198">198</xref>]. The recombinant nanoparticle vaccine known as rSARS-CoV-2 was created by Novavax and produced by Emergent BioSolutions. It is made from the complete, wild-type SARS-CoV-2 spike glycoprotein, including the transmembrane domain, as noted in a study by C. Keech et al. [<xref ref-type="bibr" rid="CR199">199</xref>].</p><p id="Par121">According to a study by Kato, vaccinations based on NPs have several drawbacks. The cellular toxicity of nanoparticles and the requirement for an adjuvant to increase vaccination efficacy are two of the main drawbacks of using them in vaccine design. Additionally, the effectiveness of vaccines is significantly impacted by the size, shape, charge, and surface area of NPs [<xref ref-type="bibr" rid="CR200">200</xref>].</p></sec><sec id="Sec29"><title>Antigen identification and selection</title><p id="Par122">It is essential but complex to determine which antigen, or combination of antigens, can elicit a robust and defensive immune response. The ability of the antigen to activate the immune system to identify and combat the infection is a requirement [<xref ref-type="bibr" rid="CR201">201</xref>]. A study by Anna et al. noted that the need for more knowledge about the correlates of immune protection is another challenge for researchers. This is because HIV-1 infection progresses in a complicated way, and the immune system is never able to completely eradicate the virus due to the reservoir of latently infected memory CD4&#8201;+&#8201;T-cells [<xref ref-type="bibr" rid="CR202">202</xref>]. The procedure frequently entails an in-depth analysis of the structure and functionality of the pathogen. It is finding viral surface proteins, such as the spike protein of SARS-CoV-2, that may be one way to combat viruses. However, developing new viruses proved extremely difficult because they had to be inexpensive and safe to employ [<xref ref-type="bibr" rid="CR203">203</xref>].</p><p id="Par123">Identifying adjuvants that are both safe and effective can boost immunity without having adverse side effects. They can aid in lowering the required dose of antigen and enhancing the vaccine's overall effectiveness. Adjuvants must, however, undergo thorough testing to ensure their efficacy and safety [<xref ref-type="bibr" rid="CR204">204</xref>]. There are noted challenges during vaccine development due to increasing production levels without sacrificing the vaccine's uniformity and quality. Transferring laboratory-scale production procedures to industrial-scale manufacturing is necessary to maintain the vaccine's safety and effectiveness even when produced in significant quantities. Maintaining uniformity among batches is crucial [<xref ref-type="bibr" rid="CR205">205</xref>].</p></sec><sec id="Sec30"><title>Transportation and storage</title><p id="Par124">There are noted challenges in guaranteeing the vaccinations' stability while being transported and stored. Many vaccinations must be refrigerated, and others must be stored at extremely low temperatures. Maintaining these conditions along the supply chain is challenging, especially in environments with limited resources [<xref ref-type="bibr" rid="CR206">206</xref>].In addition to offering a vaccination with high efficacy and no logistical difficulties during distribution, a study by Waded S et al. found that a significant logistical mode of distribution is required. This is due to the ease of infection and mutation of SARS-CoV-2 [<xref ref-type="bibr" rid="CR207">207</xref>]. This resembles the influenza virus, which is susceptible to mutation and necessitates a yearly update of vaccine strains [<xref ref-type="bibr" rid="CR208">208</xref>].</p><p id="Par125">By guidelines published by the World Health Organization (WHO), vaccine manufacturer, CDC (Centers for Disease Control and Prevention), and FDA, a study by Nugroho et al. compiled several distribution, storage, and packaging requirements. In addition, this study is anticipated to help technology developers (engineers), expedition/logistics businesspeople, legislators, authors, and field implementers carry out the immunization campaign. It is crucial because stakeholders need to be aware of vaccination management [<xref ref-type="bibr" rid="CR209">209</xref>].</p><p id="Par126">Antibodies generated by vaccinations can become resistant to pathogens through evolution. Certain infections with high mutation rates have the potential to produce strains that are resistant to vaccinations [<xref ref-type="bibr" rid="CR210">210</xref>]. To solve this issue, vaccines must be updated and monitored continuously. Furthermore, a study by Dan et al. noted there is a challenge in the production of the HIV vaccine since HIV-1-positive individuals are unable to eradicate the virus; another major obstacle is the absence of distinct immunological correlates of protection in humans [<xref ref-type="bibr" rid="CR211">211</xref>].</p></sec><sec id="Sec31"><title>Overcoming immunosuppression</title><p id="Par127">Overcoming immunosuppression in the context of vaccine development presents significant challenges, especially in populations with either compromised immune systems like cancer patients or transplant recipients or autoimmunity [<xref ref-type="bibr" rid="CR212">212</xref>]. The mechanism by which immunosuppression can negatively impact the effectiveness of vaccines lies in its ability to hinder the body from producing a proper immune response, compromising our approach to being well-protected [<xref ref-type="bibr" rid="CR213">213</xref>]. Immune-compromised hosts are likely to have attenuated or insufficient immune responses; hence, prophylactic (therapeutic) vaccines may not have as much effect [<xref ref-type="bibr" rid="CR214">214</xref>], leading to partial protection against infection or insufficient therapeutic benefit in diseases like cancer [<xref ref-type="bibr" rid="CR215">215</xref>]. Developing vaccines for immunosuppressed patients [<xref ref-type="bibr" rid="CR216">216</xref>] brings a problematic trade-off between benefit and harm [<xref ref-type="bibr" rid="CR217">217</xref>]. These include potential antibody-dependent enhancement problems with vaccines that use live attenuated viruses or other potent immunostimulatory adjuvants, and such individuals may have an exaggerated immune response from a vaccine [<xref ref-type="bibr" rid="CR218">218</xref>]. Immunosuppression may be affected by immunosuppressant type, and the degree of severity can vary greatly (e.g., medication-induced, disease-mediated). Such variation makes designing vaccines that will work for all individuals in these groups more challenging [<xref ref-type="bibr" rid="CR219">219</xref>] strategies for overcoming immunosuppression are as follows.</p><sec id="Sec32"><title>Optimized vaccine formulations</title><p id="Par128">One approach is to develop vaccines with enhanced immunogenicity. Some include designing vaccines that provoke more robust immune responses, such as modern Adjuvants, even in immunocompromised persons. Higher antigens or booster doses may also be necessary for an immunity percentage [<xref ref-type="bibr" rid="CR220">220</xref>].</p></sec><sec id="Sec33"><title>Targeted vaccine delivery</title><p id="Par129">Innovative delivery systems, such as nanoparticle-based vaccines or vaccines delivered directly to immunocompromised cells, will improve the outcome in immunosuppressed persons [<xref ref-type="bibr" rid="CR221">221</xref>] by targeting the areas of weakness that need immunological surveillance and protection [<xref ref-type="bibr" rid="CR134">134</xref>].</p></sec><sec id="Sec34"><title>Personalized vaccination schedules</title><p id="Par130">It is possible to alter the vaccination schedule depending on the specific level of immunosuppression by either increasing the intervals between the vaccines or diversifying the type of vaccine given to an individual [<xref ref-type="bibr" rid="CR222">222</xref>]. In the case of therapeutic vaccines, an example of which is cancer immunotherapy [<xref ref-type="bibr" rid="CR223">223</xref>], using adjuvants such as Immunomodulatory agents [<xref ref-type="bibr" rid="CR224">224</xref>] that mitigate the immunosuppressive pathways tends to boost the vaccine's effectiveness [<xref ref-type="bibr" rid="CR225">225</xref>]. Monitoring immune responses after vaccine administration in the immunosuppressed population helps to make booster doses or other measures to maintain the protection level [<xref ref-type="bibr" rid="CR226">226</xref>].</p></sec></sec><sec id="Sec35"><title>Vaccine hesitancy</title><p id="Par131">Vaccine hesitancy is a multi-faceted issue where safety is just one among several concerns that people may have. Others are cultural and traditional practices, fear of side effects, e.g., vaccination causes infertility, lack of health information, or misinformation. Distrust in health caregivers or other systems, cost, and geographical location [<xref ref-type="bibr" rid="CR227">227</xref>]. Communication is a critical factor in managing these concerns and has been reported to lead to increased vaccine acceptance [<xref ref-type="bibr" rid="CR228">228</xref>]. This hesitancy is not confined to high-income countries but is a complex, evolving global issue that varies significantly across different regions [<xref ref-type="bibr" rid="CR229">229</xref>]. Immunization managers in the WHO regions have said public hesitancy affects some rural ethnic minorities and remote localities. However, elsewhere, there has been mistrust among wealthy city residents over vaccine safety [<xref ref-type="bibr" rid="CR230">230</xref>]. There is also concern regarding religious or philosophical beliefs [<xref ref-type="bibr" rid="CR231">231</xref>]. The factors that help or hinder the acceptance of vaccines are, for example, education is a factor. In contrast, in one setting, its effects may have a negative influence; in other settings, its effects may be optimistic. An example of how such beliefs can affect an individual is the fear of needles, leading to rejection of vaccination [<xref ref-type="bibr" rid="CR232">232</xref>].</p></sec></sec><sec id="Sec36"><title>Ethical and regulatory considerations in vaccine development</title><p id="Par132">During vaccine development, distribution, and implementation of vaccinations, the four bioethics principles should be considered: justice, non-maleficence, autonomy, and beneficence. There are usually some challenges during the implementation of the ethics [<xref ref-type="bibr" rid="CR233">233</xref>]. Distributive justice, rights-based justice, and legal justice are the three components of a fair decision that make up justice. Distributive justice refers to the equitable allocation of limited resources to all; equality denotes the lack of avoidable or compensable differences between various groups, nations, racial and ethnic groups, and societies at large [<xref ref-type="bibr" rid="CR234">234</xref>].</p><p id="Par133">Concerning the justice principle, the limited supply of COVID-19 vaccines that have been licensed, the strong demand from many nations, and nationalism, it may be extremely difficult or even impossible to distribute vaccines equitably [<xref ref-type="bibr" rid="CR235">235</xref>]. According to the Adejumo et al. study, concerns like the differences in the economic standing of the nation's signing contracts with vaccine manufacturers and the lack of logistical support should not stand in the way of guaranteeing universal access to vaccines in line with the sustainable development goals&#8212;concerns like the elderly and healthcare workers being prioritized [<xref ref-type="bibr" rid="CR236">236</xref>].</p><p id="Par134">Vaccine makers must consider inclusion and exclusion criteria, such as laboratory and clinical evaluations when conducting clinical trials to include healthy people in the study [<xref ref-type="bibr" rid="CR237">237</xref>]. As soon as the sponsors and health department inspectors verify safety and temporary efficacy, participants receiving a placebo in a clinical trial should have the right to obtain the vaccine, which should be guaranteed and safeguarded. This right should also be mentioned in the informed consent forms [<xref ref-type="bibr" rid="CR238">238</xref>].</p><p id="Par135">The existence of a comprehensive treatment facility is another problem, as it guarantees trial participants access to care and treatment in the event of any significant adverse events connected to the results of clinical trials [<xref ref-type="bibr" rid="CR239">239</xref>]. The right to autonomy in healthcare refers to the patient's ability to make decisions about their treatment plans based on their values, attitudes, and assessments [<xref ref-type="bibr" rid="CR240">240</xref>]. Furthermore, To "not harm" the essential and foundational tenets of medical care and research is to adhere to non-maleficence, sometimes known as "not to harm" [<xref ref-type="bibr" rid="CR241">241</xref>].The Advisory Committee states that while allocating the COVID-19 vaccine, consideration should be given to four principles: maximizing benefits and reducing harm, promoting fairness, alleviating health inequities, and encouraging transparency [<xref ref-type="bibr" rid="CR242">242</xref>].</p><p id="Par136">The principles of beneficence and non-maleficence must be approached holistically by the notion of beneficence. Public gains thus outweigh public harms. Thus, the beneficence concept merits special consideration in clinical trials and immunization programs. In order to do this, researchers should ensure that the cumulative benefits of public health interventions surpass the drawbacks and play a significant role in containing and preventing the COVID-19 outbreak, both during the vaccine development and immunization stages [<xref ref-type="bibr" rid="CR243">243</xref>].</p><p id="Par137">Furthermore, the concept of beneficence may impact the principle of autonomy in the event of a national pandemic threat. In order to vaccinate children and adolescents, accurate information regarding the immunogenicity of vaccines should be available [<xref ref-type="bibr" rid="CR233">233</xref>]. The public's willingness to accept the vaccine may be impacted by a lack of faith in the vaccine's efficacy and safety resulting from mistrust of scientific research, a lack of proof and information, exposure to false information about the vaccine, fear of politicization, and pharmaceutical industry misuse of the vaccine [<xref ref-type="bibr" rid="CR244">244</xref>]. Consequently, a reliable information system must be in place for the community to make an informed decision regarding vaccinations [<xref ref-type="bibr" rid="CR245">245</xref>].</p></sec><sec id="Sec37"><title>Conclusion and future prospects</title><p id="Par138">Finding vaccination platforms capable of achieving high immunogenicity is essential, even if therapeutic cancer vaccines represent an intriguing new frontier to overcome the long-standing cancer treatment conundrum [<xref ref-type="bibr" rid="CR246">246</xref>]. Furthermore, individual differences in tumor antigens must be addressed for an improved anti-tumor response. In order to improve clinical results, future research should concentrate on refining vaccination platforms and optimizing combination therapy to increase immunogenicity [<xref ref-type="bibr" rid="CR247">247</xref>]. Delivering cargo with predetermined release kinetics and duration of impact to a target location or site is the goal of a drug/vaccine delivery system. As vaccination research becomes more specialized and focused, we must constantly create new delivery methods to keep up with the times. While targeting and efficiency in delivery systems are essential, the safety and practicality of clinical translation of the delivery system itself should receive greater emphasis [<xref ref-type="bibr" rid="CR248">248</xref>].</p><p id="Par139">Prospective progress toward the clinical effectiveness of therapeutic cancer vaccines is focused on multiple critical domains, such as detecting immunogenic neoantigens, refining vectors and delivery systems, and overcoming the immunosuppressive tumor microenvironment. The goal of ongoing research is to improve vaccine technology. This includes investigating various expression forms, enhancing co-stimulation elements, and determining appropriate prime-boost strategies [<xref ref-type="bibr" rid="CR247">247</xref>]. Developing a therapeutic or preventive HIV vaccine is still critically important and will require ongoing research from all scientists [<xref ref-type="bibr" rid="CR201">201</xref>]. Their widespread use in the HIV vaccine was constrained by safety concerns and their incapacity to produce bNAbs. Consequently, scientists are now focusing more on a few cutting-edge vaccination approaches. The consensus or mosaic immunogens were created by in silico analysis of global HIV-1 sequences to give maximum coverage of viral sequence variety and address the genetic diversity of HIV-1 strains circulating worldwide [<xref ref-type="bibr" rid="CR202">202</xref>].</p><p id="Par140">In order to prevent unintended reactions, peptide-based vaccinations may also enable the choice of adjuvants that effectively modulate the immune system as needed. Depending on further research, this might be used as a better option than the existing mRNA, viral vector, and dormant entire virus vaccines [<xref ref-type="bibr" rid="CR249">249</xref>]. Minimum vaccine-associated effects will be crucial as risk&#8211;benefit ratios become more contentious as disease prevalence drops. However, achieving zero risk is unachievable, and there will always be a conflict between the imperatives of public health and the regulatory need to mitigate even hypothetical and distant threats [<xref ref-type="bibr" rid="CR250">250</xref>].</p><p id="Par141">Motivated by their success in COVID-19, BioNtech is developing a vaccine based on mRNA technology and the R21 and PfSPZ vaccines. This strategy might solve the difficulties in developing a malaria vaccine, such as the parasite's ability to evade immune defenses. An mRNA malaria vaccine is anticipated to be very effective, simple to produce, and safe for everyone [<xref ref-type="bibr" rid="CR251">251</xref>]. Patients with prevalent infections may also be predicted to be free of infections caused by other forms of HPV. Prophylactic HPV vaccinations to prevent disease caused by residual disease or neoplastic cells that persist after therapy have limited scientific validity. Additional research, as well as clinical trials, are required [<xref ref-type="bibr" rid="CR252">252</xref>]. The future of biomedical science in vaccine development holds promise, with anticipated advancements in personalized medicine, nanotechnology, and artificial intelligence (AI) poised to revolutionize research and clinical practice [<xref ref-type="bibr" rid="CR253">253</xref>].</p><p id="Par142">The transformative impact of biomedical science on vaccine development is evident through advances in both prophylactic and therapeutic approaches. With significant progress in virology, immunology, and molecular biology, innovations like mRNA vaccines and reverse vaccinology have reshaped how vaccines are designed, making them more effective and allowing rapid responses to emerging health threats. These developments have paved the way for a new era of precision in vaccine creation. Despite these advancements, the journey remains complex. Challenges such as stringent regulatory frameworks, emerging diseases, market uncertainties, and vaccine hesitancy still pose significant hurdles. Addressing these requires a concerted effort from scientists, healthcare professionals, regulators, and global public health organizations. Public education and trust-building initiatives will play a critical role in ensuring broader acceptance and uptake of vaccines. The future of vaccine development looks promising with the integration of cutting-edge technologies like AI, nanotechnology, and personalized medicine. These advancements can revolutionize vaccine production by shortening development timelines, tailoring vaccines to individual needs, and improving overall clinical outcomes. As the field progresses, interdisciplinary collaboration will remain essential to overcoming existing barriers and fostering innovation. By leveraging ongoing scientific breakthroughs, the potential for more efficient, accessible, and effective vaccines becomes increasingly tangible. These innovations promise to improve global health and ensure a more resilient and prepared response to future pandemics and infectious disease threats. The continuous evolution of the biomedical field will be vital in shaping a healthier future for all.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>RNA</term><def><p id="Par2">Ribonucleic Acid</p></def></def-item><def-item><term>mRNA</term><def><p id="Par3">Messenger Ribonucleic Acid</p></def></def-item><def-item><term>DNA</term><def><p id="Par4">Deoxyribonucleic Acid</p></def></def-item><def-item><term>HIV</term><def><p id="Par5">Human Immunodeficiency Virus</p></def></def-item><def-item><term>HPV</term><def><p id="Par6">Human Papillomavirus</p></def></def-item><def-item><term>IND</term><def><p id="Par7">Investigational New Drug</p></def></def-item><def-item><term>FDA</term><def><p id="Par8">Food and Drug Administration</p></def></def-item><def-item><term>ABM</term><def><p id="Par9">Agent-based Modelling</p></def></def-item><def-item><term>NITAG</term><def><p id="Par10">National Immunization Technical Advisory Group</p></def></def-item><def-item><term>DCs</term><def><p id="Par11">Dendritic Cells</p></def></def-item><def-item><term>TB</term><def><p id="Par12">Tuberculosis</p></def></def-item><def-item><term>GSK</term><def><p id="Par13">GlaxoSmithKline</p></def></def-item><def-item><term>BCG</term><def><p id="Par14">Bacillus Calmette-Guerin</p></def></def-item><def-item><term>ART</term><def><p id="Par15">Antiretroviral Therapy</p></def></def-item><def-item><term>CIM</term><def><p id="Par16">Center of Molecular Immunology</p></def></def-item><def-item><term>EGF</term><def><p id="Par17">Epidermal Growth Factor</p></def></def-item><def-item><term>PRRs</term><def><p id="Par18">Pattern Recognition Receptors</p></def></def-item><def-item><term>APCs</term><def><p id="Par19">Antigen-Presenting cells</p></def></def-item><def-item><term>LNPs</term><def><p id="Par20">Lipid Nanoparticles</p></def></def-item><def-item><term>HA</term><def><p id="Par21">Hemagglutinin</p></def></def-item><def-item><term>CMV</term><def><p id="Par22">Cytomegalovirus</p></def></def-item><def-item><term>RSV</term><def><p id="Par23">Respiratory Syncytial Virus</p></def></def-item><def-item><term>IRVs</term><def><p id="Par24">Inactivated Rabies Vaccines</p></def></def-item><def-item><term>TAAS</term><def><p id="Par25">Tumor-Associated Antigens</p></def></def-item><def-item><term>GBM</term><def><p id="Par26">Glioblastoma</p></def></def-item><def-item><term>NSCLCs</term><def><p id="Par27">Non-small Cell Lung Cancers</p></def></def-item><def-item><term>TNBC</term><def><p id="Par28">Triple Negative Breast Cancer</p></def></def-item><def-item><term>CTL</term><def><p id="Par29">Cytotoxic T cell</p></def></def-item><def-item><term>CFTR</term><def><p id="Par30">Cystic Fibrosis Transmembrane Conductance Regulator</p></def></def-item><def-item><term>NTPs</term><def><p id="Par31">Nucleotide Triphosphates</p></def></def-item><def-item><term>VZV</term><def><p id="Par32">Varicella Zoster Virus</p></def></def-item><def-item><term>VLPs</term><def><p id="Par33">Virus-like Particles</p></def></def-item><def-item><term>HBsAg</term><def><p id="Par34">Hepatitis B surface Antigen</p></def></def-item><def-item><term>DSB</term><def><p id="Par35">Double-Strand Break</p></def></def-item><def-item><term>AAV</term><def><p id="Par36">Adeno-associated Virus</p></def></def-item><def-item><term>RSVF</term><def><p id="Par37">Respiratory Syncytial Virus Fusion</p></def></def-item><def-item><term>RBD</term><def><p id="Par38">Receptor-Binding Domain</p></def></def-item><def-item><term>CDC</term><def><p id="Par39">Centers for Disease Control and Prevention</p></def></def-item><def-item><term>WHO</term><def><p id="Par40">World Health Organization</p></def></def-item><def-item><term>AI</term><def><p id="Par41">Artificial Intelligence</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to convey our special thanks to the research house of the institution.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>Induni Nayodhara Weerarathna: Conceptualization, Methodology, Data visualization, Writing original draft, Visualization, Creating figures. Elijah Skarlus Doelakeh: Writing- review and editing. Lydia Kiwanuka: Writing- review and editing. Praveen Kumar: Methodology, Review and editing, Visualization, Supervision. Sanvi Arora: Writing- review and editing.&#160;All authors have read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Datta Meghe Institute of Higher Education and Research.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar5"><title>Ethics approval and consent to participate</title><p id="Par143">Not applicable.</p></notes><notes id="FPar6"><title>Consent for publication</title><p id="Par144">All authors provide their consent for the publication of this review article. We confirm that all data and information presented in this article have been obtained, analyzed, and reported in accordance with ethical standards and guidelines. There are no individual person&#8217;s data included in the manuscript that would require additional consent for publication.</p></notes><notes id="FPar7" notes-type="COI-statement"><title>Competing interests</title><p id="Par145">The authors declare no conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omboni</surname><given-names>S</given-names></name><name name-style="western"><surname>Padwal</surname><given-names>RS</given-names></name><name name-style="western"><surname>Alessa</surname><given-names>T</given-names></name><name name-style="western"><surname>Bencz&#250;r</surname><given-names>B</given-names></name><name name-style="western"><surname>Green</surname><given-names>BB</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>I</given-names></name><etal/></person-group><article-title>The worldwide impact of telemedicine during COVID-19: current evidence and recommendations for the future</article-title><source>Connect Health</source><year>2022</year><volume>1</volume><fpage>7</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.20517/ch.2021.03</pub-id><pub-id pub-id-type="pmid">35233563</pub-id><pub-id pub-id-type="pmcid">PMC7612439</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Omboni S, Padwal RS, Alessa T, Bencz&#250;r B, Green BB, Hubbard I, et al. The worldwide impact of telemedicine during COVID-19: current evidence and recommendations for the future. Connect Health. 2022;1:7&#8211;35. 10.20517/ch.2021.03.<pub-id pub-id-type="pmid">35233563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20517/ch.2021.03</pub-id><pub-id pub-id-type="pmcid">PMC7612439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimka</surname><given-names>J</given-names></name><name name-style="western"><surname>van Doren</surname><given-names>TP</given-names></name><name name-style="western"><surname>Battles</surname><given-names>HT</given-names></name></person-group><article-title>Pandemics, past and present: the role of biological anthropology in interdisciplinary pandemic studies</article-title><source>Am J Biol Anthropol</source><year>2022</year><volume>178</volume><fpage>256</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1002/ajpa.24517</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Dimka J, van Doren TP, Battles HT. Pandemics, past and present: the role of biological anthropology in interdisciplinary pandemic studies. Am J Biol Anthropol. 2022;178:256&#8211;91. 10.1002/ajpa.24517.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Handlovsky</surname><given-names>I</given-names></name><name name-style="western"><surname>Wonsiak</surname><given-names>T</given-names></name><name name-style="western"><surname>Amato</surname><given-names>AT</given-names></name><name name-style="western"><surname>Halpin</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferlatte</surname><given-names>O</given-names></name><name name-style="western"><surname>Kia</surname><given-names>H</given-names></name></person-group><article-title>Between two pandemics: older, gay men&#8217;s experiences across HIV/AIDS and COVID-19</article-title><source>Ssm Qual Res Health</source><year>2023</year><volume>3</volume><fpage>100233</fpage><pub-id pub-id-type="doi">10.1016/j.ssmqr.2023.100233</pub-id><pub-id pub-id-type="pmid">36777813</pub-id><pub-id pub-id-type="pmcid">PMC9905043</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Handlovsky I, Wonsiak T, Amato AT, Halpin M, Ferlatte O, Kia H. Between two pandemics: older, gay men&#8217;s experiences across HIV/AIDS and COVID-19. Ssm Qual Res Health. 2023;3:100233. 10.1016/j.ssmqr.2023.100233.<pub-id pub-id-type="pmid">36777813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ssmqr.2023.100233</pub-id><pub-id pub-id-type="pmcid">PMC9905043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Excler</surname><given-names>J-L</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M</given-names></name><name name-style="western"><surname>Privor-Dumm</surname><given-names>L</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S</given-names></name><name name-style="western"><surname>Hortez</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P</given-names></name><etal/></person-group><article-title>Factors, enablers and challenges for COVID-19 vaccine development</article-title><source>BMJ Glob Health</source><year>2023</year><volume>8</volume><fpage>e011879</fpage><pub-id pub-id-type="doi">10.1136/bmjgh-2023-011879</pub-id><pub-id pub-id-type="pmid">37277195</pub-id><pub-id pub-id-type="pmcid">PMC10255030</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Excler J-L, Saville M, Privor-Dumm L, Gilbert S, Hortez PJ, Thompson P, et al. Factors, enablers and challenges for COVID-19 vaccine development. BMJ Glob Health. 2023;8:e011879. 10.1136/bmjgh-2023-011879.<pub-id pub-id-type="pmid">37277195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjgh-2023-011879</pub-id><pub-id pub-id-type="pmcid">PMC10255030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>K-B</given-names></name><name name-style="western"><surname>Quan</surname><given-names>F-S</given-names></name></person-group><article-title>Respiratory viruses and virus-like particle vaccine development: how far have we advanced?</article-title><source>Viruses</source><year>2023</year><volume>15</volume><fpage>392</fpage><pub-id pub-id-type="doi">10.3390/v15020392</pub-id><pub-id pub-id-type="pmid">36851606</pub-id><pub-id pub-id-type="pmcid">PMC9965150</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Chu K-B, Quan F-S. Respiratory viruses and virus-like particle vaccine development: how far have we advanced? Viruses. 2023;15:392. 10.3390/v15020392.<pub-id pub-id-type="pmid">36851606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v15020392</pub-id><pub-id pub-id-type="pmcid">PMC9965150</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeill</surname><given-names>VF</given-names></name></person-group><article-title>Airborne transmission of SARS-CoV-2: evidence and implications for engineering controls</article-title><source>Annu Rev Chem Biomol Eng</source><year>2022</year><volume>13</volume><fpage>123</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1146/annurev-chembioeng-092220-111631</pub-id><pub-id pub-id-type="pmid">35300517</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">McNeill VF. Airborne transmission of SARS-CoV-2: evidence and implications for engineering controls. Annu Rev Chem Biomol Eng. 2022;13:123&#8211;40. 10.1146/annurev-chembioeng-092220-111631.<pub-id pub-id-type="pmid">35300517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-chembioeng-092220-111631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porter-Stransky</surname><given-names>KA</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>K</given-names></name><name name-style="western"><surname>VanDerKolk</surname><given-names>K</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>RA</given-names></name><name name-style="western"><surname>Graves</surname><given-names>LE</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E</given-names></name><etal/></person-group><article-title>How medical students apply their biomedical science knowledge to patient care in the family medicine clerkship</article-title><source>Med Sci Educ</source><year>2022</year><volume>33</volume><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s40670-022-01697-5</pub-id><pub-id pub-id-type="pmid">36467744</pub-id><pub-id pub-id-type="pmcid">PMC9702919</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Porter-Stransky KA, Gibson K, VanDerKolk K, Edwards RA, Graves LE, Smith E, et al. How medical students apply their biomedical science knowledge to patient care in the family medicine clerkship. Med Sci Educ. 2022;33:63&#8211;72. 10.1007/s40670-022-01697-5.<pub-id pub-id-type="pmid">36467744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40670-022-01697-5</pub-id><pub-id pub-id-type="pmcid">PMC9702919</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>D-G</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H-J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M-H</given-names></name><etal/></person-group><article-title>Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel Coronavirus Disease 2019 (COVID-19)</article-title><source>J Microbiol Biotechnol</source><year>2020</year><volume>30</volume><fpage>313</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.4014/jmb.2003.03011</pub-id><pub-id pub-id-type="pmid">32238757</pub-id><pub-id pub-id-type="pmcid">PMC9728410</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ahn D-G, Shin H-J, Kim M-H, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30:313&#8211;24. 10.4014/jmb.2003.03011.<pub-id pub-id-type="pmid">32238757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4014/jmb.2003.03011</pub-id><pub-id pub-id-type="pmcid">PMC9728410</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Odenthal</surname><given-names>M</given-names></name><name name-style="western"><surname>Fries</surname><given-names>JWU</given-names></name></person-group><article-title>Exosomes as miRNA carriers: formation&#8211;function&#8211;future</article-title><source>Int J Mol Sci</source><year>2028</year><volume>2016</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.3390/ijms17122028</pub-id><pub-id pub-id-type="pmcid">PMC5187828</pub-id><pub-id pub-id-type="pmid">27918449</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Yu X, Odenthal M, Fries JWU. Exosomes as miRNA carriers: formation&#8211;function&#8211;future. Int J Mol Sci. 2028;2016:17. 10.3390/ijms17122028.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms17122028</pub-id><pub-id pub-id-type="pmcid">PMC5187828</pub-id><pub-id pub-id-type="pmid">27918449</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Rando HM, Lordan R, Kolla L, Sell E,Lee AJ, Wellhausen N, et al.: The Coming of Age of Nucleic Acid Vaccines during COVID-19. mSystems. 8:e00928&#8211;22. 10.1128/msystems.00928-22<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/msystems.00928-22</pub-id><pub-id pub-id-type="pmcid">PMC10134841</pub-id><pub-id pub-id-type="pmid">36861992</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shapiro</surname><given-names>SZ</given-names></name></person-group><article-title>HIV vaccine development: 35 years of experimenting in the funding of biomedical research</article-title><source>Viruses</source><year>2020</year><volume>12</volume><fpage>1469</fpage><pub-id pub-id-type="doi">10.3390/v12121469</pub-id><pub-id pub-id-type="pmid">33352755</pub-id><pub-id pub-id-type="pmcid">PMC7767134</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Shapiro SZ. HIV vaccine development: 35 years of experimenting in the funding of biomedical research. Viruses. 2020;12:1469. 10.3390/v12121469.<pub-id pub-id-type="pmid">33352755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v12121469</pub-id><pub-id pub-id-type="pmcid">PMC7767134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>MJ</given-names></name></person-group><article-title>Recent advances in vaccine technologies</article-title><source>Vet Clin North Am Small Anim Pract</source><year>2018</year><volume>48</volume><fpage>231</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/j.cvsm.2017.10.002</pub-id><pub-id pub-id-type="pmid">29217317</pub-id><pub-id pub-id-type="pmcid">PMC7132473</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Francis MJ. Recent advances in vaccine technologies. Vet Clin North Am Small Anim Pract. 2018;48:231&#8211;41. 10.1016/j.cvsm.2017.10.002.<pub-id pub-id-type="pmid">29217317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cvsm.2017.10.002</pub-id><pub-id pub-id-type="pmcid">PMC7132473</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Saleh A, Qamar S, Tekin A, Singh R, Kashyap R: Vaccine Development Throughout History. Cureus. Published Online First: 26 July 2021. 10.7759/cureus.16635.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.16635</pub-id><pub-id pub-id-type="pmcid">PMC8386248</pub-id><pub-id pub-id-type="pmid">34462676</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Sahu U, Khare P: Evolution and development of vaccines against major human infections. In: System Vaccinology. Elsevier; 2022. 17&#8211;30.10.1016/B978-0-323-85941-7.00011-5.</mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rawal</surname><given-names>K</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>R</given-names></name><name name-style="western"><surname>Abbasi</surname><given-names>BA</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>A</given-names></name><name name-style="western"><surname>Nath</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>P</given-names></name><etal/></person-group><article-title>Identification of vaccine targets in pathogens and design of a vaccine using computational approaches</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>17626</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-96863-x</pub-id><pub-id pub-id-type="pmid">34475453</pub-id><pub-id pub-id-type="pmcid">PMC8413327</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Rawal K, Sinha R, Abbasi BA, Chaudhary A, Nath SK, Kumari P, et al. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci Rep. 2021;11:17626. 10.1038/s41598-021-96863-x.<pub-id pub-id-type="pmid">34475453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-96863-x</pub-id><pub-id pub-id-type="pmcid">PMC8413327</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McArthur</surname><given-names>DB</given-names></name></person-group><article-title>Emerging infectious diseases</article-title><source>Nurs Clin North Am</source><year>2019</year><volume>54</volume><fpage>297</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.cnur.2019.02.006</pub-id><pub-id pub-id-type="pmid">31027668</pub-id><pub-id pub-id-type="pmcid">PMC7096727</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">McArthur DB. Emerging infectious diseases. Nurs Clin North Am. 2019;54:297&#8211;311. 10.1016/j.cnur.2019.02.006.<pub-id pub-id-type="pmid">31027668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cnur.2019.02.006</pub-id><pub-id pub-id-type="pmcid">PMC7096727</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">In brief: The innate and adaptive immune systems. In: InformedHealth.org . Institute for Quality and Efficiency in Health Care (IQWiG); 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK279396">https://www.ncbi.nlm.nih.gov/books/NBK279396</ext-link>.</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">17.2: Innate Immunity. Biol. Libr. 2017. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://bio.libretexts.org/Bookshelves/Introductory_and_General_Biology/Concepts_in_Biology_(OpenStax)/17%3A_The_Immune_System_and_Disease/17.02%3A_Innate_Immunity">https://bio.libretexts.org/Bookshelves/Introductory_and_General_Biology/Concepts_in_Biology_(OpenStax)/17%3A_The_Immune_System_and_Disease/17.02%3A_Innate_Immunity</ext-link>. Accessed 6 Sept 2024.</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clem</surname><given-names>AS</given-names></name></person-group><article-title>Fundamentals of vaccine immunology</article-title><source>J Glob Infect Dis</source><year>2011</year><volume>3</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.4103/0974-777X.77299</pub-id><pub-id pub-id-type="pmid">21572612</pub-id><pub-id pub-id-type="pmcid">PMC3068582</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3:73&#8211;8. 10.4103/0974-777X.77299.<pub-id pub-id-type="pmid">21572612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0974-777X.77299</pub-id><pub-id pub-id-type="pmcid">PMC3068582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Justiz Vaillant AA, Sabir S, Jan A: Physiology, Immune Response. In: StatPearls. StatPearls Publishing: Treasure Island (FL); 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK539801">https://www.ncbi.nlm.nih.gov/books/NBK539801</ext-link>.<pub-id pub-id-type="pmid">30969623</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>JC</given-names></name><name name-style="western"><surname>Ugolini</surname><given-names>S</given-names></name><name name-style="western"><surname>Vivier</surname><given-names>E</given-names></name></person-group><article-title>Immunological memory within the innate immune system</article-title><source>EMBO J</source><year>2014</year><volume>33</volume><fpage>1295</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1002/embj.201387651</pub-id><pub-id pub-id-type="pmid">24674969</pub-id><pub-id pub-id-type="pmcid">PMC4194120</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Sun JC, Ugolini S, Vivier E. Immunological memory within the innate immune system. EMBO J. 2014;33:1295&#8211;303. 10.1002/embj.201387651.<pub-id pub-id-type="pmid">24674969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/embj.201387651</pub-id><pub-id pub-id-type="pmcid">PMC4194120</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Charles A Janeway J, Travers P, Walport M, Shlomchik MJ: Immunological memory. In: Immunobiology: The Immune System in Health and Disease. 5th edition. Garland Science; 2001. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK10757">https://www.ncbi.nlm.nih.gov/books/NBK10757</ext-link>.</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Baron S, editor: Introduction to Virology. In: Medical Microbiology. University of Texas Medical Branch at Galveston: Galveston (TX); 1996. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK8098">https://www.ncbi.nlm.nih.gov/books/NBK8098</ext-link>.<pub-id pub-id-type="pmid">21413295</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P: Introduction to Pathogens. In: Molecular Biology of the Cell. 4th edition. Garland Science; 2002. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK21054">https://www.ncbi.nlm.nih.gov/books/NBK21054</ext-link>.</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balloux</surname><given-names>F</given-names></name><name name-style="western"><surname>van Dorp</surname><given-names>L</given-names></name></person-group><article-title>Q&amp;A: what are pathogens, and what have they done to and for us?</article-title><source>BMC Biol</source><year>2017</year><volume>15</volume><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s12915-017-0433-z</pub-id><pub-id pub-id-type="pmid">29052511</pub-id><pub-id pub-id-type="pmcid">PMC5648414</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Balloux F, van Dorp L. Q&amp;A: what are pathogens, and what have they done to and for us? BMC Biol. 2017;15:91. 10.1186/s12915-017-0433-z.<pub-id pub-id-type="pmid">29052511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12915-017-0433-z</pub-id><pub-id pub-id-type="pmcid">PMC5648414</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P: Introduction to Pathogens. In: Molecular Biology of the Cell. 4th edition. Garland Science; 2002.</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Mukhopadhyay R, Nath S, Kumar D, Sahana N, Mandal S: Basics of the Molecular Biology: From Genes to Its Function. In: Anjoy P, Kumar K, Chandra G, Gaikwad K, eds. Genomics Data Analysis for Crop Improvement. Springer Nature: Singapore; 2024. 343&#8211;74.10.1007/978-981-99-6913-5_14.</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Biology NRC (US) C on RO in: Molecular Structure and Function. In: Opportunities in Biology. National Academies Press (US); 1989. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK217812">https://www.ncbi.nlm.nih.gov/books/NBK217812</ext-link>.</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobson</surname><given-names>CS</given-names></name><name name-style="western"><surname>Reich</surname><given-names>AN</given-names></name><name name-style="western"><surname>Gaglione</surname><given-names>S</given-names></name><etal/></person-group><article-title>Antigen identification and high-throughput interaction mapping by reprogramming viral entry</article-title><source>Nat Methods</source><year>2022</year><volume>19</volume><fpage>449</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/s41592-022-01436-z</pub-id><pub-id pub-id-type="pmid">35396484</pub-id><pub-id pub-id-type="pmcid">PMC9012700</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Dobson CS, Reich AN, Gaglione S, et al. Antigen identification and high-throughput interaction mapping by reprogramming viral entry. Nat Methods. 2022;19:449&#8211;60. 10.1038/s41592-022-01436-z.<pub-id pub-id-type="pmid">35396484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41592-022-01436-z</pub-id><pub-id pub-id-type="pmcid">PMC9012700</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>JS</given-names></name><name name-style="western"><surname>Warrington</surname><given-names>R</given-names></name><name name-style="western"><surname>Watson</surname><given-names>W</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HL</given-names></name></person-group><article-title>An introduction to immunology and immunopathology</article-title><source>Allergy Asthma Clin Immunol</source><year>2018</year><volume>14</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s13223-018-0278-1</pub-id><pub-id pub-id-type="pmid">30263032</pub-id><pub-id pub-id-type="pmcid">PMC6156898</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2018;14:49. 10.1186/s13223-018-0278-1.<pub-id pub-id-type="pmid">30263032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13223-018-0278-1</pub-id><pub-id pub-id-type="pmcid">PMC6156898</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiller</surname><given-names>JT</given-names></name><name name-style="western"><surname>Lowy</surname><given-names>DR</given-names></name></person-group><article-title>Vaccines to prevent infections by oncoviruses</article-title><source>Annu Rev Microbiol</source><year>2010</year><volume>64</volume><fpage>23</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1146/annurev.micro.112408.134019</pub-id><pub-id pub-id-type="pmid">20420520</pub-id><pub-id pub-id-type="pmcid">PMC6264788</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Schiller JT, Lowy DR. Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol. 2010;64:23&#8211;41. 10.1146/annurev.micro.112408.134019.<pub-id pub-id-type="pmid">20420520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.micro.112408.134019</pub-id><pub-id pub-id-type="pmcid">PMC6264788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>C</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>M</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K</given-names></name></person-group><article-title>SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>682</fpage><pub-id pub-id-type="doi">10.3390/vaccines11030682</pub-id><pub-id pub-id-type="pmid">36992266</pub-id><pub-id pub-id-type="pmcid">PMC10054865</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Chakraborty C, Bhattacharya M, Dhama K. SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic. Vaccines. 2023;11:682. 10.3390/vaccines11030682.<pub-id pub-id-type="pmid">36992266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11030682</pub-id><pub-id pub-id-type="pmcid">PMC10054865</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenwood</surname><given-names>B</given-names></name></person-group><article-title>The contribution of vaccination to global health: past, present and future</article-title><source>Philos Trans R Soc B Biol Sci</source><year>2014</year><volume>369</volume><fpage>20130433</fpage><pub-id pub-id-type="doi">10.1098/rstb.2013.0433</pub-id><pub-id pub-id-type="pmcid">PMC4024226</pub-id><pub-id pub-id-type="pmid">24821919</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc B Biol Sci. 2014;369:20130433. 10.1098/rstb.2013.0433.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rstb.2013.0433</pub-id><pub-id pub-id-type="pmcid">PMC4024226</pub-id><pub-id pub-id-type="pmid">24821919</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chabot</surname><given-names>I</given-names></name><name name-style="western"><surname>Goetghebeur</surname><given-names>MM</given-names></name><name name-style="western"><surname>Gr&#233;goire</surname><given-names>J-P</given-names></name></person-group><article-title>The societal value of universal childhood vaccination</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>1992</fpage><lpage>2005</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.10.027</pub-id><pub-id pub-id-type="pmid">15121312</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Chabot I, Goetghebeur MM, Gr&#233;goire J-P. The societal value of universal childhood vaccination. Vaccine. 2004;22:1992&#8211;2005. 10.1016/j.vaccine.2003.10.027.<pub-id pub-id-type="pmid">15121312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2003.10.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hong</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Nam</surname><given-names>J</given-names></name></person-group><article-title>Influenza vaccines: Past, present, and future</article-title><source>Rev Med Virol</source><year>2022</year><volume>32</volume><fpage>e2243</fpage><pub-id pub-id-type="doi">10.1002/rmv.2243</pub-id><pub-id pub-id-type="pmid">33949021</pub-id><pub-id pub-id-type="pmcid">PMC8209895</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Kim Y, Hong K, Kim H, Nam J. Influenza vaccines: Past, present, and future. Rev Med Virol. 2022;32:e2243. 10.1002/rmv.2243.<pub-id pub-id-type="pmid">33949021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rmv.2243</pub-id><pub-id pub-id-type="pmcid">PMC8209895</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>S</given-names></name></person-group><article-title>Clinical vaccine development</article-title><source>Clin Exp Vaccine Res</source><year>2015</year><volume>4</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.7774/cevr.2015.4.1.46</pub-id><pub-id pub-id-type="pmid">25648742</pub-id><pub-id pub-id-type="pmcid">PMC4313108</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Han S. Clinical vaccine development. Clin Exp Vaccine Res. 2015;4:46. 10.7774/cevr.2015.4.1.46.<pub-id pub-id-type="pmid">25648742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7774/cevr.2015.4.1.46</pub-id><pub-id pub-id-type="pmcid">PMC4313108</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilleman</surname><given-names>MR</given-names></name></person-group><article-title>Vaccines in historic evolution and perspective: a narrative of vaccine discoveries</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>1436</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00434-X</pub-id><pub-id pub-id-type="pmid">10618541</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine. 2000;18:1436&#8211;47. 10.1016/S0264-410X(99)00434-X.<pub-id pub-id-type="pmid">10618541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(99)00434-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilbourne</surname><given-names>ED</given-names></name></person-group><article-title>Influenza pandemics of the 20th century</article-title><source>Emerg Infect Dis</source><year>2006</year><volume>12</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.3201/eid1201.051254</pub-id><pub-id pub-id-type="pmid">16494710</pub-id><pub-id pub-id-type="pmcid">PMC3291411</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12:9&#8211;14. 10.3201/eid1201.051254.<pub-id pub-id-type="pmid">16494710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1201.051254</pub-id><pub-id pub-id-type="pmcid">PMC3291411</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gostin</surname><given-names>LO</given-names></name><name name-style="western"><surname>Lucey</surname><given-names>D</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>A</given-names></name></person-group><article-title>The ebola epidemic: a global health emergency</article-title><source>JAMA</source><year>2014</year><volume>312</volume><fpage>1095</fpage><pub-id pub-id-type="doi">10.1001/jama.2014.11176</pub-id><pub-id pub-id-type="pmid">25111044</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Gostin LO, Lucey D, Phelan A. The ebola epidemic: a global health emergency. JAMA. 2014;312:1095. 10.1001/jama.2014.11176.<pub-id pub-id-type="pmid">25111044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2014.11176</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonanni</surname><given-names>P</given-names></name><name name-style="western"><surname>Zanella</surname><given-names>B</given-names></name><name name-style="western"><surname>Santomauro</surname><given-names>F</given-names></name><name name-style="western"><surname>Lorini</surname><given-names>C</given-names></name><name name-style="western"><surname>Bechini</surname><given-names>A</given-names></name><name name-style="western"><surname>Boccalini</surname><given-names>S</given-names></name></person-group><article-title>Safety and perception: what are the greatest enemies of HPV vaccination programmes?</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>5424</fpage><lpage>5429</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.071</pub-id><pub-id pub-id-type="pmid">28610824</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Bonanni P, Zanella B, Santomauro F, Lorini C, Bechini A, Boccalini S. Safety and perception: what are the greatest enemies of HPV vaccination programmes? Vaccine. 2018;36:5424&#8211;9. 10.1016/j.vaccine.2017.05.071.<pub-id pub-id-type="pmid">28610824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.05.071</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bechini</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonanni</surname><given-names>P</given-names></name><name name-style="western"><surname>Zanella</surname><given-names>B</given-names></name><etal/></person-group><article-title>Vaccine production process: how much does the general population know about this topic?</article-title><source>A Web-Based Survey Vaccines</source><year>2021</year><volume>9</volume><fpage>564</fpage><pub-id pub-id-type="doi">10.3390/vaccines9060564</pub-id><pub-id pub-id-type="pmid">34072288</pub-id><pub-id pub-id-type="pmcid">PMC8229207</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Bechini A, Bonanni P, Zanella B, et al. Vaccine production process: how much does the general population know about this topic? A Web-Based Survey Vaccines. 2021;9:564. 10.3390/vaccines9060564.<pub-id pub-id-type="pmid">34072288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9060564</pub-id><pub-id pub-id-type="pmcid">PMC8229207</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefanoff</surname><given-names>P</given-names></name><name name-style="western"><surname>Mamelund</surname><given-names>S-E</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tracking parental attitudes on vaccination across European countries: The Vaccine Safety, Attitudes, Training and Communication Project (VACSATC)</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>5731</fpage><lpage>5737</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.06.009</pub-id><pub-id pub-id-type="pmid">20558250</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Stefanoff P, Mamelund S-E, Robinson M, et al. Tracking parental attitudes on vaccination across European countries: The Vaccine Safety, Attitudes, Training and Communication Project (VACSATC). Vaccine. 2010;28:5731&#8211;7. 10.1016/j.vaccine.2010.06.009.<pub-id pub-id-type="pmid">20558250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.06.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harmsen</surname><given-names>IA</given-names></name><name name-style="western"><surname>Mollema</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruiter</surname><given-names>RA</given-names></name><name name-style="western"><surname>Paulussen</surname><given-names>TG</given-names></name><name name-style="western"><surname>De Melker</surname><given-names>HE</given-names></name><name name-style="western"><surname>Kok</surname><given-names>G</given-names></name></person-group><article-title>Why parents refuse childhood vaccination: a qualitative study using online focus groups</article-title><source>BMC Public Health</source><year>2013</year><volume>13</volume><fpage>1183</fpage><pub-id pub-id-type="doi">10.1186/1471-2458-13-1183</pub-id><pub-id pub-id-type="pmid">24341406</pub-id><pub-id pub-id-type="pmcid">PMC3878652</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Harmsen IA, Mollema L, Ruiter RA, Paulussen TG, De Melker HE, Kok G. Why parents refuse childhood vaccination: a qualitative study using online focus groups. BMC Public Health. 2013;13:1183. 10.1186/1471-2458-13-1183.<pub-id pub-id-type="pmid">24341406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2458-13-1183</pub-id><pub-id pub-id-type="pmcid">PMC3878652</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>While</surname><given-names>AE</given-names></name><name name-style="western"><surname>Norman</surname><given-names>IJ</given-names></name></person-group><article-title>Knowledge and attitudes regarding influenza vaccination among nurses: a research review</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>7207</fpage><lpage>7214</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.08.065</pub-id><pub-id pub-id-type="pmid">20804802</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Zhang J, While AE, Norman IJ. Knowledge and attitudes regarding influenza vaccination among nurses: a research review. Vaccine. 2010;28:7207&#8211;14. 10.1016/j.vaccine.2010.08.065.<pub-id pub-id-type="pmid">20804802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.08.065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gualano</surname><given-names>M</given-names></name><name name-style="western"><surname>Olivero</surname><given-names>E</given-names></name><name name-style="western"><surname>Voglino</surname><given-names>G</given-names></name><etal/></person-group><article-title>Knowledge, attitudes and beliefs towards compulsory vaccination: a systematic review</article-title><source>Hum Vaccines Immunother</source><year>2019</year><volume>15</volume><fpage>918</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1564437</pub-id><pub-id pub-id-type="pmcid">PMC6605844</pub-id><pub-id pub-id-type="pmid">30633626</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Gualano M, Olivero E, Voglino G, et al. Knowledge, attitudes and beliefs towards compulsory vaccination: a systematic review. Hum Vaccines Immunother. 2019;15:918&#8211;31. 10.1080/21645515.2018.1564437.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2018.1564437</pub-id><pub-id pub-id-type="pmcid">PMC6605844</pub-id><pub-id pub-id-type="pmid">30633626</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geoghegan</surname><given-names>S</given-names></name><name name-style="western"><surname>O&#8217;Callaghan</surname><given-names>KP</given-names></name><name name-style="western"><surname>Offit</surname><given-names>PA</given-names></name></person-group><article-title>Vaccine safety: myths and misinformation</article-title><source>Front Microbiol</source><year>2020</year><volume>11</volume><fpage>372</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.00372</pub-id><pub-id pub-id-type="pmid">32256465</pub-id><pub-id pub-id-type="pmcid">PMC7090020</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Geoghegan S, O&#8217;Callaghan KP, Offit PA. Vaccine safety: myths and misinformation. Front Microbiol. 2020;11:372. 10.3389/fmicb.2020.00372.<pub-id pub-id-type="pmid">32256465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2020.00372</pub-id><pub-id pub-id-type="pmcid">PMC7090020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az Crescitelli</surname><given-names>ME</given-names></name><name name-style="western"><surname>Ghirotto</surname><given-names>L</given-names></name><name name-style="western"><surname>Sisson</surname><given-names>H</given-names></name><etal/></person-group><article-title>A meta-synthesis study of the key elements involved in childhood vaccine hesitancy</article-title><source>Public Health</source><year>2020</year><volume>180</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.puhe.2019.10.027</pub-id><pub-id pub-id-type="pmid">31838344</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">D&#237;az Crescitelli ME, Ghirotto L, Sisson H, et al. A meta-synthesis study of the key elements involved in childhood vaccine hesitancy. Public Health. 2020;180:38&#8211;45. 10.1016/j.puhe.2019.10.027.<pub-id pub-id-type="pmid">31838344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.puhe.2019.10.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gidengil</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Parker</surname><given-names>AM</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>S</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>L</given-names></name></person-group><article-title>Beliefs around childhood vaccines in the United States: a systematic review</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>6793</fpage><lpage>6802</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.08.068</pub-id><pub-id pub-id-type="pmid">31562000</pub-id><pub-id pub-id-type="pmcid">PMC6949013</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Gidengil C, Chen C, Parker AM, Nowak S, Matthews L. Beliefs around childhood vaccines in the United States: a systematic review. Vaccine. 2019;37:6793&#8211;802. 10.1016/j.vaccine.2019.08.068.<pub-id pub-id-type="pmid">31562000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.08.068</pub-id><pub-id pub-id-type="pmcid">PMC6949013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peetermans</surname><given-names>J</given-names></name></person-group><article-title>Production, quality control and characterization of an inactivated hepatitis a vaccine</article-title><source>Vaccine</source><year>1992</year><volume>10</volume><fpage>S99</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(92)90557-Z</pub-id><pub-id pub-id-type="pmid">1335671</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Peetermans J. Production, quality control and characterization of an inactivated hepatitis a vaccine. Vaccine. 1992;10:S99&#8211;101. 10.1016/0264-410X(92)90557-Z.<pub-id pub-id-type="pmid">1335671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0264-410x(92)90557-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bechini</surname><given-names>A</given-names></name><name name-style="western"><surname>Zanobini</surname><given-names>P</given-names></name><name name-style="western"><surname>Zanella</surname><given-names>B</given-names></name><name name-style="western"><surname>Ancillotti</surname><given-names>L</given-names></name><name name-style="western"><surname>Moscadelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonanni</surname><given-names>P</given-names></name><etal/></person-group><article-title>Travelers&#8217; attitudes, behaviors, and practices on the prevention of infectious diseases: a study for Non-European destinations</article-title><source>Int J Environ Res Public Health</source><year>2021</year><volume>18</volume><fpage>3110</fpage><pub-id pub-id-type="doi">10.3390/ijerph18063110</pub-id><pub-id pub-id-type="pmid">33803553</pub-id><pub-id pub-id-type="pmcid">PMC8002973</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Bechini A, Zanobini P, Zanella B, Ancillotti L, Moscadelli A, Bonanni P, et al. Travelers&#8217; attitudes, behaviors, and practices on the prevention of infectious diseases: a study for Non-European destinations. Int J Environ Res Public Health. 2021;18:3110. 10.3390/ijerph18063110.<pub-id pub-id-type="pmid">33803553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph18063110</pub-id><pub-id pub-id-type="pmcid">PMC8002973</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Baylor NW: The regulatory evaluation of vaccines for human use. In: Thomas S, ed. Vaccine Design. Springer New York: New York, NY; 2016. 773&#8211;87. 10.1007/978-1-4939-3389-1_51.</mixed-citation></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappalardo</surname><given-names>F</given-names></name><name name-style="western"><surname>Flower</surname><given-names>D</given-names></name><name name-style="western"><surname>Russo</surname><given-names>G</given-names></name><name name-style="western"><surname>Pennisi</surname><given-names>M</given-names></name><name name-style="western"><surname>Motta</surname><given-names>S</given-names></name></person-group><article-title>Computational modelling approaches to vaccinology</article-title><source>Pharmacol Res</source><year>2015</year><volume>92</volume><fpage>40</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2014.08.006</pub-id><pub-id pub-id-type="pmid">25224605</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Pappalardo F, Flower D, Russo G, Pennisi M, Motta S. Computational modelling approaches to vaccinology. Pharmacol Res. 2015;92:40&#8211;5. 10.1016/j.phrs.2014.08.006.<pub-id pub-id-type="pmid">25224605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2014.08.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name></person-group><article-title>Reverse vaccinology</article-title><source>Curr Opin Microbiol</source><year>2000</year><volume>3</volume><issue>5</issue><fpage>445</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/s1369-5274(00)00119-3</pub-id><pub-id pub-id-type="pmid">11050440</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3(5):445&#8211;50. 10.1016/s1369-5274(00)00119-3.<pub-id pub-id-type="pmid">11050440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1369-5274(00)00119-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>J</given-names></name><name name-style="western"><surname>Mahapatra</surname><given-names>SR</given-names></name><name name-style="western"><surname>Singh</surname><given-names>PK</given-names></name><name name-style="western"><surname>Prabhuswamimath</surname><given-names>SC</given-names></name><name name-style="western"><surname>Misra</surname><given-names>N</given-names></name><name name-style="western"><surname>Suar</surname><given-names>M</given-names></name></person-group><article-title>Designing of multi-epitope peptide vaccine against Acinetobacter baumannii through combined immunoinformatics and protein interaction-based approaches</article-title><source>Immunol Res</source><year>2023</year><volume>71</volume><issue>4</issue><fpage>639</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1007/s12026-023-09374-4</pub-id><pub-id pub-id-type="pmid">37022613</pub-id><pub-id pub-id-type="pmcid">PMC10078064</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Dey J, Mahapatra SR, Singh PK, Prabhuswamimath SC, Misra N, Suar M. Designing of multi-epitope peptide vaccine against Acinetobacter baumannii through combined immunoinformatics and protein interaction-based approaches. Immunol Res. 2023;71(4):639&#8211;62. 10.1007/s12026-023-09374-4.<pub-id pub-id-type="pmid">37022613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-023-09374-4</pub-id><pub-id pub-id-type="pmcid">PMC10078064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pennisi</surname><given-names>M</given-names></name><name name-style="western"><surname>Pappalardo</surname><given-names>F</given-names></name><name name-style="western"><surname>Palladini</surname><given-names>A</given-names></name><name name-style="western"><surname>Nicoletti</surname><given-names>G</given-names></name><name name-style="western"><surname>Nanni</surname><given-names>P</given-names></name><name name-style="western"><surname>Lollini</surname><given-names>P-L</given-names></name><etal/></person-group><article-title>Modeling the competition between lung metastases and the immune system using agents</article-title><source>BMC Bioinform</source><year>2010</year><volume>11</volume><fpage>S13</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-11-S7-S13</pub-id><pub-id pub-id-type="pmcid">PMC2957681</pub-id><pub-id pub-id-type="pmid">21106120</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Pennisi M, Pappalardo F, Palladini A, Nicoletti G, Nanni P, Lollini P-L, et al. Modeling the competition between lung metastases and the immune system using agents. BMC Bioinform. 2010;11:S13. 10.1186/1471-2105-11-S7-S13.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-11-S7-S13</pub-id><pub-id pub-id-type="pmcid">PMC2957681</pub-id><pub-id pub-id-type="pmid">21106120</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillogly</surname><given-names>ME</given-names></name><name name-style="western"><surname>Kallinteris</surname><given-names>NL</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Gulfo</surname><given-names>JV</given-names></name><name name-style="western"><surname>Humphreys</surname><given-names>RE</given-names></name><name name-style="western"><surname>Murray</surname><given-names>JL</given-names></name></person-group><article-title>Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer</article-title><source>Cancer Immunol Immunother CII</source><year>2004</year><volume>53</volume><fpage>490</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1007/s00262-003-0463-y</pub-id><pub-id pub-id-type="pmid">14740174</pub-id><pub-id pub-id-type="pmcid">PMC11032913</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother CII. 2004;53:490&#8211;6. 10.1007/s00262-003-0463-y.<pub-id pub-id-type="pmid">14740174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-003-0463-y</pub-id><pub-id pub-id-type="pmcid">PMC11032913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saul</surname><given-names>A</given-names></name></person-group><article-title>Models of phase 1 vaccine trials: optimization of trial design to minimize risks of multiple serious adverse events</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>3068</fpage><lpage>3075</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.10.048</pub-id><pub-id pub-id-type="pmid">15811654</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Saul A. Models of phase 1 vaccine trials: optimization of trial design to minimize risks of multiple serious adverse events. Vaccine. 2005;23:3068&#8211;75. 10.1016/j.vaccine.2004.10.048.<pub-id pub-id-type="pmid">15811654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2004.10.048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>L</given-names></name><name name-style="western"><surname>McPhee</surname><given-names>R</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>H</given-names></name><name name-style="western"><surname>Pajon</surname><given-names>R</given-names></name><name name-style="western"><surname>Nestorova</surname><given-names>B</given-names></name><etal/></person-group><article-title>A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2791</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.02.007</pub-id><pub-id pub-id-type="pmid">33707061</pub-id><pub-id pub-id-type="pmcid">PMC7871769</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021;39:2791&#8211;9. 10.1016/j.vaccine.2021.02.007.<pub-id pub-id-type="pmid">33707061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.02.007</pub-id><pub-id pub-id-type="pmcid">PMC7871769</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name><name name-style="western"><surname>Sobieszczyk</surname><given-names>ME</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>I</given-names></name><name name-style="western"><surname>Sproule</surname><given-names>S</given-names></name><name name-style="western"><surname>Robb</surname><given-names>ML</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L</given-names></name><etal/></person-group><article-title>Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>2348</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2105290</pub-id><pub-id pub-id-type="pmid">34587382</pub-id><pub-id pub-id-type="pmcid">PMC8522798</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021;385:2348&#8211;60. 10.1056/NEJMoa2105290.<pub-id pub-id-type="pmid">34587382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2105290</pub-id><pub-id pub-id-type="pmcid">PMC8522798</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>N</given-names></name><name name-style="western"><surname>Ju</surname><given-names>JH</given-names></name><name name-style="western"><surname>Park</surname><given-names>I-S</given-names></name><name name-style="western"><surname>Hong</surname><given-names>JT</given-names></name><name name-style="western"><surname>Oh</surname><given-names>HJ</given-names></name></person-group><article-title>Accelerated national lot release on COVID-19 vaccines in Republic of Korea</article-title><source>Biologicals</source><year>2022</year><volume>77</volume><fpage>24</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2022.05.002</pub-id><pub-id pub-id-type="pmid">35680495</pub-id><pub-id pub-id-type="pmcid">PMC9160014</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Yang M, Lee N, Ju JH, Park I-S, Hong JT, Oh HJ. Accelerated national lot release on COVID-19 vaccines in Republic of Korea. Biologicals. 2022;77:24&#8211;7. 10.1016/j.biologicals.2022.05.002.<pub-id pub-id-type="pmid">35680495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biologicals.2022.05.002</pub-id><pub-id pub-id-type="pmcid">PMC9160014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>Development of therapeutic vaccines for the treatment of diseases</article-title><source>Mol Biomed</source><year>2022</year><volume>3</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s43556-022-00098-9</pub-id><pub-id pub-id-type="pmid">36477638</pub-id><pub-id pub-id-type="pmcid">PMC9729511</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Tian Y, Hu D, Li Y, Yang L. Development of therapeutic vaccines for the treatment of diseases. Mol Biomed. 2022;3:40. 10.1186/s43556-022-00098-9.<pub-id pub-id-type="pmid">36477638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s43556-022-00098-9</pub-id><pub-id pub-id-type="pmcid">PMC9729511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saxena</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Der Burg</surname><given-names>SH</given-names></name><name name-style="western"><surname>Melief</surname><given-names>CJM</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group><article-title>Therapeutic cancer vaccines</article-title><source>Nat Rev Cancer</source><year>2021</year><volume>21</volume><fpage>360</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00346-0</pub-id><pub-id pub-id-type="pmid">33907315</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Saxena M, Van Der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360&#8211;78. 10.1038/s41568-021-00346-0.<pub-id pub-id-type="pmid">33907315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-021-00346-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barra</surname><given-names>F</given-names></name><name name-style="western"><surname>Della Corte</surname><given-names>L</given-names></name><name name-style="western"><surname>Noberasco</surname><given-names>G</given-names></name><name name-style="western"><surname>Foreste</surname><given-names>V</given-names></name><name name-style="western"><surname>Riemma</surname><given-names>G</given-names></name><name name-style="western"><surname>Di Filippo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia</article-title><source>J Obstet Gynaecol Res</source><year>2020</year><volume>46</volume><fpage>989</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1111/jog.14276</pub-id><pub-id pub-id-type="pmid">32390320</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Barra F, Della Corte L, Noberasco G, Foreste V, Riemma G, Di Filippo C, et al. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia. J Obstet Gynaecol Res. 2020;46:989&#8211;1006. 10.1111/jog.14276.<pub-id pub-id-type="pmid">32390320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jog.14276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoogeveen</surname><given-names>RC</given-names></name><name name-style="western"><surname>Boonstra</surname><given-names>A</given-names></name></person-group><article-title>Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>401</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00401</pub-id><pub-id pub-id-type="pmid">32194573</pub-id><pub-id pub-id-type="pmcid">PMC7064714</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Hoogeveen RC, Boonstra A. Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection. Front Immunol. 2020;11:401. 10.3389/fimmu.2020.00401.<pub-id pub-id-type="pmid">32194573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00401</pub-id><pub-id pub-id-type="pmcid">PMC7064714</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>E</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Kosinska</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Enhancing Virus-Specific Immunity In Vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection</article-title><source>PLoS Pathog</source><year>2014</year><volume>10</volume><fpage>e1003856</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1003856</pub-id><pub-id pub-id-type="pmid">24391505</pub-id><pub-id pub-id-type="pmcid">PMC3879364</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, et al. Enhancing Virus-Specific Immunity In Vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog. 2014;10:e1003856. 10.1371/journal.ppat.1003856.<pub-id pub-id-type="pmid">24391505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1003856</pub-id><pub-id pub-id-type="pmcid">PMC3879364</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bigna</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Noubiap</surname><given-names>JJ</given-names></name></person-group><article-title>The rising burden of non-communicable diseases in sub-Saharan Africa</article-title><source>Lancet Glob Health</source><year>2019</year><volume>7</volume><fpage>e1295</fpage><lpage>e1296</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(19)30370-5</pub-id><pub-id pub-id-type="pmid">31537347</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Bigna JJ, Noubiap JJ. The rising burden of non-communicable diseases in sub-Saharan Africa. Lancet Glob Health. 2019;7:e1295&#8211;6. 10.1016/S2214-109X(19)30370-5.<pub-id pub-id-type="pmid">31537347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(19)30370-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutayeb</surname><given-names>A</given-names></name></person-group><article-title>The double burden of communicable and non-communicable diseases in developing countries</article-title><source>Trans R Soc Trop Med Hyg</source><year>2006</year><volume>100</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.trstmh.2005.07.021</pub-id><pub-id pub-id-type="pmid">16274715</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Boutayeb A. The double burden of communicable and non-communicable diseases in developing countries. Trans R Soc Trop Med Hyg. 2006;100:191&#8211;9. 10.1016/j.trstmh.2005.07.021.<pub-id pub-id-type="pmid">16274715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trstmh.2005.07.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>A</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>E</given-names></name><name name-style="western"><surname>Wu</surname><given-names>TC</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C-F</given-names></name></person-group><article-title>Perspectives for therapeutic HPV vaccine development</article-title><source>J Biomed Sci</source><year>2016</year><volume>23</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s12929-016-0293-9</pub-id><pub-id pub-id-type="pmid">27809842</pub-id><pub-id pub-id-type="pmcid">PMC5096309</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Yang A, Farmer E, Wu TC, Hung C-F. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23:75. 10.1186/s12929-016-0293-9.<pub-id pub-id-type="pmid">27809842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-016-0293-9</pub-id><pub-id pub-id-type="pmcid">PMC5096309</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkwood</surname><given-names>JM</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>LH</given-names></name><name name-style="western"><surname>Tarhini</surname><given-names>AA</given-names></name><name name-style="western"><surname>Zarour</surname><given-names>H</given-names></name><name name-style="western"><surname>Kalinski</surname><given-names>P</given-names></name><name name-style="western"><surname>Ferrone</surname><given-names>S</given-names></name></person-group><article-title>Immunotherapy of cancer in 2012</article-title><source>CA Cancer J Clin</source><year>2012</year><volume>62</volume><fpage>309</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.3322/caac.20132</pub-id><pub-id pub-id-type="pmid">22576456</pub-id><pub-id pub-id-type="pmcid">PMC3445708</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309&#8211;35. 10.3322/caac.20132.<pub-id pub-id-type="pmid">22576456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.20132</pub-id><pub-id pub-id-type="pmcid">PMC3445708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>JD</given-names></name><name name-style="western"><surname>Gould</surname><given-names>KG</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K</given-names></name></person-group><article-title>Richard Pfeiffer&#8217;s typhoid vaccine and Almroth Wright&#8217;s claim to priority</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2074</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.017</pub-id><pub-id pub-id-type="pmid">33726955</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Williamson JD, Gould KG, Brown K. Richard Pfeiffer&#8217;s typhoid vaccine and Almroth Wright&#8217;s claim to priority. Vaccine. 2021;39:2074&#8211;9. 10.1016/j.vaccine.2021.03.017.<pub-id pub-id-type="pmid">33726955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.03.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Handy</surname><given-names>CE</given-names></name><name name-style="western"><surname>Antonarakis</surname><given-names>ES</given-names></name></person-group><article-title>Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions</article-title><source>Future Oncol</source><year>2018</year><volume>14</volume><fpage>907</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.2217/fon-2017-0531</pub-id><pub-id pub-id-type="pmid">29260582</pub-id><pub-id pub-id-type="pmcid">PMC5925432</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Handy CE, Antonarakis ES. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018;14:907&#8211;17. 10.2217/fon-2017-0531.<pub-id pub-id-type="pmid">29260582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fon-2017-0531</pub-id><pub-id pub-id-type="pmcid">PMC5925432</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wan</surname><given-names>D</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name></person-group><article-title>Cancer vaccines as promising immuno-therapeutics: platforms and current progress</article-title><source>J Hematol OncolJ Hematol Oncol</source><year>2022</year><volume>15</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01247-x</pub-id><pub-id pub-id-type="pmid">35303904</pub-id><pub-id pub-id-type="pmcid">PMC8931585</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol OncolJ Hematol Oncol. 2022;15:28. 10.1186/s13045-022-01247-x.<pub-id pub-id-type="pmid">35303904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-022-01247-x</pub-id><pub-id pub-id-type="pmcid">PMC8931585</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamaru</surname><given-names>R</given-names></name><name name-style="western"><surname>Nakagami</surname><given-names>H</given-names></name><name name-style="western"><surname>Rakugi</surname><given-names>H</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>R</given-names></name></person-group><article-title>Future Directions of Therapeutic Vaccines for Chronic Diseases</article-title><source>Circ J</source><year>2020</year><volume>84</volume><fpage>1895</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-20-0703</pub-id><pub-id pub-id-type="pmid">32908041</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Nakamaru R, Nakagami H, Rakugi H, Morishita R. Future Directions of Therapeutic Vaccines for Chronic Diseases. Circ J. 2020;84:1895&#8211;902. 10.1253/circj.CJ-20-0703.<pub-id pub-id-type="pmid">32908041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.CJ-20-0703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Rethinking therapeutic cancer vaccines. Nat Rev Drug Discov. 2009, 8:685&#8211;6. 10.1038/nrd2994.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd2994</pub-id><pub-id pub-id-type="pmid">19721436</pub-id></mixed-citation></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">Lockhart S, Gruber WC: Chapter 3. Clinical trials in the development of vaccines for infectious diseases. In: Prasad AK, ed. drug development and pharmaceutical science. Royal Society of Chemistry: Cambridge; 2022. 50&#8211;90. 10.1039/9781839162572-00050</mixed-citation></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahnazari</surname><given-names>M</given-names></name><name name-style="western"><surname>Samadi</surname><given-names>P</given-names></name><name name-style="western"><surname>Pourjafar</surname><given-names>M</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>A</given-names></name></person-group><article-title>Therapeutic vaccines for colorectal cancer: the progress and future prospect</article-title><source>Int Immunopharmacol</source><year>2020</year><volume>88</volume><fpage>106944</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106944</pub-id><pub-id pub-id-type="pmid">33182032</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Shahnazari M, Samadi P, Pourjafar M, Jalali A. Therapeutic vaccines for colorectal cancer: the progress and future prospect. Int Immunopharmacol. 2020;88:106944. 10.1016/j.intimp.2020.106944.<pub-id pub-id-type="pmid">33182032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.106944</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lei</surname><given-names>H</given-names></name><name name-style="western"><surname>Hong</surname><given-names>W</given-names></name><etal/></person-group><article-title>Trimeric protein vaccine based on Beta variant elicits robust immune response against BA.4/5-included SARS-CoV-2 Omicron variants</article-title><source>Mol Biomed</source><year>2023</year><volume>4</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s43556-023-00121-7</pub-id><pub-id pub-id-type="pmid">36894743</pub-id><pub-id pub-id-type="pmcid">PMC9998262</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">He C, Chen L, Yang J, Chen Z, Lei H, Hong W, et al. Trimeric protein vaccine based on Beta variant elicits robust immune response against BA.4/5-included SARS-CoV-2 Omicron variants. Mol Biomed. 2023;4:9. 10.1186/s43556-023-00121-7.<pub-id pub-id-type="pmid">36894743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s43556-023-00121-7</pub-id><pub-id pub-id-type="pmcid">PMC9998262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazoura</surname><given-names>E</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V</given-names></name></person-group><article-title>Rational peptide-based vaccine design for cancer immunotherapeutic applications</article-title><source>Curr Med Chem</source><year>2005</year><volume>12</volume><fpage>629</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.2174/0929867053202188</pub-id><pub-id pub-id-type="pmid">15790302</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Lazoura E, Apostolopoulos V. Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem. 2005;12:629&#8211;39. 10.2174/0929867053202188.<pub-id pub-id-type="pmid">15790302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867053202188</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ura</surname><given-names>T</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>M</given-names></name></person-group><article-title>Developments in viral vector-based vaccines</article-title><source>Vaccines</source><year>2014</year><volume>2</volume><fpage>624</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.3390/vaccines2030624</pub-id><pub-id pub-id-type="pmid">26344749</pub-id><pub-id pub-id-type="pmcid">PMC4494222</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014;2:624&#8211;41. 10.3390/vaccines2030624.<pub-id pub-id-type="pmid">26344749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines2030624</pub-id><pub-id pub-id-type="pmcid">PMC4494222</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>R</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name></person-group><article-title>Yeast-based vaccines: new perspective in vaccine development and application</article-title><source>FEMS Yeast Res</source><year>2019</year><volume>19</volume><fpage>foz007</fpage><pub-id pub-id-type="doi">10.1093/femsyr/foz007</pub-id><pub-id pub-id-type="pmid">30668686</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Kumar R, Kumar P. Yeast-based vaccines: new perspective in vaccine development and application. FEMS Yeast Res. 2019;19:foz007. 10.1093/femsyr/foz007.<pub-id pub-id-type="pmid">30668686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femsyr/foz007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>PM</given-names></name><name name-style="western"><surname>Butterfield</surname><given-names>LH</given-names></name></person-group><article-title>Dendritic cell-based cancer vaccines</article-title><source>J Immunol</source><year>2018</year><volume>200</volume><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1701024</pub-id><pub-id pub-id-type="pmid">29311386</pub-id><pub-id pub-id-type="pmcid">PMC5880540</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. J Immunol. 2018;200:443&#8211;9. 10.4049/jimmunol.1701024.<pub-id pub-id-type="pmid">29311386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1701024</pub-id><pub-id pub-id-type="pmcid">PMC5880540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>D</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Duan</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Su</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Enhanced anti-tumor immunity against breast cancer induced by whole tumor cell vaccines genetically modified expressing &#945;-Gal epitopes</article-title><source>Oncol Rep</source><year>2016</year><volume>36</volume><fpage>2843</fpage><lpage>2851</lpage><pub-id pub-id-type="doi">10.3892/or.2016.5128</pub-id><pub-id pub-id-type="pmid">27666541</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Xue D, Liang Y, Duan S, He J, Su J, Zhu J, et al. Enhanced anti-tumor immunity against breast cancer induced by whole tumor cell vaccines genetically modified expressing &#945;-Gal epitopes. Oncol Rep. 2016;36:2843&#8211;51. 10.3892/or.2016.5128.<pub-id pub-id-type="pmid">27666541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2016.5128</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermaelen</surname><given-names>K</given-names></name></person-group><article-title>Vaccine strategies to improve anti-cancer cellular immune responses</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00008</pub-id><pub-id pub-id-type="pmid">30723469</pub-id><pub-id pub-id-type="pmcid">PMC6349827</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Vermaelen K. Vaccine strategies to improve anti-cancer cellular immune responses. Front Immunol. 2019;10:8. 10.3389/fimmu.2019.00008.<pub-id pub-id-type="pmid">30723469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00008</pub-id><pub-id pub-id-type="pmcid">PMC6349827</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheever</surname><given-names>MA</given-names></name><name name-style="western"><surname>Higano</surname><given-names>CS</given-names></name></person-group><article-title>PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>3520</fpage><lpage>3526</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-3126</pub-id><pub-id pub-id-type="pmid">21471425</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520&#8211;6. 10.1158/1078-0432.CCR-10-3126.<pub-id pub-id-type="pmid">21471425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-10-3126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrucci</surname><given-names>PF</given-names></name><name name-style="western"><surname>Pala</surname><given-names>L</given-names></name><name name-style="western"><surname>Conforti</surname><given-names>F</given-names></name><name name-style="western"><surname>Cocorocchio</surname><given-names>E</given-names></name></person-group><article-title>Talimogene Laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma</article-title><source>Cancers</source><year>2021</year><volume>13</volume><fpage>1383</fpage><pub-id pub-id-type="doi">10.3390/cancers13061383</pub-id><pub-id pub-id-type="pmid">33803762</pub-id><pub-id pub-id-type="pmcid">PMC8003308</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021;13:1383. 10.3390/cancers13061383.<pub-id pub-id-type="pmid">33803762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13061383</pub-id><pub-id pub-id-type="pmcid">PMC8003308</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monie</surname><given-names>A</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C-F</given-names></name><name name-style="western"><surname>Roden</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T-C</given-names></name></person-group><article-title>Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer</article-title><source>Biol Targets Ther</source><year>2008</year><volume>2</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="pmcid">PMC2727782</pub-id><pub-id pub-id-type="pmid">19707432</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Monie A, Hung C-F, Roden R, Wu T-C. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biol Targets Ther. 2008;2:97&#8211;105.<pub-id pub-id-type="pmcid">PMC2727782</pub-id><pub-id pub-id-type="pmid">19707432</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="other">Okafor CN, Rewane A, Momodu II: Bacillus Calmette Guerin. In: StatPearls. StatPearls Publishing: Treasure Island (FL); 2024.<pub-id pub-id-type="pmid">30844212</pub-id></mixed-citation></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhuyan</surname><given-names>PK</given-names></name><name name-style="western"><surname>Dallas</surname><given-names>M</given-names></name><name name-style="western"><surname>Kraynyak</surname><given-names>K</given-names></name><name name-style="western"><surname>Herring</surname><given-names>T</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>M</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL</article-title><source>Hum Vaccines Immunother</source><year>2021</year><volume>17</volume><fpage>1288</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1823778</pub-id><pub-id pub-id-type="pmcid">PMC8078703</pub-id><pub-id pub-id-type="pmid">33175656</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Bhuyan PK, Dallas M, Kraynyak K, Herring T, Morrow M, Boyer J, et al. Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL. Hum Vaccines Immunother. 2021;17:1288&#8211;93. 10.1080/21645515.2020.1823778.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2020.1823778</pub-id><pub-id pub-id-type="pmcid">PMC8078703</pub-id><pub-id pub-id-type="pmid">33175656</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Julg</surname><given-names>B</given-names></name></person-group><article-title>Therapeutic vaccines for the treatment of HIV</article-title><source>Transl Res</source><year>2020</year><volume>223</volume><fpage>61</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2020.04.008</pub-id><pub-id pub-id-type="pmid">32438074</pub-id><pub-id pub-id-type="pmcid">PMC8188575</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Chen Z, Julg B. Therapeutic vaccines for the treatment of HIV. Transl Res. 2020;223:61&#8211;75. 10.1016/j.trsl.2020.04.008.<pub-id pub-id-type="pmid">32438074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2020.04.008</pub-id><pub-id pub-id-type="pmcid">PMC8188575</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hudu</surname><given-names>S</given-names></name><name name-style="western"><surname>Jimoh</surname><given-names>A</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>K</given-names></name><name name-style="western"><surname>Alshrari</surname><given-names>A</given-names></name></person-group><article-title>Hepatitis B therapeutic vaccine: a patent review</article-title><source>Pharmaceuticals</source><year>2022</year><volume>15</volume><fpage>1542</fpage><pub-id pub-id-type="doi">10.3390/ph15121542</pub-id><pub-id pub-id-type="pmid">36558991</pub-id><pub-id pub-id-type="pmcid">PMC9783911</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Hudu S, Jimoh A, Ibrahim K, Alshrari A. Hepatitis B therapeutic vaccine: a patent review. Pharmaceuticals. 2022;15:1542. 10.3390/ph15121542.<pub-id pub-id-type="pmid">36558991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph15121542</pub-id><pub-id pub-id-type="pmcid">PMC9783911</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crombet Ramos</surname><given-names>T</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>PC</given-names></name><name name-style="western"><surname>Neninger Vinageras</surname><given-names>E</given-names></name><name name-style="western"><surname>Garcia Verdecia</surname><given-names>B</given-names></name><name name-style="western"><surname>Lage Davila</surname><given-names>A</given-names></name></person-group><article-title>CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer</article-title><source>Expert Rev Vaccines</source><year>2015</year><volume>14</volume><fpage>1303</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.1079488</pub-id><pub-id pub-id-type="pmid">26295963</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Crombet Ramos T, Rodr&#237;guez PC, Neninger Vinageras E, Garcia Verdecia B, Lage Davila A. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines. 2015;14:1303&#8211;11. 10.1586/14760584.2015.1079488.<pub-id pub-id-type="pmid">26295963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2015.1079488</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>BS</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>P</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name></person-group><article-title>Emerging concepts in the science of vaccine adjuvants</article-title><source>Nat Rev Drug Discov.</source><year>2021</year><volume>20</volume><fpage>454</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Pulendran BS, Arunachalam P, O&#8217;Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20:454&#8211;75. 10.1038/s41573-021-00163-y.<pub-id pub-id-type="pmid">33824489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>F</given-names></name><name name-style="western"><surname>Lor&#233;</surname><given-names>K</given-names></name></person-group><article-title>Local innate immune responses in the vaccine adjuvant-injected muscle</article-title><source>Clin Transl Immunol</source><year>2016</year><volume>5</volume><fpage>e74</fpage><pub-id pub-id-type="doi">10.1038/cti.2016.19</pub-id><pub-id pub-id-type="pmcid">PMC4855268</pub-id><pub-id pub-id-type="pmid">27195117</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Liang F, Lor&#233; K. Local innate immune responses in the vaccine adjuvant-injected muscle. Clin Transl Immunol. 2016;5:e74. 10.1038/cti.2016.19.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cti.2016.19</pub-id><pub-id pub-id-type="pmcid">PMC4855268</pub-id><pub-id pub-id-type="pmid">27195117</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>F</given-names></name><name name-style="western"><surname>Lindgren</surname><given-names>G</given-names></name><name name-style="western"><surname>Sandgren</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>EA</given-names></name><name name-style="western"><surname>Francica</surname><given-names>JR</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake</article-title><source>Sci Transl Med</source><year>2017</year><volume>9</volume><fpage>eaal2094</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aal2094</pub-id><pub-id pub-id-type="pmid">28592561</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Liang F, Lindgren G, Sandgren KJ, Thompson EA, Francica JR, Seubert A, et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci Transl Med. 2017;9:eaal2094. 10.1126/scitranslmed.aal2094.<pub-id pub-id-type="pmid">28592561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aal2094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gornati</surname><given-names>L</given-names></name><name name-style="western"><surname>Zanoni</surname><given-names>I</given-names></name><name name-style="western"><surname>Granucci</surname><given-names>F</given-names></name></person-group><article-title>Dendritic cells in the cross hair for the generation of tailored vaccines</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>1484</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01484</pub-id><pub-id pub-id-type="pmid">29997628</pub-id><pub-id pub-id-type="pmcid">PMC6030256</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Gornati L, Zanoni I, Granucci F. Dendritic cells in the cross hair for the generation of tailored vaccines. Front Immunol. 2018;9:1484. 10.3389/fimmu.2018.01484.<pub-id pub-id-type="pmid">29997628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.01484</pub-id><pub-id pub-id-type="pmcid">PMC6030256</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eickhoff</surname><given-names>S</given-names></name><name name-style="western"><surname>Brewitz</surname><given-names>A</given-names></name><name name-style="western"><surname>Gerner</surname><given-names>MY</given-names></name><name name-style="western"><surname>Klauschen</surname><given-names>F</given-names></name><name name-style="western"><surname>Komander</surname><given-names>K</given-names></name><name name-style="western"><surname>Hemmi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Robust anti-viral immunity requires multiple distinct t cell-dendritic cell interactions</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>1322</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.004</pub-id><pub-id pub-id-type="pmid">26296422</pub-id><pub-id pub-id-type="pmcid">PMC4567961</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Eickhoff S, Brewitz A, Gerner MY, Klauschen F, Komander K, Hemmi H, et al. Robust anti-viral immunity requires multiple distinct t cell-dendritic cell interactions. Cell. 2015;162:1322&#8211;37. 10.1016/j.cell.2015.08.004.<pub-id pub-id-type="pmid">26296422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.08.004</pub-id><pub-id pub-id-type="pmcid">PMC4567961</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heather</surname><given-names>JM</given-names></name><name name-style="western"><surname>Chain</surname><given-names>B</given-names></name></person-group><article-title>The sequence of sequencers: The history of sequencing DNA</article-title><source>Genomics</source><year>2016</year><volume>107</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ygeno.2015.11.003</pub-id><pub-id pub-id-type="pmid">26554401</pub-id><pub-id pub-id-type="pmcid">PMC4727787</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Heather JM, Chain B. The sequence of sequencers: The history of sequencing DNA. Genomics. 2016;107:1&#8211;8. 10.1016/j.ygeno.2015.11.003.<pub-id pub-id-type="pmid">26554401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygeno.2015.11.003</pub-id><pub-id pub-id-type="pmcid">PMC4727787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dorp</surname><given-names>L</given-names></name><name name-style="western"><surname>Acman</surname><given-names>M</given-names></name><name name-style="western"><surname>Richard</surname><given-names>D</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>LP</given-names></name><name name-style="western"><surname>Ford</surname><given-names>CE</given-names></name><name name-style="western"><surname>Ormond</surname><given-names>L</given-names></name><etal/></person-group><article-title>Emergence of genomic diversity and recurrent mutations in SARS-CoV-2</article-title><source>Infect Genet Evol</source><year>2020</year><volume>83</volume><fpage>104351</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2020.104351</pub-id><pub-id pub-id-type="pmid">32387564</pub-id><pub-id pub-id-type="pmcid">PMC7199730</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, et al. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol. 2020;83:104351. 10.1016/j.meegid.2020.104351.<pub-id pub-id-type="pmid">32387564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.meegid.2020.104351</pub-id><pub-id pub-id-type="pmcid">PMC7199730</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rambaut</surname><given-names>A</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>EC</given-names></name><name name-style="western"><surname>O'Toole</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Hill</surname><given-names>V</given-names></name><name name-style="western"><surname>McCrone</surname><given-names>JT</given-names></name><name name-style="western"><surname>Ruis</surname><given-names>C</given-names></name><etal/></person-group><article-title>A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology</article-title><source>Nat Microbiol</source><year>2020</year><volume>5</volume><fpage>1403</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0770-5</pub-id><pub-id pub-id-type="pmid">32669681</pub-id><pub-id pub-id-type="pmcid">PMC7610519</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Rambaut A, Holmes EC, O&#8217;Toole &#193;, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5:1403&#8211;7. 10.1038/s41564-020-0770-5.<pub-id pub-id-type="pmid">32669681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-020-0770-5</pub-id><pub-id pub-id-type="pmcid">PMC7610519</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Siddell</surname><given-names>SG</given-names></name><name name-style="western"><surname>Lefkowitz</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Mushegian</surname><given-names>AR</given-names></name><name name-style="western"><surname>Dempsey</surname><given-names>DM</given-names></name><name name-style="western"><surname>Dutilh</surname><given-names>BE</given-names></name><etal/></person-group><article-title>Changes to virus taxonomy and the international code of virus classification and nomenclature ratified by the international committee on taxonomy of viruses (2019)</article-title><source>Arch Virol</source><year>2019</year><volume>164</volume><fpage>2417</fpage><lpage>2429</lpage><pub-id pub-id-type="doi">10.1007/s00705-019-04306-w</pub-id><pub-id pub-id-type="pmid">31187277</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Walker PJ, Siddell SG, Lefkowitz EJ, Mushegian AR, Dempsey DM, Dutilh BE, et al. Changes to virus taxonomy and the international code of virus classification and nomenclature ratified by the international committee on taxonomy of viruses (2019). Arch Virol. 2019;164:2417&#8211;29. 10.1007/s00705-019-04306-w.<pub-id pub-id-type="pmid">31187277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00705-019-04306-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadfield</surname><given-names>J</given-names></name><name name-style="western"><surname>Megill</surname><given-names>C</given-names></name><name name-style="western"><surname>Bell</surname><given-names>SM</given-names></name><name name-style="western"><surname>Huddleston</surname><given-names>J</given-names></name><name name-style="western"><surname>Potter</surname><given-names>B</given-names></name><name name-style="western"><surname>Callender</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nextstrain: real-time tracking of pathogen evolution</article-title><source>Bioinformatics</source><year>2018</year><volume>34</volume><fpage>4121</fpage><lpage>4123</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty407</pub-id><pub-id pub-id-type="pmid">29790939</pub-id><pub-id pub-id-type="pmcid">PMC6247931</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;34:4121&#8211;3. 10.1093/bioinformatics/bty407.<pub-id pub-id-type="pmid">29790939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bty407</pub-id><pub-id pub-id-type="pmcid">PMC6247931</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vries</surname><given-names>RP</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W</given-names></name><name name-style="western"><surname>Grant</surname><given-names>OC</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Bouwman</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Three mutations switch H7N9 influenza to human-type receptor specificity</article-title><source>PLOS Pathog</source><year>2017</year><volume>13</volume><fpage>e1006390</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1006390</pub-id><pub-id pub-id-type="pmid">28617868</pub-id><pub-id pub-id-type="pmcid">PMC5472306</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">de Vries RP, Peng W, Grant OC, Thompson AJ, Zhu X, Bouwman KM, et al. Three mutations switch H7N9 influenza to human-type receptor specificity. PLOS Pathog. 2017;13:e1006390. 10.1371/journal.ppat.1006390.<pub-id pub-id-type="pmid">28617868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1006390</pub-id><pub-id pub-id-type="pmcid">PMC5472306</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faria</surname><given-names>NR</given-names></name><name name-style="western"><surname>Quick</surname><given-names>J</given-names></name><name name-style="western"><surname>Claro</surname><given-names>IM</given-names></name><name name-style="western"><surname>Th&#233;z&#233;</surname><given-names>J</given-names></name><name name-style="western"><surname>de Jesus</surname><given-names>JG</given-names></name><name name-style="western"><surname>Giovanetti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Establishment and cryptic transmission of Zika virus in Brazil and the Americas</article-title><source>Nature</source><year>2017</year><volume>546</volume><fpage>406</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1038/nature22401</pub-id><pub-id pub-id-type="pmid">28538727</pub-id><pub-id pub-id-type="pmcid">PMC5722632</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Faria NR, Quick J, Claro IM, Th&#233;z&#233; J, de Jesus JG, Giovanetti M, et al. Establishment and cryptic transmission of Zika virus in Brazil and the Americas. Nature. 2017;546:406&#8211;10. 10.1038/nature22401.<pub-id pub-id-type="pmid">28538727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature22401</pub-id><pub-id pub-id-type="pmcid">PMC5722632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eyre</surname><given-names>DW</given-names></name></person-group><article-title>Infection prevention and control insights from a decade of pathogen whole-genome sequencing</article-title><source>J Hosp Infect</source><year>2022</year><volume>122</volume><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2022.01.024</pub-id><pub-id pub-id-type="pmid">35157991</pub-id><pub-id pub-id-type="pmcid">PMC8837474</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Eyre DW. Infection prevention and control insights from a decade of pathogen whole-genome sequencing. J Hosp Infect. 2022;122:180&#8211;6. 10.1016/j.jhin.2022.01.024.<pub-id pub-id-type="pmid">35157991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhin.2022.01.024</pub-id><pub-id pub-id-type="pmcid">PMC8837474</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elbe</surname><given-names>S</given-names></name><name name-style="western"><surname>Buckland-Merrett</surname><given-names>G</given-names></name></person-group><article-title>Data, disease and diplomacy: GISAID&#8217;s innovative contribution to global health</article-title><source>Glob Chall</source><year>2017</year><volume>1</volume><fpage>33</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1002/gch2.1018</pub-id><pub-id pub-id-type="pmid">31565258</pub-id><pub-id pub-id-type="pmcid">PMC6607375</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID&#8217;s innovative contribution to global health. Glob Chall. 2017;1:33&#8211;46. 10.1002/gch2.1018.<pub-id pub-id-type="pmid">31565258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gch2.1018</pub-id><pub-id pub-id-type="pmcid">PMC6607375</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>JK</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>COVID-19 vaccines for patients with cancer: benefits likely outweigh risks</article-title><source>J Hematol OncolJ Hematol Oncol</source><year>2021</year><volume>14</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s13045-021-01046-w</pub-id><pub-id pub-id-type="pmid">33640005</pub-id><pub-id pub-id-type="pmcid">PMC7910769</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Hwang JK, Zhang T, Wang AZ, Li Z. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. J Hematol OncolJ Hematol Oncol. 2021;14:38. 10.1186/s13045-021-01046-w.<pub-id pub-id-type="pmid">33640005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-021-01046-w</pub-id><pub-id pub-id-type="pmcid">PMC7910769</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mbala-Kingebeni</surname><given-names>P</given-names></name><name name-style="western"><surname>Villabona-Arenas</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>N</given-names></name><name name-style="western"><surname>Likofata</surname><given-names>J</given-names></name><name name-style="western"><surname>Nsio-Mbeta</surname><given-names>J</given-names></name><name name-style="western"><surname>Makiala-Mandanda</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rapid confirmation of the zaire ebola virus in the outbreak of the equateur province in the democratic Republic of Congo: implications for public health interventions</article-title><source>Clin Infect Dis</source><year>2019</year><volume>68</volume><fpage>330</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy527</pub-id><pub-id pub-id-type="pmid">29961823</pub-id><pub-id pub-id-type="pmcid">PMC6321851</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Mbala-Kingebeni P, Villabona-Arenas CJ, Vidal N, Likofata J, Nsio-Mbeta J, Makiala-Mandanda S, et al. Rapid confirmation of the zaire ebola virus in the outbreak of the equateur province in the democratic Republic of Congo: implications for public health interventions. Clin Infect Dis. 2019;68:330&#8211;3. 10.1093/cid/ciy527.<pub-id pub-id-type="pmid">29961823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciy527</pub-id><pub-id pub-id-type="pmcid">PMC6321851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>CA</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>RAM</given-names></name><name name-style="western"><surname>Ghaswalla</surname><given-names>P</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y</given-names></name><name name-style="western"><surname>Vicic</surname><given-names>N</given-names></name><name name-style="western"><surname>Ananworanich</surname><given-names>J</given-names></name><name name-style="western"><surname>Nachbagauer</surname><given-names>R</given-names></name><etal/></person-group><article-title>Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines</article-title><source>Hum Vaccines Immunother</source><year>2024</year><volume>20</volume><fpage>2336357</fpage><pub-id pub-id-type="doi">10.1080/21645515.2024.2336357</pub-id><pub-id pub-id-type="pmcid">PMC11020595</pub-id><pub-id pub-id-type="pmid">38619079</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Russell CA, Fouchier RAM, Ghaswalla P, Park Y, Vicic N, Ananworanich J, Nachbagauer R, et al. Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines. Hum Vaccines Immunother. 2024;20:2336357. 10.1080/21645515.2024.2336357.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2024.2336357</pub-id><pub-id pub-id-type="pmcid">PMC11020595</pub-id><pub-id pub-id-type="pmid">38619079</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ling</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Marin-Lopez</surname><given-names>A</given-names></name></person-group><article-title>Current advances in zika vaccine development</article-title><source>Vaccines</source><year>1816</year><volume>2022</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.3390/vaccines10111816</pub-id><pub-id pub-id-type="pmcid">PMC9694033</pub-id><pub-id pub-id-type="pmid">36366325</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Wang Y, Ling L, Zhang Z, Marin-Lopez A. Current advances in zika vaccine development. Vaccines. 1816;2022:10. 10.3390/vaccines10111816.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines10111816</pub-id><pub-id pub-id-type="pmcid">PMC9694033</pub-id><pub-id pub-id-type="pmid">36366325</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Aleem</surname><given-names>A</given-names></name><name name-style="western"><surname>Akbar Samad</surname><given-names>AB</given-names></name><name name-style="western"><surname>Vaqar</surname><given-names>S</given-names></name></person-group><article-title>Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)</article-title><source>In: StatPearls</source><year>2024</year><publisher-loc>Treasure Island (FL)</publisher-loc><publisher-name>StatPearls Publishing</publisher-name><pub-id pub-id-type="pmid">34033342</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="book">Aleem A, Akbar Samad AB, Vaqar S. Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19). In: In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.<pub-id pub-id-type="pmid">34033342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunkle</surname><given-names>LM</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>KL</given-names></name><name name-style="western"><surname>Gay</surname><given-names>CL</given-names></name><name name-style="western"><surname>&#193;&#241;ez</surname><given-names>G</given-names></name><name name-style="western"><surname>Adelglass</surname><given-names>JM</given-names></name><name name-style="western"><surname>Barrat Hern&#225;ndez</surname><given-names>AQ</given-names></name><etal/></person-group><article-title>Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico</article-title><source>N Engl J Med</source><year>2022</year><volume>386</volume><fpage>531</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2116185</pub-id><pub-id pub-id-type="pmid">34910859</pub-id><pub-id pub-id-type="pmcid">PMC8693692</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Dunkle LM, Kotloff KL, Gay CL, &#193;&#241;ez G, Adelglass JM, Barrat Hern&#225;ndez AQ, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386:531&#8211;43. 10.1056/NEJMoa2116185.<pub-id pub-id-type="pmid">34910859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2116185</pub-id><pub-id pub-id-type="pmcid">PMC8693692</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagashima</surname><given-names>KA</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>JJ</given-names></name></person-group><article-title>Next-generation influenza HA immunogens and adjuvants in pursuit of a broadly protective vaccine</article-title><source>Viruses</source><year>2021</year><volume>13</volume><fpage>546</fpage><pub-id pub-id-type="doi">10.3390/v13040546</pub-id><pub-id pub-id-type="pmid">33805245</pub-id><pub-id pub-id-type="pmcid">PMC8064354</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Nagashima KA, Mousa JJ. Next-generation influenza HA immunogens and adjuvants in pursuit of a broadly protective vaccine. Viruses. 2021;13:546. 10.3390/v13040546.<pub-id pub-id-type="pmid">33805245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13040546</pub-id><pub-id pub-id-type="pmcid">PMC8064354</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><mixed-citation publication-type="other">Katalin Karik&#243; and Drew Weissman Win 2023 Nobel Prize in Medicine. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pennmedicine.org/news/news-releases/2023/october/katalin-kariko-and-drew-weissman-win-2023-nobel-prize-in-medicine">https://www.pennmedicine.org/news/news-releases/2023/october/katalin-kariko-and-drew-weissman-win-2023-nobel-prize-in-medicine</ext-link>. Accessed 1Sept 2024.</mixed-citation></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>SP</given-names></name></person-group><article-title>Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273</article-title><source>J Pharm Pract</source><year>2022</year><volume>35</volume><fpage>947</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1177/08971900211009650</pub-id><pub-id pub-id-type="pmid">33840294</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Teo SP. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. J Pharm Pract. 2022;35:947&#8211;51. 10.1177/08971900211009650.<pub-id pub-id-type="pmid">33840294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/08971900211009650</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Fayez</surname><given-names>N</given-names></name><name name-style="western"><surname>Nassar</surname><given-names>MS</given-names></name><name name-style="western"><surname>Alshehri</surname><given-names>AA</given-names></name><name name-style="western"><surname>Alnefaie</surname><given-names>MK</given-names></name><name name-style="western"><surname>Almughem</surname><given-names>FA</given-names></name><name name-style="western"><surname>Alshehri</surname><given-names>BY</given-names></name><etal/></person-group><article-title>Recent advancement in mRNA vaccine development and applications</article-title><source>Pharmaceutics</source><year>1972</year><volume>2023</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15071972</pub-id><pub-id pub-id-type="pmcid">PMC10384963</pub-id><pub-id pub-id-type="pmid">37514158</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Al Fayez N, Nassar MS, Alshehri AA, Alnefaie MK, Almughem FA, Alshehri BY, et al. Recent advancement in mRNA vaccine development and applications. Pharmaceutics. 1972;2023:15. 10.3390/pharmaceutics15071972.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15071972</pub-id><pub-id pub-id-type="pmcid">PMC10384963</pub-id><pub-id pub-id-type="pmid">37514158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karik&#243;</surname><given-names>K</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>FA</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>J</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>Incorporation of pseudouridine Into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability</article-title><source>Mol Ther</source><year>2008</year><volume>16</volume><fpage>1833</fpage><lpage>1840</lpage><pub-id pub-id-type="doi">10.1038/mt.2008.200</pub-id><pub-id pub-id-type="pmid">18797453</pub-id><pub-id pub-id-type="pmcid">PMC2775451</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Karik&#243; K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine Into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16:1833&#8211;40. 10.1038/mt.2008.200.<pub-id pub-id-type="pmid">18797453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2008.200</pub-id><pub-id pub-id-type="pmcid">PMC2775451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Porter</surname><given-names>FW</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>mRNA vaccines &#8212; a new era in vaccinology</article-title><source>Nat Rev Drug Discov</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines &#8212; a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261&#8211;79. 10.1038/nrd.2017.243.<pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Billingsley</surname><given-names>MM</given-names></name><name name-style="western"><surname>Haley</surname><given-names>RM</given-names></name><name name-style="western"><surname>Wechsler</surname><given-names>ME</given-names></name><name name-style="western"><surname>Peppas</surname><given-names>NA</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R</given-names></name></person-group><article-title>Engineering precision nanoparticles for drug delivery</article-title><source>Nat Rev Drug Discov</source><year>2021</year><volume>20</volume><fpage>101</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/s41573-020-0090-8</pub-id><pub-id pub-id-type="pmid">33277608</pub-id><pub-id pub-id-type="pmcid">PMC7717100</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101&#8211;24. 10.1038/s41573-020-0090-8.<pub-id pub-id-type="pmid">33277608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-020-0090-8</pub-id><pub-id pub-id-type="pmcid">PMC7717100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>NAC</given-names></name><name name-style="western"><surname>Kester</surname><given-names>KE</given-names></name><name name-style="western"><surname>Casimiro</surname><given-names>D</given-names></name><name name-style="western"><surname>Gurunathan</surname><given-names>S</given-names></name><name name-style="western"><surname>DeRosa</surname><given-names>F</given-names></name></person-group><article-title>The promise of mRNA vaccines: a biotech and industrial perspective</article-title><source>Npj Vaccines</source><year>2020</year><volume>5</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/s41541-020-0159-8</pub-id><pub-id pub-id-type="pmid">32047656</pub-id><pub-id pub-id-type="pmcid">PMC7000814</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. Npj Vaccines. 2020;5:1&#8211;6. 10.1038/s41541-020-0159-8.<pub-id pub-id-type="pmid">32047656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-020-0159-8</pub-id><pub-id pub-id-type="pmcid">PMC7000814</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>PC</given-names></name><name name-style="western"><surname>Makhene</surname><given-names>M</given-names></name><name name-style="western"><surname>Coler</surname><given-names>RN</given-names></name><etal/></person-group><article-title>An mRNA Vaccine against SARS-CoV-2 &#8212; preliminary report</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>1920</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2022483</pub-id><pub-id pub-id-type="pmid">32663912</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 &#8212; preliminary report. N Engl J Med. 2020;383:1920&#8211;31. 10.1056/NEJMoa2022483.<pub-id pub-id-type="pmid">32663912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2022483</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>Development of vaccines and antivirals for combating viral pandemics</article-title><source>Nat Biomed Eng</source><year>2020</year><volume>4</volume><fpage>1128</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1038/s41551-020-00658-w</pub-id><pub-id pub-id-type="pmid">33293724</pub-id><pub-id pub-id-type="pmcid">PMC8336060</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Pardi N, Weissman D. Development of vaccines and antivirals for combating viral pandemics. Nat Biomed Eng. 2020;4:1128&#8211;33. 10.1038/s41551-020-00658-w.<pub-id pub-id-type="pmid">33293724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-020-00658-w</pub-id><pub-id pub-id-type="pmcid">PMC8336060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabiani</surname><given-names>M</given-names></name><name name-style="western"><surname>Puopolo</surname><given-names>M</given-names></name><name name-style="western"><surname>Morciano</surname><given-names>C</given-names></name><name name-style="western"><surname>Spuri</surname><given-names>M</given-names></name><name name-style="western"><surname>Spila Alegiani</surname><given-names>S</given-names></name><name name-style="western"><surname>Filia</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study</article-title><source>BMJ</source><year>2022</year><volume>376</volume><fpage>e069052</fpage><pub-id pub-id-type="doi">10.1136/bmj-2021-069052</pub-id><pub-id pub-id-type="pmid">35144968</pub-id><pub-id pub-id-type="pmcid">PMC8829820</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Fabiani M, Puopolo M, Morciano C, Spuri M, Spila Alegiani S, Filia A, et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study. BMJ. 2022;376:e069052. 10.1136/bmj-2021-069052.<pub-id pub-id-type="pmid">35144968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj-2021-069052</pub-id><pub-id pub-id-type="pmcid">PMC8829820</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monslow</surname><given-names>MA</given-names></name><name name-style="western"><surname>Elbashir</surname><given-names>S</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>NL</given-names></name><name name-style="western"><surname>Thiriot</surname><given-names>DS</given-names></name><name name-style="western"><surname>Ahl</surname><given-names>P</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J</given-names></name><etal/></person-group><article-title>Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>5793</fpage><lpage>5802</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.06.062</pub-id><pub-id pub-id-type="pmid">32703745</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Monslow MA, Elbashir S, Sullivan NL, Thiriot DS, Ahl P, Smith J, et al. Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates. Vaccine. 2020;38:5793&#8211;802. 10.1016/j.vaccine.2020.06.062.<pub-id pub-id-type="pmid">32703745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2020.06.062</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richner</surname><given-names>JM</given-names></name><name name-style="western"><surname>Himansu</surname><given-names>S</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>KA</given-names></name><name name-style="western"><surname>Butler</surname><given-names>SL</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>V</given-names></name><name name-style="western"><surname>Fox</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Modified mRNA vaccines protect against zika virus infection</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>1114</fpage><lpage>1125.e10</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.02.017</pub-id><pub-id pub-id-type="pmid">28222903</pub-id><pub-id pub-id-type="pmcid">PMC5388441</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. Modified mRNA vaccines protect against zika virus infection. Cell. 2017;168:1114&#8211;1125.e10. 10.1016/j.cell.2017.02.017.<pub-id pub-id-type="pmid">28222903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.02.017</pub-id><pub-id pub-id-type="pmcid">PMC5388441</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petsch</surname><given-names>B</given-names></name><name name-style="western"><surname>Schnee</surname><given-names>M</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>AB</given-names></name><name name-style="western"><surname>Lange</surname><given-names>E</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>B</given-names></name><name name-style="western"><surname>Voss</surname><given-names>D</given-names></name><etal/></person-group><article-title>Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection</article-title><source>Nat Biotechnol</source><year>2012</year><volume>30</volume><fpage>1210</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1038/nbt.2436</pub-id><pub-id pub-id-type="pmid">23159882</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012;30:1210&#8211;6. 10.1038/nbt.2436.<pub-id pub-id-type="pmid">23159882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2436</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><name name-style="western"><surname>Hou</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Makrinos</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>A</given-names></name><name name-style="western"><surname>Koch</surname><given-names>M</given-names></name><etal/></person-group><article-title>Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults</article-title><source>J Virol</source><year>2024</year><volume>98</volume><fpage>e01603</fpage><lpage>e1623</lpage><pub-id pub-id-type="doi">10.1128/jvi.01603-23</pub-id><pub-id pub-id-type="pmid">38526054</pub-id><pub-id pub-id-type="pmcid">PMC11019844</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Wu K, Hou YJ, Makrinos D, Liu R, Zhu A, Koch M, et al. Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults. J Virol. 2024;98:e01603&#8211;e1623. 10.1128/jvi.01603-23.<pub-id pub-id-type="pmid">38526054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.01603-23</pub-id><pub-id pub-id-type="pmcid">PMC11019844</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espeseth</surname><given-names>AS</given-names></name><name name-style="western"><surname>Cejas</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Citron</surname><given-names>MP</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>DiStefano</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection</article-title><source>Npj Vaccines</source><year>2020</year><volume>5</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41541-020-0163-z</pub-id><pub-id pub-id-type="pmid">32128257</pub-id><pub-id pub-id-type="pmcid">PMC7021756</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Espeseth AS, Cejas PJ, Citron MP, Wang D, DiStefano DJ, Callahan C, et al. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. Npj Vaccines. 2020;5:1&#8211;14. 10.1038/s41541-020-0163-z.<pub-id pub-id-type="pmid">32128257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-020-0163-z</pub-id><pub-id pub-id-type="pmcid">PMC7021756</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Fang</surname><given-names>E</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>An mRNA vaccine against rabies provides strong and durable protection in mice</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1288879</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1288879</pub-id><pub-id pub-id-type="pmid">37954577</pub-id><pub-id pub-id-type="pmcid">PMC10639119</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Li M, Fang E, Wang Y, Shi L, Li J, Peng Q, et al. An mRNA vaccine against rabies provides strong and durable protection in mice. Front Immunol. 2023;14:1288879. 10.3389/fimmu.2023.1288879.<pub-id pub-id-type="pmid">37954577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1288879</pub-id><pub-id pub-id-type="pmcid">PMC10639119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fortner</surname><given-names>A</given-names></name><name name-style="western"><surname>Bucur</surname><given-names>O</given-names></name></person-group><article-title>mRNA-based vaccine technology for HIV</article-title><source>Discoveries</source><year>2022</year><volume>10</volume><fpage>e150</fpage><pub-id pub-id-type="doi">10.15190/d.2022.9</pub-id><pub-id pub-id-type="pmid">36438441</pub-id><pub-id pub-id-type="pmcid">PMC9683993</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Fortner A, Bucur O. mRNA-based vaccine technology for HIV. Discoveries. 2022;10:e150. 10.15190/d.2022.9.<pub-id pub-id-type="pmid">36438441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15190/d.2022.9</pub-id><pub-id pub-id-type="pmcid">PMC9683993</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><mixed-citation publication-type="other">Rando HM, Lordan R, Lee AJ, Naik A, Wellhausen N, Sell E, et al.: Application of Traditional Vaccine Development Strategies to SARS-CoV-2. ArXiv. 2023, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://arxiv.org/abs/2208.08907v2">arXiv:2208.08907v2</ext-link>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/msystems.00927-22</pub-id><pub-id pub-id-type="pmcid">PMC10134813</pub-id><pub-id pub-id-type="pmid">36861991</pub-id></mixed-citation></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosa</surname><given-names>SS</given-names></name><name name-style="western"><surname>Prazeres</surname><given-names>DMF</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>AM</given-names></name><name name-style="western"><surname>Marques</surname><given-names>MPC</given-names></name></person-group><article-title>mRNA vaccines manufacturing: Challenges and bottlenecks</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2190</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.038</pub-id><pub-id pub-id-type="pmid">33771389</pub-id><pub-id pub-id-type="pmcid">PMC7987532</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021;39:2190&#8211;200. 10.1016/j.vaccine.2021.03.038.<pub-id pub-id-type="pmid">33771389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.03.038</pub-id><pub-id pub-id-type="pmcid">PMC7987532</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gote</surname><given-names>V</given-names></name><name name-style="western"><surname>Bolla</surname><given-names>PK</given-names></name><name name-style="western"><surname>Kommineni</surname><given-names>N</given-names></name><name name-style="western"><surname>Butreddy</surname><given-names>A</given-names></name><name name-style="western"><surname>Nukala</surname><given-names>PK</given-names></name><name name-style="western"><surname>Palakurthi</surname><given-names>SS</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W</given-names></name></person-group><article-title>A comprehensive review of mRNA vaccines</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>2700</fpage><pub-id pub-id-type="doi">10.3390/ijms24032700</pub-id><pub-id pub-id-type="pmid">36769023</pub-id><pub-id pub-id-type="pmcid">PMC9917162</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24:2700. 10.3390/ijms24032700.<pub-id pub-id-type="pmid">36769023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24032700</pub-id><pub-id pub-id-type="pmcid">PMC9917162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>MN</given-names></name><name name-style="western"><surname>Roni</surname><given-names>MA</given-names></name></person-group><article-title>Challenges of storage and stability of mRNA-based COVID-19 vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>1033</fpage><pub-id pub-id-type="doi">10.3390/vaccines9091033</pub-id><pub-id pub-id-type="pmid">34579270</pub-id><pub-id pub-id-type="pmcid">PMC8473088</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Uddin MN, Roni MA. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines. 2021;9:1033. 10.3390/vaccines9091033.<pub-id pub-id-type="pmid">34579270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9091033</pub-id><pub-id pub-id-type="pmcid">PMC8473088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nitika</surname><given-names>W</given-names></name></person-group><article-title>J, Hui A-M: The Delivery of mRNA Vaccines for Therapeutics</article-title><source>Life</source><year>2022</year><volume>12</volume><fpage>1254</fpage><pub-id pub-id-type="doi">10.3390/life12081254</pub-id><pub-id pub-id-type="pmid">36013433</pub-id><pub-id pub-id-type="pmcid">PMC9410089</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Nitika W. J, Hui A-M: The Delivery of mRNA Vaccines for Therapeutics. Life. 2022;12:1254. 10.3390/life12081254.<pub-id pub-id-type="pmid">36013433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life12081254</pub-id><pub-id pub-id-type="pmcid">PMC9410089</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donnelly</surname><given-names>RF</given-names></name></person-group><article-title>Vaccine delivery systems</article-title><source>Hum Vaccines Immunother</source><year>2017</year><volume>13</volume><fpage>17</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1259043</pub-id><pub-id pub-id-type="pmcid">PMC5287301</pub-id><pub-id pub-id-type="pmid">28125375</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Donnelly RF. Vaccine delivery systems. Hum Vaccines Immunother. 2017;13:17&#8211;8. 10.1080/21645515.2016.1259043.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2016.1259043</pub-id><pub-id pub-id-type="pmcid">PMC5287301</pub-id><pub-id pub-id-type="pmid">28125375</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rzymski</surname><given-names>P</given-names></name><name name-style="western"><surname>Zeyland</surname><given-names>J</given-names></name><name name-style="western"><surname>Poniedzia&#322;ek</surname><given-names>B</given-names></name><name name-style="western"><surname>Ma&#322;ecka</surname><given-names>I</given-names></name><name name-style="western"><surname>Wysocki</surname><given-names>J</given-names></name></person-group><article-title>The perception and attitudes toward COVID-19 vaccines: a cross-sectional study in Poland</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>382</fpage><pub-id pub-id-type="doi">10.3390/vaccines9040382</pub-id><pub-id pub-id-type="pmid">33919672</pub-id><pub-id pub-id-type="pmcid">PMC8069794</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Rzymski P, Zeyland J, Poniedzia&#322;ek B, Ma&#322;ecka I, Wysocki J. The perception and attitudes toward COVID-19 vaccines: a cross-sectional study in Poland. Vaccines. 2021;9:382. 10.3390/vaccines9040382.<pub-id pub-id-type="pmid">33919672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9040382</pub-id><pub-id pub-id-type="pmcid">PMC8069794</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chehelgerdi</surname><given-names>M</given-names></name><name name-style="western"><surname>Chehelgerdi</surname><given-names>M</given-names></name></person-group><article-title>The use of RNA-based treatments in the field of cancer immunotherapy</article-title><source>Mol Cancer</source><year>2023</year><volume>22</volume><fpage>106</fpage><pub-id pub-id-type="doi">10.1186/s12943-023-01807-w</pub-id><pub-id pub-id-type="pmid">37420174</pub-id><pub-id pub-id-type="pmcid">PMC10401791</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Chehelgerdi M, Chehelgerdi M. The use of RNA-based treatments in the field of cancer immunotherapy. Mol Cancer. 2023;22:106. 10.1186/s12943-023-01807-w.<pub-id pub-id-type="pmid">37420174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01807-w</pub-id><pub-id pub-id-type="pmcid">PMC10401791</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polewska</surname><given-names>K</given-names></name><name name-style="western"><surname>Tylicki</surname><given-names>P</given-names></name><name name-style="western"><surname>Biedunkiewicz</surname><given-names>B</given-names></name><etal/></person-group><article-title>Safety and tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project</article-title><source>Medicina (Mex)</source><year>2021</year><volume>57</volume><fpage>732</fpage><pub-id pub-id-type="doi">10.3390/medicina57070732</pub-id><pub-id pub-id-type="pmcid">PMC8307559</pub-id><pub-id pub-id-type="pmid">34357013</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Polewska K, Tylicki P, Biedunkiewicz B, et al. Safety and tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project. Medicina (Mex). 2021;57:732. 10.3390/medicina57070732.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/medicina57070732</pub-id><pub-id pub-id-type="pmcid">PMC8307559</pub-id><pub-id pub-id-type="pmid">34357013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemente</surname><given-names>B</given-names></name><name name-style="western"><surname>Denis</surname><given-names>M</given-names></name><name name-style="western"><surname>Silveira</surname><given-names>CP</given-names></name><name name-style="western"><surname>Schiavetti</surname><given-names>F</given-names></name><name name-style="western"><surname>Brazzoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Stranges</surname><given-names>D</given-names></name></person-group><article-title>Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1294929</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1294929</pub-id><pub-id pub-id-type="pmid">38090568</pub-id><pub-id pub-id-type="pmcid">PMC10711611</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Clemente B, Denis M, Silveira CP, Schiavetti F, Brazzoli M, Stranges D. Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design. Front Immunol. 2023;14:1294929. 10.3389/fimmu.2023.1294929.<pub-id pub-id-type="pmid">38090568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1294929</pub-id><pub-id pub-id-type="pmcid">PMC10711611</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chivukula</surname><given-names>S</given-names></name><name name-style="western"><surname>Plitnik</surname><given-names>T</given-names></name><name name-style="western"><surname>Tibbitts</surname><given-names>T</given-names></name><name name-style="western"><surname>Karve</surname><given-names>S</given-names></name><name name-style="western"><surname>Dias</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>153</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00420-6</pub-id><pub-id pub-id-type="pmid">34916519</pub-id><pub-id pub-id-type="pmcid">PMC8677760</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Chivukula S, Plitnik T, Tibbitts T, Karve S, Dias A, Zhang D, et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. NPJ Vaccines. 2021;6:153. 10.1038/s41541-021-00420-6.<pub-id pub-id-type="pmid">34916519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-021-00420-6</pub-id><pub-id pub-id-type="pmcid">PMC8677760</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papachristofilou</surname><given-names>A</given-names></name><name name-style="western"><surname>Hipp</surname><given-names>MM</given-names></name><name name-style="western"><surname>Klinkhardt</surname><given-names>U</given-names></name><name name-style="western"><surname>Fr&#252;h</surname><given-names>M</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>M</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer</article-title><source>J Immunother Cancer</source><year>2019</year><volume>7</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0520-5</pub-id><pub-id pub-id-type="pmid">30736848</pub-id><pub-id pub-id-type="pmcid">PMC6368815</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Papachristofilou A, Hipp MM, Klinkhardt U, Fr&#252;h M, Sebastian M, Weiss C, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2019;7:38. 10.1186/s40425-019-0520-5.<pub-id pub-id-type="pmid">30736848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-019-0520-5</pub-id><pub-id pub-id-type="pmcid">PMC6368815</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilgenhof</surname><given-names>S</given-names></name><name name-style="western"><surname>Van Nuffel</surname><given-names>AMT</given-names></name><name name-style="western"><surname>Benteyn</surname><given-names>D</given-names></name><name name-style="western"><surname>Corthals</surname><given-names>J</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>C</given-names></name><name name-style="western"><surname>Heirman</surname><given-names>C</given-names></name><etal/></person-group><article-title>A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><fpage>2686</fpage><lpage>2693</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt245</pub-id><pub-id pub-id-type="pmid">23904461</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Wilgenhof S, Van Nuffel AMT, Benteyn D, Corthals J, Aerts C, Heirman C, et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol. 2013;24:2686&#8211;93. 10.1093/annonc/mdt245.<pub-id pub-id-type="pmid">23904461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdt245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kruse</surname><given-names>V</given-names></name><name name-style="western"><surname>Corthals</surname><given-names>J</given-names></name><name name-style="western"><surname>Schats</surname><given-names>K</given-names></name><name name-style="western"><surname>van Dam</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Seremet</surname><given-names>T</given-names></name><etal/></person-group><article-title>A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases</article-title><source>Cancer Immunol Immunother</source><year>2020</year><volume>69</volume><fpage>2589</fpage><lpage>2598</lpage><pub-id pub-id-type="doi">10.1007/s00262-020-02618-4</pub-id><pub-id pub-id-type="pmid">32591862</pub-id><pub-id pub-id-type="pmcid">PMC11027452</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Jansen Y, Kruse V, Corthals J, Schats K, van Dam PJ, Seremet T, et al. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol Immunother. 2020;69:2589&#8211;98. 10.1007/s00262-020-02618-4.<pub-id pub-id-type="pmid">32591862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-020-02618-4</pub-id><pub-id pub-id-type="pmcid">PMC11027452</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnholtz-Sloan</surname><given-names>JS</given-names></name><name name-style="western"><surname>Ostrom</surname><given-names>QT</given-names></name><name name-style="western"><surname>Cote</surname><given-names>D</given-names></name></person-group><article-title>Epidemiology of Brain Tumors</article-title><source>Neurol Clin</source><year>2018</year><volume>36</volume><fpage>395</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.ncl.2018.04.001</pub-id><pub-id pub-id-type="pmid">30072062</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of Brain Tumors. Neurol Clin. 2018;36:395&#8211;419. 10.1016/j.ncl.2018.04.001.<pub-id pub-id-type="pmid">30072062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ncl.2018.04.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melnick</surname><given-names>K</given-names></name><name name-style="western"><surname>Dastmalchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>D</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M</given-names></name><name name-style="western"><surname>Sayour</surname><given-names>EJ</given-names></name></person-group><article-title>Contemporary RNA therapeutics for glioblastoma</article-title><source>NeuroMolecular Med</source><year>2022</year><volume>24</volume><fpage>8</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s12017-021-08669-9</pub-id><pub-id pub-id-type="pmid">34101090</pub-id><pub-id pub-id-type="pmcid">PMC8186014</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Melnick K, Dastmalchi F, Mitchell D, Rahman M, Sayour EJ. Contemporary RNA therapeutics for glioblastoma. NeuroMolecular Med. 2022;24:8&#8211;12. 10.1007/s12017-021-08669-9.<pub-id pub-id-type="pmid">34101090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12017-021-08669-9</pub-id><pub-id pub-id-type="pmcid">PMC8186014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Groot</surname><given-names>PM</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Carter</surname><given-names>BW</given-names></name><name name-style="western"><surname>Munden</surname><given-names>RF</given-names></name></person-group><article-title>The epidemiology of lung cancer</article-title><source>Transl Lung Cancer Res</source><year>2018</year><volume>7</volume><fpage>220</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.21037/tlcr.2018.05.06</pub-id><pub-id pub-id-type="pmid">30050761</pub-id><pub-id pub-id-type="pmcid">PMC6037963</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">De Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7:220&#8211;33. 10.21037/tlcr.2018.05.06.<pub-id pub-id-type="pmid">30050761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr.2018.05.06</pub-id><pub-id pub-id-type="pmcid">PMC6037963</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sebastian</surname><given-names>M</given-names></name><name name-style="western"><surname>Schr&#246;der</surname><given-names>A</given-names></name><name name-style="western"><surname>Scheel</surname><given-names>B</given-names></name><name name-style="western"><surname>Hong</surname><given-names>HS</given-names></name><name name-style="western"><surname>Muth</surname><given-names>A</given-names></name><name name-style="western"><surname>von Boehmer</surname><given-names>L</given-names></name><etal/></person-group><article-title>A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer</article-title><source>Cancer Immunol Immunother</source><year>2019</year><volume>68</volume><fpage>799</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1007/s00262-019-02315-x</pub-id><pub-id pub-id-type="pmid">30770959</pub-id><pub-id pub-id-type="pmcid">PMC11028316</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Sebastian M, Schr&#246;der A, Scheel B, Hong HS, Muth A, von Boehmer L, et al. A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer. Cancer Immunol Immunother. 2019;68:799&#8211;812. 10.1007/s00262-019-02315-x.<pub-id pub-id-type="pmid">30770959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-019-02315-x</pub-id><pub-id pub-id-type="pmcid">PMC11028316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209&#8211;49. 10.3322/caac.21660.<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korzun</surname><given-names>T</given-names></name><name name-style="western"><surname>Moses</surname><given-names>AS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name><name name-style="western"><surname>Schumann</surname><given-names>C</given-names></name><name name-style="western"><surname>Levasseur</surname><given-names>PR</given-names></name><etal/></person-group><article-title>Nanoparticle-based follistatin messenger RNA therapy for reprogramming metastatic ovarian cancer and ameliorating cancer-associated Cachexia</article-title><source>Small Weinh Bergstr Ger</source><year>2022</year><volume>18</volume><fpage>e2204436</fpage><pub-id pub-id-type="doi">10.1002/smll.202204436</pub-id><pub-id pub-id-type="pmcid">PMC9633376</pub-id><pub-id pub-id-type="pmid">36098251</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Korzun T, Moses AS, Kim J, Patel S, Schumann C, Levasseur PR, et al. Nanoparticle-based follistatin messenger RNA therapy for reprogramming metastatic ovarian cancer and ameliorating cancer-associated Cachexia. Small Weinh Bergstr Ger. 2022;18:e2204436. 10.1002/smll.202204436.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202204436</pub-id><pub-id pub-id-type="pmcid">PMC9633376</pub-id><pub-id pub-id-type="pmid">36098251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>M</given-names></name><name name-style="western"><surname>Heimes</surname><given-names>A-S</given-names></name></person-group><article-title>Immunomodulating therapies in breast cancer&#8212;from prognosis to clinical practice</article-title><source>Cancers</source><year>2021</year><volume>13</volume><fpage>4883</fpage><pub-id pub-id-type="doi">10.3390/cancers13194883</pub-id><pub-id pub-id-type="pmid">34638367</pub-id><pub-id pub-id-type="pmcid">PMC8507771</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Schmidt M, Heimes A-S. Immunomodulating therapies in breast cancer&#8212;from prognosis to clinical practice. Cancers. 2021;13:4883. 10.3390/cancers13194883.<pub-id pub-id-type="pmid">34638367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13194883</pub-id><pub-id pub-id-type="pmcid">PMC8507771</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>mRNA vaccination in breast cancer: current progress and future direction</article-title><source>J Cancer Res Clin Oncol</source><year>2023</year><volume>149</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s00432-023-04805-z</pub-id><pub-id pub-id-type="pmid">37100972</pub-id><pub-id pub-id-type="pmcid">PMC10132791</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Jiang X, Liu Q. mRNA vaccination in breast cancer: current progress and future direction. J Cancer Res Clin Oncol. 2023;149:1&#8211;16. 10.1007/s00432-023-04805-z.<pub-id pub-id-type="pmid">37100972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00432-023-04805-z</pub-id><pub-id pub-id-type="pmcid">PMC10132791</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shteinberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Haq</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Polineni</surname><given-names>D</given-names></name><name name-style="western"><surname>Davies</surname><given-names>JC</given-names></name></person-group><article-title>Cystic fibrosis</article-title><source>The Lancet</source><year>2021</year><volume>397</volume><fpage>2195</fpage><lpage>2211</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32542-3</pub-id><pub-id pub-id-type="pmid">34090606</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. The Lancet. 2021;397:2195&#8211;211. 10.1016/S0140-6736(20)32542-3.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32542-3</pub-id><pub-id pub-id-type="pmid">34090606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Duan</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Hou</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Activation and induction of antigen-specific T follicular helper cells play a critical role in recombinant SARS-CoV-2 RBD vaccine-induced humoral responses</article-title><source>Mol Biomed</source><year>2023</year><volume>4</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s43556-023-00145-z</pub-id><pub-id pub-id-type="pmid">37853288</pub-id><pub-id pub-id-type="pmcid">PMC10584785</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Yang S, Duan L, Wang C, Zhang C, Hou S, Wang H, et al. Activation and induction of antigen-specific T follicular helper cells play a critical role in recombinant SARS-CoV-2 RBD vaccine-induced humoral responses. Mol Biomed. 2023;4:34. 10.1186/s43556-023-00145-z.<pub-id pub-id-type="pmid">37853288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s43556-023-00145-z</pub-id><pub-id pub-id-type="pmcid">PMC10584785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferraro</surname><given-names>B</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>MP</given-names></name><name name-style="western"><surname>Hutnick</surname><given-names>NA</given-names></name><name name-style="western"><surname>Shin</surname><given-names>TH</given-names></name><name name-style="western"><surname>Lucke</surname><given-names>CE</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></name></person-group><article-title>Clinical applications of DNA Vaccines: current progress</article-title><source>Clin Infect Dis Off Publ Infect Dis Soc Am</source><year>2011</year><volume>53</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1093/cid/cir334</pub-id><pub-id pub-id-type="pmcid">PMC3202319</pub-id><pub-id pub-id-type="pmid">21765081</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA Vaccines: current progress. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;53:296&#8211;302. 10.1093/cid/cir334.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cir334</pub-id><pub-id pub-id-type="pmcid">PMC3202319</pub-id><pub-id pub-id-type="pmid">21765081</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coban</surname><given-names>C</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Aoshi</surname><given-names>T</given-names></name><name name-style="western"><surname>Takeshita</surname><given-names>F</given-names></name><name name-style="western"><surname>Horii</surname><given-names>T</given-names></name><name name-style="western"><surname>Akira</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K</given-names></name></person-group><article-title>Novel strategies to improve DNA vaccine immunogenicity</article-title><source>Curr Gene Ther</source><year>2011</year><volume>11</volume><fpage>479</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.2174/156652311798192815</pub-id><pub-id pub-id-type="pmid">22023477</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira SJ, Ishii K. Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther. 2011;11:479&#8211;84. 10.2174/156652311798192815.<pub-id pub-id-type="pmid">22023477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/156652311798192815</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prophylactic and therapeutic HPV vaccines: current scenario and perspectives</article-title><source>Front Cell Infect Microbiol</source><year>2022</year><volume>12</volume><fpage>909223</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2022.909223</pub-id><pub-id pub-id-type="pmid">35860379</pub-id><pub-id pub-id-type="pmcid">PMC9289603</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J, et al. Prophylactic and therapeutic HPV vaccines: current scenario and perspectives. Front Cell Infect Microbiol. 2022;12:909223. 10.3389/fcimb.2022.909223.<pub-id pub-id-type="pmid">35860379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2022.909223</pub-id><pub-id pub-id-type="pmcid">PMC9289603</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joura</surname><given-names>EA</given-names></name><name name-style="western"><surname>Giuliano</surname><given-names>AR</given-names></name><name name-style="western"><surname>Iversen</surname><given-names>OE</given-names></name><name name-style="western"><surname>Bouchard</surname><given-names>C</given-names></name><name name-style="western"><surname>Mao</surname><given-names>C</given-names></name><name name-style="western"><surname>Mehlsen</surname><given-names>J</given-names></name><etal/></person-group><article-title>A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1405044</pub-id><pub-id pub-id-type="pmid">25693011</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med. 2015;372:711&#8211;23. 10.1056/NEJMoa1405044.<pub-id pub-id-type="pmid">25693011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1405044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanley</surname><given-names>M</given-names></name><name name-style="western"><surname>Joura</surname><given-names>E</given-names></name><name name-style="western"><surname>Yen</surname><given-names>GP</given-names></name><name name-style="western"><surname>Kothari</surname><given-names>S</given-names></name><name name-style="western"><surname>Luxembourg</surname><given-names>A</given-names></name><name name-style="western"><surname>Saah</surname><given-names>A</given-names></name><etal/></person-group><article-title>Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2214</fpage><lpage>2223</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.01.060</pub-id><pub-id pub-id-type="pmid">33658126</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Stanley M, Joura E, Yen GP, Kothari S, Luxembourg A, Saah A, et al. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines. Vaccine. 2021;39:2214&#8211;23. 10.1016/j.vaccine.2021.01.060.<pub-id pub-id-type="pmid">33658126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.01.060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>L</given-names></name><name name-style="western"><surname>Tumban</surname><given-names>E</given-names></name></person-group><article-title>Virus-like particle-based L2 vaccines against HPVs: where are we today?</article-title><source>Viruses</source><year>2019</year><volume>12</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.3390/v12010018</pub-id><pub-id pub-id-type="pmid">31877975</pub-id><pub-id pub-id-type="pmcid">PMC7019592</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Yadav R, Zhai L, Tumban E. Virus-like particle-based L2 vaccines against HPVs: where are we today? Viruses. 2019;12:18. 10.3390/v12010018.<pub-id pub-id-type="pmid">31877975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v12010018</pub-id><pub-id pub-id-type="pmcid">PMC7019592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adkins</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wagstaff</surname><given-names>AJ</given-names></name></person-group><article-title>Recombinant hepatitis B Vaccine*: a review of its immunogenicity and protective efficacy against hepatitis B</article-title><source>BioDrugs</source><year>1998</year><volume>10</volume><fpage>137</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.2165/00063030-199810020-00005</pub-id><pub-id pub-id-type="pmid">18020591</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Adkins JC, Wagstaff AJ. Recombinant hepatitis B Vaccine*: a review of its immunogenicity and protective efficacy against hepatitis B. BioDrugs. 1998;10:137&#8211;58. 10.2165/00063030-199810020-00005.<pub-id pub-id-type="pmid">18020591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00063030-199810020-00005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laddy</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Kutzler</surname><given-names>M</given-names></name><name name-style="western"><surname>Kobasa</surname><given-names>D</given-names></name><name name-style="western"><surname>Kobinger</surname><given-names>GP</given-names></name><name name-style="western"><surname>Khan</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><fpage>e2517</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0002517</pub-id><pub-id pub-id-type="pmid">18575608</pub-id><pub-id pub-id-type="pmcid">PMC2429965</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS, et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE. 2008;3:e2517. 10.1371/journal.pone.0002517.<pub-id pub-id-type="pmid">18575608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0002517</pub-id><pub-id pub-id-type="pmcid">PMC2429965</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Athmaram</surname><given-names>T</given-names></name><name name-style="western"><surname>Saraswat</surname><given-names>S</given-names></name><name name-style="western"><surname>Santhosh</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>AK</given-names></name><name name-style="western"><surname>Suryanarayana</surname><given-names>VVS</given-names></name><name name-style="western"><surname>Priya</surname><given-names>R</given-names></name><etal/></person-group><article-title>Yeast expressed recombinant Hemagglutinin protein of Novel H1N1 elicits neutralising antibodies in rabbits and mice</article-title><source>Virol J</source><year>2011</year><volume>8</volume><fpage>524</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-524</pub-id><pub-id pub-id-type="pmid">22126628</pub-id><pub-id pub-id-type="pmcid">PMC3251546</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Athmaram T, Saraswat S, Santhosh S, Singh AK, Suryanarayana VVS, Priya R, et al. Yeast expressed recombinant Hemagglutinin protein of Novel H1N1 elicits neutralising antibodies in rabbits and mice. Virol J. 2011;8:524. 10.1186/1743-422X-8-524.<pub-id pub-id-type="pmid">22126628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1743-422X-8-524</pub-id><pub-id pub-id-type="pmcid">PMC3251546</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>LR</given-names></name><name name-style="western"><surname>Wloch</surname><given-names>MK</given-names></name><name name-style="western"><surname>Ye</surname><given-names>M</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>LR</given-names></name><name name-style="western"><surname>Boutsaboualoy</surname><given-names>S</given-names></name><name name-style="western"><surname>Dunne</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>2565</fpage><lpage>2572</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.029</pub-id><pub-id pub-id-type="pmid">20117262</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine. 2010;28:2565&#8211;72. 10.1016/j.vaccine.2010.01.029.<pub-id pub-id-type="pmid">20117262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.01.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edupuganti</surname><given-names>S</given-names></name><name name-style="western"><surname>C De Rosa</surname><given-names>S</given-names></name><name name-style="western"><surname>Elizaga</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Swann</surname><given-names>E</given-names></name><etal/></person-group><article-title>Intramuscular and intradermal electroporation of HIV-1 PENNVAX-GP&#174; DNA vaccine and IL-12 Is Safe, tolerable, acceptable in healthy adults acceptable in healthy adults</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><fpage>741</fpage><pub-id pub-id-type="doi">10.3390/vaccines804</pub-id><pub-id pub-id-type="pmid">33297341</pub-id><pub-id pub-id-type="pmcid">PMC7762306</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Edupuganti S, C De Rosa S, Elizaga M, Lu Y, Han X, Huang Y, Swann E, et al. Intramuscular and intradermal electroporation of HIV-1 PENNVAX-GP&#174; DNA vaccine and IL-12 Is Safe, tolerable, acceptable in healthy adults acceptable in healthy adults. Vaccines. 2020;8:741. 10.3390/vaccines804.<pub-id pub-id-type="pmid">33297341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8040741</pub-id><pub-id pub-id-type="pmcid">PMC7762306</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez</surname><given-names>RD</given-names></name><name name-style="western"><surname>Huh</surname><given-names>WK</given-names></name><name name-style="western"><surname>Bae</surname><given-names>S</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>LS</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Conner</surname><given-names>MG</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>J</given-names></name><etal/></person-group><article-title>A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3)</article-title><source>Gynecol Oncol</source><year>2016</year><volume>140</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2015.11.026</pub-id><pub-id pub-id-type="pmid">26616223</pub-id><pub-id pub-id-type="pmcid">PMC4724445</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Alvarez RD, Huh WK, Bae S, Lamb LS Jr, Conner MG, Boyer J, et al. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecol Oncol. 2016;140:245&#8211;52. 10.1016/j.ygyno.2015.11.026.<pub-id pub-id-type="pmid">26616223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2015.11.026</pub-id><pub-id pub-id-type="pmcid">PMC4724445</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Changhong</surname><given-names>S</given-names></name><name name-style="western"><surname>Hai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Limei</surname><given-names>W</given-names></name><name name-style="western"><surname>Jiaze</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Tingfen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene</article-title><source>Tuberculosis</source><year>2009</year><volume>89</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2008.09.005</pub-id><pub-id pub-id-type="pmid">19056317</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Changhong S, Hai Z, Limei W, Jiaze A, Li X, Tingfen Z, et al. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene. Tuberculosis. 2009;89:54&#8211;61. 10.1016/j.tube.2008.09.005.<pub-id pub-id-type="pmid">19056317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tube.2008.09.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gootenberg</surname><given-names>JS</given-names></name><name name-style="western"><surname>Abudayyeh</surname><given-names>OO</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JW</given-names></name><name name-style="western"><surname>Essletzbichler</surname><given-names>P</given-names></name><name name-style="western"><surname>Dy</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Joung</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nucleic acid detection with CRISPR-Cas13a/C2c2</article-title><source>Science</source><year>2017</year><volume>356</volume><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1126/science.aam9321</pub-id><pub-id pub-id-type="pmid">28408723</pub-id><pub-id pub-id-type="pmcid">PMC5526198</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356:438&#8211;42. 10.1126/science.aam9321.<pub-id pub-id-type="pmid">28408723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aam9321</pub-id><pub-id pub-id-type="pmcid">PMC5526198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajan</surname><given-names>A</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>S</given-names></name></person-group><article-title>Janhawi, Kumar A, Singh AK, Arora PK: CRISPR-Cas system: from diagnostic tool to potential antiviral treatment</article-title><source>Appl Microbiol Biotechnol</source><year>2022</year><volume>106</volume><fpage>5863</fpage><lpage>5877</lpage><pub-id pub-id-type="doi">10.1007/s00253-022-12135-2</pub-id><pub-id pub-id-type="pmid">36008567</pub-id><pub-id pub-id-type="pmcid">PMC9411046</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Rajan A, Shrivastava S. Janhawi, Kumar A, Singh AK, Arora PK: CRISPR-Cas system: from diagnostic tool to potential antiviral treatment. Appl Microbiol Biotechnol. 2022;106:5863&#8211;77. 10.1007/s00253-022-12135-2.<pub-id pub-id-type="pmid">36008567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00253-022-12135-2</pub-id><pub-id pub-id-type="pmcid">PMC9411046</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;termier</surname><given-names>M</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>P</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>BS</given-names></name></person-group><article-title>Is non-homologous end-joining really an inherently error-prone process?</article-title><source>PLoS Genet</source><year>2014</year><volume>10</volume><fpage>e1004086</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1004086</pub-id><pub-id pub-id-type="pmid">24453986</pub-id><pub-id pub-id-type="pmcid">PMC3894167</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">B&#233;termier M, Bertrand P, Lopez BS. Is non-homologous end-joining really an inherently error-prone process? PLoS Genet. 2014;10:e1004086. 10.1371/journal.pgen.1004086.<pub-id pub-id-type="pmid">24453986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1004086</pub-id><pub-id pub-id-type="pmcid">PMC3894167</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cebrian-Serrano</surname><given-names>A</given-names></name><name name-style="western"><surname>Davies</surname><given-names>B</given-names></name></person-group><article-title>CRISPR-Cas orthologues and variants: optimizing the repertoire, specificity and delivery of genome engineering tools</article-title><source>Mamm Genome</source><year>2017</year><volume>28</volume><fpage>247</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1007/s00335-017-9697-4</pub-id><pub-id pub-id-type="pmid">28634692</pub-id><pub-id pub-id-type="pmcid">PMC5569134</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Cebrian-Serrano A, Davies B. CRISPR-Cas orthologues and variants: optimizing the repertoire, specificity and delivery of genome engineering tools. Mamm Genome. 2017;28:247&#8211;61. 10.1007/s00335-017-9697-4.<pub-id pub-id-type="pmid">28634692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00335-017-9697-4</pub-id><pub-id pub-id-type="pmcid">PMC5569134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>A</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Duan</surname><given-names>X</given-names></name></person-group><article-title>HBV cccDNA and its potential as a therapeutic target</article-title><source>J Clin Transl Hepatol</source><year>2019</year><volume>7</volume><fpage>258</fpage><pub-id pub-id-type="doi">10.14218/JCTH.2018.00054</pub-id><pub-id pub-id-type="pmid">31608218</pub-id><pub-id pub-id-type="pmcid">PMC6783673</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Zhu A, Liao X, Li S, Zhao H, Chen L, Xu M, Duan X. HBV cccDNA and its potential as a therapeutic target. J Clin Transl Hepatol. 2019;7:258. 10.14218/JCTH.2018.00054.<pub-id pub-id-type="pmid">31608218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14218/JCTH.2018.00054</pub-id><pub-id pub-id-type="pmcid">PMC6783673</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Removal of integrated hepatitis B virus DNA using CRISPR-Cas9</article-title><source>Front Cell Infect Microbiol</source><year>2017</year><volume>7</volume><fpage>91</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2017.00091</pub-id><pub-id pub-id-type="pmid">28382278</pub-id><pub-id pub-id-type="pmcid">PMC5360708</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Li H, Sheng C, Wang S, Yang L, Liang Y, Huang Y, et al. Removal of integrated hepatitis B virus DNA using CRISPR-Cas9. Front Cell Infect Microbiol. 2017;7:91. 10.3389/fcimb.2017.00091.<pub-id pub-id-type="pmid">28382278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2017.00091</pub-id><pub-id pub-id-type="pmcid">PMC5360708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramanan</surname><given-names>V</given-names></name><name name-style="western"><surname>Shlomai</surname><given-names>A</given-names></name><name name-style="western"><surname>Cox</surname><given-names>DB</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>RE</given-names></name><name name-style="western"><surname>Michailidis</surname><given-names>E</given-names></name><name name-style="western"><surname>Bhatta</surname><given-names>A</given-names></name><etal/></person-group><article-title>CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>10833</fpage><pub-id pub-id-type="doi">10.1038/srep10833</pub-id><pub-id pub-id-type="pmid">26035283</pub-id><pub-id pub-id-type="pmcid">PMC4649911</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Ramanan V, Shlomai A, Cox DB, Schwartz RE, Michailidis E, Bhatta A, et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep. 2015;5:10833. 10.1038/srep10833.<pub-id pub-id-type="pmid">26035283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep10833</pub-id><pub-id pub-id-type="pmcid">PMC4649911</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanaparthy</surname><given-names>R</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>G</given-names></name><name name-style="western"><surname>Vasireddy</surname><given-names>D</given-names></name><name name-style="western"><surname>Atluri</surname><given-names>P</given-names></name></person-group><article-title>Review of COVID-19 viral vector-based vaccines and COVID-19 variants</article-title><source>Infez Med</source><year>2021</year><volume>29</volume><fpage>328</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.53854/liim-2903-3</pub-id><pub-id pub-id-type="pmid">35146337</pub-id><pub-id pub-id-type="pmcid">PMC8805485</pub-id></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Vanaparthy R, Mohan G, Vasireddy D, Atluri P. Review of COVID-19 viral vector-based vaccines and COVID-19 variants. Infez Med. 2021;29:328&#8211;38. 10.53854/liim-2903-3.<pub-id pub-id-type="pmid">35146337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.53854/liim-2903-3</pub-id><pub-id pub-id-type="pmcid">PMC8805485</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>C</given-names></name><name name-style="western"><surname>Owens</surname><given-names>C</given-names></name><name name-style="western"><surname>Gamboa</surname><given-names>W</given-names></name><name name-style="western"><surname>Lopez-Yunez</surname><given-names>A</given-names></name></person-group><article-title>Evaluating Johnson and Johnson COVID-19 Vaccination Outcomes in a Low-Income Hispanic Population</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>148</fpage><pub-id pub-id-type="doi">10.3390/vaccines11010148</pub-id><pub-id pub-id-type="pmid">36679993</pub-id><pub-id pub-id-type="pmcid">PMC9865710</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Lamb C, Owens C, Gamboa W, Lopez-Yunez A. Evaluating Johnson and Johnson COVID-19 Vaccination Outcomes in a Low-Income Hispanic Population. Vaccines. 2023;11:148. 10.3390/vaccines11010148.<pub-id pub-id-type="pmid">36679993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11010148</pub-id><pub-id pub-id-type="pmcid">PMC9865710</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><mixed-citation publication-type="other">Dunne RB: How the Johnson &amp; Johnson Covid-19 Vaccine Works - The New York Times. N Y Times.</mixed-citation></ref><ref id="CR177"><label>177.</label><mixed-citation publication-type="other">Falsey Ann R., Sobieszczyk Magdalena E., Hirsch Ian, et al.: Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021, 385:2348&#8211;60. 10.1056/NEJMoa2105290<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2105290</pub-id><pub-id pub-id-type="pmcid">PMC8522798</pub-id><pub-id pub-id-type="pmid">34587382</pub-id></mixed-citation></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaznadzey</surname><given-names>A</given-names></name><name name-style="western"><surname>Tutukina</surname><given-names>M</given-names></name><name name-style="western"><surname>Bessonova</surname><given-names>T</given-names></name><name name-style="western"><surname>Kireeva</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazo</surname><given-names>I</given-names></name></person-group><article-title>BNT162b2, mRNA-1273, and Sputnik V vaccines induce comparable immune responses on a par with severe course of COVID-19</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>797918</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.797918</pub-id><pub-id pub-id-type="pmid">35493476</pub-id><pub-id pub-id-type="pmcid">PMC9044856</pub-id></element-citation><mixed-citation id="mc-CR178" publication-type="journal">Kaznadzey A, Tutukina M, Bessonova T, Kireeva M, Mazo I. BNT162b2, mRNA-1273, and Sputnik V vaccines induce comparable immune responses on a par with severe course of COVID-19. Front Immunol. 2022;13:797918. 10.3389/fimmu.2022.797918.<pub-id pub-id-type="pmid">35493476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.797918</pub-id><pub-id pub-id-type="pmcid">PMC9044856</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;nchez-Sampedro</surname><given-names>L</given-names></name><name name-style="western"><surname>Perdiguero</surname><given-names>B</given-names></name><name name-style="western"><surname>Mej&#237;as-P&#233;rez</surname><given-names>E</given-names></name><name name-style="western"><surname>Garc&#237;a-Arriaza</surname><given-names>J</given-names></name><name name-style="western"><surname>Di Pilato</surname><given-names>M</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>M</given-names></name></person-group><article-title>The evolution of poxvirus vaccines</article-title><source>Viruses</source><year>2015</year><volume>7</volume><fpage>1726</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.3390/v7041726</pub-id><pub-id pub-id-type="pmid">25853483</pub-id><pub-id pub-id-type="pmcid">PMC4411676</pub-id></element-citation><mixed-citation id="mc-CR179" publication-type="journal">S&#225;nchez-Sampedro L, Perdiguero B, Mej&#237;as-P&#233;rez E, Garc&#237;a-Arriaza J, Di Pilato M, Esteban M. The evolution of poxvirus vaccines. Viruses. 2015;7:1726&#8211;803. 10.3390/v7041726.<pub-id pub-id-type="pmid">25853483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v7041726</pub-id><pub-id pub-id-type="pmcid">PMC4411676</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name></person-group><article-title>Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells</article-title><source>Cancer Biol Ther</source><year>2014</year><volume>15</volume><fpage>1358</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.4161/cbt.29842</pub-id><pub-id pub-id-type="pmid">25019940</pub-id><pub-id pub-id-type="pmcid">PMC4130729</pub-id></element-citation><mixed-citation id="mc-CR180" publication-type="journal">Wei F, Wang H, Chen X, Li C, Huang Q. Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells. Cancer Biol Ther. 2014;15:1358&#8211;66. 10.4161/cbt.29842.<pub-id pub-id-type="pmid">25019940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/cbt.29842</pub-id><pub-id pub-id-type="pmcid">PMC4130729</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wei</surname><given-names>F</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Kan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Current status and progress of the development of prostate cancer vaccines</article-title><source>J Cancer</source><year>2023</year><volume>14</volume><fpage>835</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.7150/jca.80803</pub-id><pub-id pub-id-type="pmid">37056394</pub-id><pub-id pub-id-type="pmcid">PMC10088880</pub-id></element-citation><mixed-citation id="mc-CR181" publication-type="journal">Wang J, Zhou K, Zhu H, Wei F, Ma S, Kan Y, et al. Current status and progress of the development of prostate cancer vaccines. J Cancer. 2023;14:835&#8211;42. 10.7150/jca.80803.<pub-id pub-id-type="pmid">37056394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/jca.80803</pub-id><pub-id pub-id-type="pmcid">PMC10088880</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piya</surname><given-names>S</given-names></name><name name-style="western"><surname>White</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Klein</surname><given-names>SR</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>McDonnell</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Gomez-Manzano</surname><given-names>C</given-names></name><name name-style="western"><surname>Fueyo</surname><given-names>J</given-names></name></person-group><article-title>The E1B19K oncoprotein complexes with beclin 1 to regulate autophagy in adenovirus-Infected Cells</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><fpage>e29467</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0029467</pub-id><pub-id pub-id-type="pmid">22242123</pub-id><pub-id pub-id-type="pmcid">PMC3248451</pub-id></element-citation><mixed-citation id="mc-CR182" publication-type="journal">Piya S, White EJ, Klein SR, Jiang H, McDonnell TJ, Gomez-Manzano C, Fueyo J. The E1B19K oncoprotein complexes with beclin 1 to regulate autophagy in adenovirus-Infected Cells. PLoS ONE. 2011;6:e29467. 10.1371/journal.pone.0029467.<pub-id pub-id-type="pmid">22242123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0029467</pub-id><pub-id pub-id-type="pmcid">PMC3248451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>P</given-names></name><name name-style="western"><surname>Pal</surname><given-names>SK</given-names></name><name name-style="western"><surname>Alex</surname><given-names>A</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>N</given-names></name></person-group><article-title>Development of PROSTVAC immunotherapy in prostate cancer</article-title><source>Future Oncol</source><year>2015</year><volume>11</volume><fpage>2137</fpage><lpage>2148</lpage><pub-id pub-id-type="doi">10.2217/fon.15.120</pub-id><pub-id pub-id-type="pmid">26235179</pub-id><pub-id pub-id-type="pmcid">PMC4544699</pub-id></element-citation><mixed-citation id="mc-CR183" publication-type="journal">Singh P, Pal SK, Alex A, Agarwal N. Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol. 2015;11:2137&#8211;48. 10.2217/fon.15.120.<pub-id pub-id-type="pmid">26235179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fon.15.120</pub-id><pub-id pub-id-type="pmcid">PMC4544699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bulcha</surname><given-names>JT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H</given-names></name><name name-style="western"><surname>Tai</surname><given-names>PWL</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G</given-names></name></person-group><article-title>Viral vector platforms within the gene therapy landscape</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/s41392-021-00487-6</pub-id><pub-id pub-id-type="pmid">33558455</pub-id><pub-id pub-id-type="pmcid">PMC7868676</pub-id></element-citation><mixed-citation id="mc-CR184" publication-type="journal">Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6:1&#8211;24. 10.1038/s41392-021-00487-6.<pub-id pub-id-type="pmid">33558455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00487-6</pub-id><pub-id pub-id-type="pmcid">PMC7868676</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prado</surname><given-names>DA</given-names></name><name name-style="western"><surname>Acosta-Acero</surname><given-names>M</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>RS</given-names></name></person-group><article-title>Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease</article-title><source>Curr Opin Ophthalmol</source><year>2020</year><volume>31</volume><fpage>147</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1097/ICU.0000000000000660</pub-id><pub-id pub-id-type="pmid">32175942</pub-id></element-citation><mixed-citation id="mc-CR185" publication-type="journal">Prado DA, Acosta-Acero M, Maldonado RS. Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease. Curr Opin Ophthalmol. 2020;31:147&#8211;54. 10.1097/ICU.0000000000000660.<pub-id pub-id-type="pmid">32175942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ICU.0000000000000660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Lopata</surname><given-names>AL</given-names></name></person-group><article-title>The dichotomy of pathogens and allergens in vaccination approaches</article-title><source>Front Microbiol</source><year>2014</year><volume>5</volume><fpage>365</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2014.00365</pub-id><pub-id pub-id-type="pmid">25076945</pub-id><pub-id pub-id-type="pmcid">PMC4100532</pub-id></element-citation><mixed-citation id="mc-CR186" publication-type="journal">Baird FJ, Lopata AL. The dichotomy of pathogens and allergens in vaccination approaches. Front Microbiol. 2014;5:365. 10.3389/fmicb.2014.00365.<pub-id pub-id-type="pmid">25076945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2014.00365</pub-id><pub-id pub-id-type="pmcid">PMC4100532</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muganga</surname><given-names>N</given-names></name><name name-style="western"><surname>Uwimana</surname><given-names>J</given-names></name><name name-style="western"><surname>Fidele</surname><given-names>N</given-names></name><name name-style="western"><surname>Gahimbare</surname><given-names>L</given-names></name><name name-style="western"><surname>Gessner</surname><given-names>BD</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>JE</given-names></name><name name-style="western"><surname>Mhlanga</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Haemophilus influenzae type b conjugate vaccine impact against purulent meningitis in Rwanda</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>7001</fpage><lpage>7005</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.06.032</pub-id><pub-id pub-id-type="pmid">17709159</pub-id></element-citation><mixed-citation id="mc-CR187" publication-type="journal">Muganga N, Uwimana J, Fidele N, Gahimbare L, Gessner BD, Mueller JE, Mhlanga BR, et al. Haemophilus influenzae type b conjugate vaccine impact against purulent meningitis in Rwanda. Vaccine. 2007;25:7001&#8211;5. 10.1016/j.vaccine.2007.06.032.<pub-id pub-id-type="pmid">17709159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.06.032</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laurens</surname><given-names>MB</given-names></name></person-group><article-title>RTS, S/AS01 vaccine (Mosquiri<sup>xT</sup>M): an overview</article-title><source>Hum Vaccines Immunother</source><year>2019</year><volume>16</volume><fpage>480</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1080/21645515.2019.1669415</pub-id><pub-id pub-id-type="pmcid">PMC7227679</pub-id><pub-id pub-id-type="pmid">31545128</pub-id></element-citation><mixed-citation id="mc-CR188" publication-type="journal">Laurens MB. RTS, S/AS01 vaccine (Mosquiri<sup>xT</sup>M): an overview. Hum Vaccines Immunother. 2019;16:480&#8211;9. 10.1080/21645515.2019.1669415.</mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koupaei</surname><given-names>M</given-names></name><name name-style="western"><surname>Shadab Mehr</surname><given-names>N</given-names></name><name name-style="western"><surname>Mohamadi</surname><given-names>MH</given-names></name><name name-style="western"><surname>Asadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Abbasimoghaddam</surname><given-names>S</given-names></name><name name-style="western"><surname>Shekartabar</surname><given-names>A</given-names></name><name name-style="western"><surname>Heidary</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical symptoms, diagnosis, treatment, and outcome of COVID-19-associated encephalitis: a systematic review of case reports and case series</article-title><source>J Clin Lab Anal</source><year>2022</year><volume>36</volume><fpage>e24426</fpage><pub-id pub-id-type="doi">10.1002/jcla.24426</pub-id><pub-id pub-id-type="pmid">35435264</pub-id><pub-id pub-id-type="pmcid">PMC9102669</pub-id></element-citation><mixed-citation id="mc-CR189" publication-type="journal">Koupaei M, Shadab Mehr N, Mohamadi MH, Asadi A, Abbasimoghaddam S, Shekartabar A, Heidary M, et al. Clinical symptoms, diagnosis, treatment, and outcome of COVID-19-associated encephalitis: a systematic review of case reports and case series. J Clin Lab Anal. 2022;36: e24426. 10.1002/jcla.24426.<pub-id pub-id-type="pmid">35435264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcla.24426</pub-id><pub-id pub-id-type="pmcid">PMC9102669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lung</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>Nanoparticle formulated vaccines: opportunities and challenges</article-title><source>Nanoscale</source><year>2020</year><volume>12</volume><fpage>5746</fpage><lpage>5763</lpage><pub-id pub-id-type="doi">10.1039/C9NR08958F</pub-id><pub-id pub-id-type="pmid">32124894</pub-id></element-citation><mixed-citation id="mc-CR190" publication-type="journal">Lung P, Yang J, Li Q. Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale. 2020;12:5746&#8211;63. 10.1039/C9NR08958F.<pub-id pub-id-type="pmid">32124894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9nr08958f</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curley</surname><given-names>SM</given-names></name><name name-style="western"><surname>Putnam</surname><given-names>D</given-names></name></person-group><article-title>Biological nanoparticles in vaccine development</article-title><source>Front Bioeng Biotechnol</source><year>2022</year><volume>10</volume><fpage>867119</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2022.867119</pub-id><pub-id pub-id-type="pmid">35402394</pub-id><pub-id pub-id-type="pmcid">PMC8984165</pub-id></element-citation><mixed-citation id="mc-CR191" publication-type="journal">Curley SM, Putnam D. Biological nanoparticles in vaccine development. Front Bioeng Biotechnol. 2022;10:867119. 10.3389/fbioe.2022.867119.<pub-id pub-id-type="pmid">35402394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbioe.2022.867119</pub-id><pub-id pub-id-type="pmcid">PMC8984165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villa</surname><given-names>LL</given-names></name><name name-style="western"><surname>Costa</surname><given-names>RL</given-names></name><name name-style="western"><surname>Petta</surname><given-names>CA</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>RP</given-names></name><name name-style="western"><surname>Ault</surname><given-names>KA</given-names></name><name name-style="western"><surname>Giuliano</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial</article-title><source>Lancet Oncol</source><year>2005</year><volume>6</volume><fpage>271</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(05)70101-7</pub-id><pub-id pub-id-type="pmid">15863374</pub-id></element-citation><mixed-citation id="mc-CR192" publication-type="journal">Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271&#8211;8. 10.1016/S1470-2045(05)70101-7.<pub-id pub-id-type="pmid">15863374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(05)70101-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>August</surname><given-names>A</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>GM</given-names></name><name name-style="western"><surname>Kpamegan</surname><given-names>E</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>SP</given-names></name><name name-style="western"><surname>Jani</surname><given-names>D</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><etal/></person-group><article-title>A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>3749</fpage><lpage>3759</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.045</pub-id><pub-id pub-id-type="pmid">28579233</pub-id></element-citation><mixed-citation id="mc-CR193" publication-type="journal">August A, Glenn GM, Kpamegan E, Hickman SP, Jani D, Lu H, et al. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017;35:3749&#8211;59. 10.1016/j.vaccine.2017.05.045.<pub-id pub-id-type="pmid">28579233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.05.045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Self-Assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys</article-title><source>Bioconjug Chem</source><year>2021</year><volume>32</volume><fpage>1034</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.1c00208</pub-id><pub-id pub-id-type="pmid">33951913</pub-id></element-citation><mixed-citation id="mc-CR194" publication-type="journal">Li H, Guo L, Zheng H, Li J, Zhao X, Li J, et al. Self-Assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys. Bioconjug Chem. 2021;32:1034&#8211;46. 10.1021/acs.bioconjchem.1c00208.<pub-id pub-id-type="pmid">33951913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.bioconjchem.1c00208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Pelc</surname><given-names>RS</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>H</given-names></name><name name-style="western"><surname>DeMaso</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination</article-title><source>Nature</source><year>2017</year><volume>543</volume><fpage>248</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/nature21428</pub-id><pub-id pub-id-type="pmid">28151488</pub-id><pub-id pub-id-type="pmcid">PMC5344708</pub-id></element-citation><mixed-citation id="mc-CR195" publication-type="journal">Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543:248&#8211;51. 10.1038/nature21428.<pub-id pub-id-type="pmid">28151488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature21428</pub-id><pub-id pub-id-type="pmcid">PMC5344708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>mRNA vaccine for cancer immunotherapy</article-title><source>Mol Cancer</source><year>2021</year><volume>20</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmid">33632261</pub-id><pub-id pub-id-type="pmcid">PMC7905014</pub-id></element-citation><mixed-citation id="mc-CR196" publication-type="journal">Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20:41. 10.1186/s12943-021-01335-5.<pub-id pub-id-type="pmid">33632261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmcid">PMC7905014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>KC</given-names></name></person-group><article-title>Advances of medical nanorobots for future cancer treatments</article-title><source>J Hematol OncolJ Hematol Oncol</source><year>2023</year><volume>16</volume><fpage>74</fpage><pub-id pub-id-type="doi">10.1186/s13045-023-01463-z</pub-id><pub-id pub-id-type="pmid">37452423</pub-id><pub-id pub-id-type="pmcid">PMC10347767</pub-id></element-citation><mixed-citation id="mc-CR197" publication-type="journal">Kong X, Gao P, Wang J, Fang Y, Hwang KC. Advances of medical nanorobots for future cancer treatments. J Hematol OncolJ Hematol Oncol. 2023;16:74. 10.1186/s13045-023-01463-z.<pub-id pub-id-type="pmid">37452423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-023-01463-z</pub-id><pub-id pub-id-type="pmcid">PMC10347767</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pati</surname><given-names>R</given-names></name><name name-style="western"><surname>Shevtsov</surname><given-names>M</given-names></name><name name-style="western"><surname>Sonawane</surname><given-names>A</given-names></name></person-group><article-title>Nanoparticle vaccines against infectious diseases</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>2224</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02224</pub-id><pub-id pub-id-type="pmid">30337923</pub-id><pub-id pub-id-type="pmcid">PMC6180194</pub-id></element-citation><mixed-citation id="mc-CR198" publication-type="journal">Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol. 2018;9:2224. 10.3389/fimmu.2018.02224.<pub-id pub-id-type="pmid">30337923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.02224</pub-id><pub-id pub-id-type="pmcid">PMC6180194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A</given-names></name><name name-style="western"><surname>Reed</surname><given-names>P</given-names></name><name name-style="western"><surname>Neal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phase 1&#8211;2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2320</fpage><lpage>2332</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></element-citation><mixed-citation id="mc-CR199" publication-type="journal">Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1&#8211;2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320&#8211;32. 10.1056/NEJMoa2026920.<pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Takami</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kumar Deo</surname><given-names>V</given-names></name><name name-style="western"><surname>Park</surname><given-names>EY</given-names></name></person-group><article-title>Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells</article-title><source>J Biotechnol</source><year>2019</year><volume>306</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2019.10.007</pub-id><pub-id pub-id-type="pmid">31614169</pub-id><pub-id pub-id-type="pmcid">PMC7114102</pub-id></element-citation><mixed-citation id="mc-CR200" publication-type="journal">Kato T, Takami Y, Kumar Deo V, Park EY. Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells. J Biotechnol. 2019;306:177&#8211;84. 10.1016/j.jbiotec.2019.10.007.<pub-id pub-id-type="pmid">31614169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbiotec.2019.10.007</pub-id><pub-id pub-id-type="pmcid">PMC7114102</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H-B</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Q-H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>HIV vaccine research: the challenge and the way forward</article-title><source>J Immunol Res</source><year>2015</year><volume>2015</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1155/2015/503978</pub-id><pub-id pub-id-type="pmcid">PMC4377490</pub-id><pub-id pub-id-type="pmid">25861656</pub-id></element-citation><mixed-citation id="mc-CR201" publication-type="journal">Wang H-B, Mo Q-H, Yang Z. HIV vaccine research: the challenge and the way forward. J Immunol Res. 2015;2015:1&#8211;5. 10.1155/2015/503978.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/503978</pub-id><pub-id pub-id-type="pmcid">PMC4377490</pub-id><pub-id pub-id-type="pmid">25861656</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hargrave</surname><given-names>A</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>AS</given-names></name><name name-style="western"><surname>Hanif</surname><given-names>A</given-names></name><name name-style="western"><surname>Tunio</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hanif</surname><given-names>SNM</given-names></name></person-group><article-title>Current status of HIV-1 vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>1026</fpage><pub-id pub-id-type="doi">10.3390/vaccines9091026</pub-id><pub-id pub-id-type="pmid">34579263</pub-id><pub-id pub-id-type="pmcid">PMC8471857</pub-id></element-citation><mixed-citation id="mc-CR202" publication-type="journal">Hargrave A, Mustafa AS, Hanif A, Tunio JH, Hanif SNM. Current status of HIV-1 vaccines. Vaccines. 2021;9:1026. 10.3390/vaccines9091026.<pub-id pub-id-type="pmid">34579263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9091026</pub-id><pub-id pub-id-type="pmcid">PMC8471857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarlagadda</surname><given-names>H</given-names></name><name name-style="western"><surname>Patel</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>V</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>T</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>S</given-names></name><name name-style="western"><surname>Shaheen</surname><given-names>N</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R</given-names></name></person-group><article-title>COVID-19 vaccine challenges in developing and developed countries</article-title><source>Cureus</source><year>2022</year><volume>14</volume><fpage>e23951</fpage><pub-id pub-id-type="doi">10.7759/cureus.23951</pub-id><pub-id pub-id-type="pmid">35547442</pub-id><pub-id pub-id-type="pmcid">PMC9085716</pub-id></element-citation><mixed-citation id="mc-CR203" publication-type="journal">Yarlagadda H, Patel MA, Gupta V, Bansal T, Upadhyay S, Shaheen N, Jain R. COVID-19 vaccine challenges in developing and developed countries. Cureus. 2022;14:e23951. 10.7759/cureus.23951.<pub-id pub-id-type="pmid">35547442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.23951</pub-id><pub-id pub-id-type="pmcid">PMC9085716</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204.</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson-Welder</surname><given-names>JH</given-names></name><name name-style="western"><surname>Torres</surname><given-names>MP</given-names></name><name name-style="western"><surname>Kipper</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Mallapragada</surname><given-names>SK</given-names></name><name name-style="western"><surname>Wannemuehler</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>B</given-names></name></person-group><article-title>Vaccine adjuvants: current challenges and future approaches</article-title><source>J Pharm Sci</source><year>2009</year><volume>98</volume><fpage>1278</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1002/jps.21523</pub-id><pub-id pub-id-type="pmid">18704954</pub-id><pub-id pub-id-type="pmcid">PMC8092333</pub-id></element-citation><mixed-citation id="mc-CR204" publication-type="journal">Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci. 2009;98:1278&#8211;316. 10.1002/jps.21523.<pub-id pub-id-type="pmid">18704954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.21523</pub-id><pub-id pub-id-type="pmcid">PMC8092333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205.</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z</given-names></name><name name-style="western"><surname>Williams</surname><given-names>RO</given-names></name></person-group><article-title>The COVID-19 vaccine race: challenges and opportunities in vaccine formulation</article-title><source>AAPS PharmSciTech</source><year>2020</year><volume>21</volume><fpage>225</fpage><pub-id pub-id-type="doi">10.1208/s12249-020-01744-7</pub-id><pub-id pub-id-type="pmid">32761294</pub-id><pub-id pub-id-type="pmcid">PMC7405756</pub-id></element-citation><mixed-citation id="mc-CR205" publication-type="journal">Wang J, Peng Y, Xu H, Cui Z, Williams RO. The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech. 2020;21:225. 10.1208/s12249-020-01744-7.<pub-id pub-id-type="pmid">32761294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12249-020-01744-7</pub-id><pub-id pub-id-type="pmcid">PMC7405756</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206.</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dastgoshade</surname><given-names>S</given-names></name><name name-style="western"><surname>Shafiee</surname><given-names>M</given-names></name><name name-style="western"><surname>Klibi</surname><given-names>W</given-names></name><name name-style="western"><surname>Shishebori</surname><given-names>D</given-names></name></person-group><article-title>Social equity-based distribution networks design for the COVID-19 vaccine</article-title><source>Int J Prod Econ</source><year>2022</year><volume>250</volume><fpage>108684</fpage><pub-id pub-id-type="doi">10.1016/j.ijpe.2022.108684</pub-id><pub-id pub-id-type="pmid">36337682</pub-id><pub-id pub-id-type="pmcid">PMC9627533</pub-id></element-citation><mixed-citation id="mc-CR206" publication-type="journal">Dastgoshade S, Shafiee M, Klibi W, Shishebori D. Social equity-based distribution networks design for the COVID-19 vaccine. Int J Prod Econ. 2022;250:108684. 10.1016/j.ijpe.2022.108684.<pub-id pub-id-type="pmid">36337682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpe.2022.108684</pub-id><pub-id pub-id-type="pmcid">PMC9627533</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207.</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Qahtani</surname><given-names>W</given-names></name><name name-style="western"><surname>Safhi</surname><given-names>F</given-names></name></person-group><article-title>A commentary on realities of developing COVID-19 vaccines discussed through the global health safety perspective</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>274</fpage><pub-id pub-id-type="doi">10.3390/vaccines9030274</pub-id><pub-id pub-id-type="pmid">33803704</pub-id><pub-id pub-id-type="pmcid">PMC8003031</pub-id></element-citation><mixed-citation id="mc-CR207" publication-type="journal">Al-Qahtani W, Safhi F. A commentary on realities of developing COVID-19 vaccines discussed through the global health safety perspective. Vaccines. 2021;9:274. 10.3390/vaccines9030274.<pub-id pub-id-type="pmid">33803704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9030274</pub-id><pub-id pub-id-type="pmcid">PMC8003031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208.</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarro-Torn&#233;</surname><given-names>A</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>F</given-names></name><name name-style="western"><surname>Kersti&#235;ns</surname><given-names>B</given-names></name><name name-style="western"><surname>Aguar</surname><given-names>P</given-names></name><name name-style="western"><surname>Matthiessen</surname><given-names>L</given-names></name></person-group><article-title>Public health-driven research and innovation for next-generation influenza vaccines European Union</article-title><source>Emerg Infect Dis</source><year>2019</year><volume>25</volume><fpage>e180359</fpage><pub-id pub-id-type="doi">10.3201/eid2502.180359</pub-id><pub-id pub-id-type="pmid">30666948</pub-id><pub-id pub-id-type="pmcid">PMC6346458</pub-id></element-citation><mixed-citation id="mc-CR208" publication-type="journal">Navarro-Torn&#233; A, Hanrahan F, Kersti&#235;ns B, Aguar P, Matthiessen L. Public health-driven research and innovation for next-generation influenza vaccines European Union. Emerg Infect Dis. 2019;25:e180359. 10.3201/eid2502.180359.<pub-id pub-id-type="pmid">30666948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2502.180359</pub-id><pub-id pub-id-type="pmcid">PMC6346458</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209.</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pambudi</surname><given-names>NA</given-names></name><name name-style="western"><surname>Sarifudin</surname><given-names>A</given-names></name><name name-style="western"><surname>Gandidi</surname><given-names>IM</given-names></name><name name-style="western"><surname>Romadhon</surname><given-names>R</given-names></name></person-group><article-title>Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs</article-title><source>Energy Rep</source><year>2022</year><volume>8</volume><fpage>955</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1016/j.egyr.2021.12.039</pub-id></element-citation><mixed-citation id="mc-CR209" publication-type="journal">Pambudi NA, Sarifudin A, Gandidi IM, Romadhon R. Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs. Energy Rep. 2022;8:955&#8211;72. 10.1016/j.egyr.2021.12.039.</mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210.</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></name><name name-style="western"><surname>Wiehe</surname><given-names>K</given-names></name><name name-style="western"><surname>Borrow</surname><given-names>P</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>KO</given-names></name><name name-style="western"><surname>Korber</surname><given-names>B</given-names></name><name name-style="western"><surname>Wagh</surname><given-names>K</given-names></name><etal/></person-group><article-title>Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies</article-title><source>Nat Rev Immunol</source><year>2023</year><volume>23</volume><fpage>142</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00753-w</pub-id><pub-id pub-id-type="pmid">35962033</pub-id><pub-id pub-id-type="pmcid">PMC9372928</pub-id></element-citation><mixed-citation id="mc-CR210" publication-type="journal">Haynes BF, Wiehe K, Borrow P, Saunders KO, Korber B, Wagh K, et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol. 2023;23:142&#8211;58. 10.1038/s41577-022-00753-w.<pub-id pub-id-type="pmid">35962033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-022-00753-w</pub-id><pub-id pub-id-type="pmcid">PMC9372928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211.</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barouch</surname><given-names>DH</given-names></name></person-group><article-title>Challenges in the development of an HIV-1 vaccine</article-title><source>Nature</source><year>2008</year><volume>455</volume><issue>7213</issue><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1038/nature07352</pub-id><pub-id pub-id-type="pmid">18833271</pub-id><pub-id pub-id-type="pmcid">PMC2572109</pub-id></element-citation><mixed-citation id="mc-CR211" publication-type="journal">Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008;455(7213):613&#8211;9. 10.1038/nature07352.<pub-id pub-id-type="pmid">18833271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature07352</pub-id><pub-id pub-id-type="pmcid">PMC2572109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212.</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deepak</surname><given-names>P</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W</given-names></name><name name-style="western"><surname>Paley</surname><given-names>MA</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Carvidi</surname><given-names>AB</given-names></name><name name-style="western"><surname>Demissie</surname><given-names>EG</given-names></name><etal/></person-group><article-title>Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: a prospective cohort study</article-title><source>Ann Intern Med</source><year>2021</year><volume>174</volume><fpage>1572</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.7326/M21-1757</pub-id><pub-id pub-id-type="pmid">34461029</pub-id><pub-id pub-id-type="pmcid">PMC8407518</pub-id></element-citation><mixed-citation id="mc-CR212" publication-type="journal">Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: a prospective cohort study. Ann Intern Med. 2021;174:1572&#8211;85. 10.7326/M21-1757.<pub-id pub-id-type="pmid">34461029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M21-1757</pub-id><pub-id pub-id-type="pmcid">PMC8407518</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213.</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alnaimat</surname><given-names>F</given-names></name><name name-style="western"><surname>Sweis</surname><given-names>JJG</given-names></name><name name-style="western"><surname>Jansz</surname><given-names>J</given-names></name><name name-style="western"><surname>Modi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S</given-names></name><name name-style="western"><surname>AbuHelal</surname><given-names>A</given-names></name><etal/></person-group><article-title>vaccination in the era of immunosuppression</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>1446</fpage><pub-id pub-id-type="doi">10.3390/vaccines11091446</pub-id><pub-id pub-id-type="pmid">37766123</pub-id><pub-id pub-id-type="pmcid">PMC10537746</pub-id></element-citation><mixed-citation id="mc-CR213" publication-type="journal">Alnaimat F, Sweis JJG, Jansz J, Modi Z, Prasad S, AbuHelal A, et al. vaccination in the era of immunosuppression. Vaccines. 2023;11:1446. 10.3390/vaccines11091446.<pub-id pub-id-type="pmid">37766123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11091446</pub-id><pub-id pub-id-type="pmcid">PMC10537746</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214.</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kennedy</surname><given-names>RB</given-names></name><name name-style="western"><surname>Ovsyannikova</surname><given-names>IG</given-names></name><name name-style="western"><surname>Palese</surname><given-names>P</given-names></name><name name-style="western"><surname>Poland</surname><given-names>GA</given-names></name></person-group><article-title>Current challenges in vaccinology</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>1181</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01181</pub-id><pub-id pub-id-type="pmid">32670279</pub-id><pub-id pub-id-type="pmcid">PMC7329983</pub-id></element-citation><mixed-citation id="mc-CR214" publication-type="journal">Kennedy RB, Ovsyannikova IG, Palese P, Poland GA. Current challenges in vaccinology. Front Immunol. 2020;11:1181. 10.3389/fimmu.2020.01181.<pub-id pub-id-type="pmid">32670279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.01181</pub-id><pub-id pub-id-type="pmcid">PMC7329983</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215.</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grivennikov</surname><given-names>SI</given-names></name><name name-style="western"><surname>Greten</surname><given-names>FR</given-names></name><name name-style="western"><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>Immunity, inflammation, and cancer</article-title><source>Cell</source><year>2010</year><volume>140</volume><fpage>883</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.01.025</pub-id><pub-id pub-id-type="pmid">20303878</pub-id><pub-id pub-id-type="pmcid">PMC2866629</pub-id></element-citation><mixed-citation id="mc-CR215" publication-type="journal">Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883&#8211;99. 10.1016/j.cell.2010.01.025.<pub-id pub-id-type="pmid">20303878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2010.01.025</pub-id><pub-id pub-id-type="pmcid">PMC2866629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216.</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arvas</surname><given-names>A</given-names></name></person-group><article-title>Vaccination in patients with immunosuppression</article-title><source>T&#252;rk Pediatri Ar&#351;</source><year>2014</year><volume>49</volume><fpage>181</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.5152/tpa.2014.2206</pub-id><pub-id pub-id-type="pmid">26078660</pub-id><pub-id pub-id-type="pmcid">PMC4462293</pub-id></element-citation><mixed-citation id="mc-CR216" publication-type="journal">Arvas A. Vaccination in patients with immunosuppression. T&#252;rk Pediatri Ar&#351;. 2014;49:181&#8211;5. 10.5152/tpa.2014.2206.<pub-id pub-id-type="pmid">26078660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5152/tpa.2014.2206</pub-id><pub-id pub-id-type="pmcid">PMC4462293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217.</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoham</surname><given-names>S</given-names></name><name name-style="western"><surname>Batista</surname><given-names>C</given-names></name><name name-style="western"><surname>Ben Amor</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ergonul</surname><given-names>O</given-names></name><name name-style="western"><surname>Hassanain</surname><given-names>M</given-names></name><name name-style="western"><surname>Hotez</surname><given-names>P</given-names></name><etal/></person-group><article-title>Vaccines and therapeutics for immunocompromised patients with COVID-19</article-title><source>eClinicalMedicine</source><year>2023</year><volume>59</volume><fpage>101965</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.101965</pub-id><pub-id pub-id-type="pmid">37070102</pub-id><pub-id pub-id-type="pmcid">PMC10091856</pub-id></element-citation><mixed-citation id="mc-CR217" publication-type="journal">Shoham S, Batista C, Ben Amor Y, Ergonul O, Hassanain M, Hotez P, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. eClinicalMedicine. 2023;59:101965. 10.1016/j.eclinm.2023.101965.<pub-id pub-id-type="pmid">37070102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.101965</pub-id><pub-id pub-id-type="pmcid">PMC10091856</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218.</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>S</given-names></name></person-group><article-title>Antibody dependent enhancement: unavoidable problems in vaccine development. In: advances in Immunology</article-title><source>Elsevier</source><year>2021</year><volume>151</volume><fpage>99</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/bs.ai.2021.08.003</pub-id><pub-id pub-id-type="pmcid">PMC8438590</pub-id><pub-id pub-id-type="pmid">34656289</pub-id></element-citation><mixed-citation id="mc-CR218" publication-type="journal">Xu L, Ma Z, Li Y, Pang Z, Xiao S. Antibody dependent enhancement: unavoidable problems in vaccine development. In: advances in Immunology. Elsevier. 2021;151:99&#8211;133. 10.1016/bs.ai.2021.08.003.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.ai.2021.08.003</pub-id><pub-id pub-id-type="pmcid">PMC8438590</pub-id><pub-id pub-id-type="pmid">34656289</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219.</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyagawa</surname><given-names>F</given-names></name><name name-style="western"><surname>Asada</surname><given-names>H</given-names></name></person-group><article-title>Current perspective regarding the immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS)</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>2147</fpage><pub-id pub-id-type="doi">10.3390/ijms22042147</pub-id><pub-id pub-id-type="pmid">33670052</pub-id><pub-id pub-id-type="pmcid">PMC7927043</pub-id></element-citation><mixed-citation id="mc-CR219" publication-type="journal">Miyagawa F, Asada H. Current perspective regarding the immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS). Int J Mol Sci. 2021;22:2147. 10.3390/ijms22042147.<pub-id pub-id-type="pmid">33670052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22042147</pub-id><pub-id pub-id-type="pmcid">PMC7927043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220.</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Amico</surname><given-names>C</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>F</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>R</given-names></name><name name-style="western"><surname>Santos</surname><given-names>HA</given-names></name></person-group><article-title>Development of vaccine formulations: past, present, and future</article-title><source>Drug Deliv Transl Res</source><year>2021</year><volume>11</volume><fpage>353</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1007/s13346-021-00924-7</pub-id><pub-id pub-id-type="pmid">33598818</pub-id><pub-id pub-id-type="pmcid">PMC7889058</pub-id></element-citation><mixed-citation id="mc-CR220" publication-type="journal">D&#8217;Amico C, Fontana F, Cheng R, Santos HA. Development of vaccine formulations: past, present, and future. Drug Deliv Transl Res. 2021;11:353&#8211;72. 10.1007/s13346-021-00924-7.<pub-id pub-id-type="pmid">33598818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13346-021-00924-7</pub-id><pub-id pub-id-type="pmcid">PMC7889058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221.</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahrs</surname><given-names>C</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>N</given-names></name></person-group><article-title>Vaccine response in the immunocompromised patient with focus on cellular immunity</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><fpage>882</fpage><pub-id pub-id-type="doi">10.3390/vaccines10060882</pub-id><pub-id pub-id-type="pmid">35746489</pub-id><pub-id pub-id-type="pmcid">PMC9230619</pub-id></element-citation><mixed-citation id="mc-CR221" publication-type="journal">Bahrs C, Harrison N. Vaccine response in the immunocompromised patient with focus on cellular immunity. Vaccines. 2022;10:882. 10.3390/vaccines10060882.<pub-id pub-id-type="pmid">35746489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines10060882</pub-id><pub-id pub-id-type="pmcid">PMC9230619</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222.</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ksi&#261;&#380;ek</surname><given-names>R</given-names></name><name name-style="western"><surname>Kap&#322;an</surname><given-names>R</given-names></name><name name-style="western"><surname>Gdowska</surname><given-names>K</given-names></name><name name-style="western"><surname>&#321;ebkowski</surname><given-names>P</given-names></name></person-group><article-title>Vaccination schedule under conditions of limited vaccine production rate</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><fpage>116</fpage><pub-id pub-id-type="doi">10.3390/vaccines10010116</pub-id><pub-id pub-id-type="pmid">35062776</pub-id><pub-id pub-id-type="pmcid">PMC8781133</pub-id></element-citation><mixed-citation id="mc-CR222" publication-type="journal">Ksi&#261;&#380;ek R, Kap&#322;an R, Gdowska K, &#321;ebkowski P. Vaccination schedule under conditions of limited vaccine production rate. Vaccines. 2022;10:116. 10.3390/vaccines10010116.<pub-id pub-id-type="pmid">35062776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines10010116</pub-id><pub-id pub-id-type="pmcid">PMC8781133</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223.</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>C</given-names></name><name name-style="western"><surname>Denlinger</surname><given-names>N</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>Recent advances and challenges in cancer immunotherapy</article-title><source>Cancers</source><year>2022</year><volume>14</volume><fpage>3972</fpage><pub-id pub-id-type="doi">10.3390/cancers14163972</pub-id><pub-id pub-id-type="pmid">36010965</pub-id><pub-id pub-id-type="pmcid">PMC9406446</pub-id></element-citation><mixed-citation id="mc-CR223" publication-type="journal">Peterson C, Denlinger N, Yang Y. Recent advances and challenges in cancer immunotherapy. Cancers. 2022;14:3972. 10.3390/cancers14163972.<pub-id pub-id-type="pmid">36010965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14163972</pub-id><pub-id pub-id-type="pmcid">PMC9406446</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224.</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yap</surname><given-names>RXL</given-names></name><name name-style="western"><surname>Lai</surname><given-names>YW</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C</given-names></name><name name-style="western"><surname>Ng</surname><given-names>JJW</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Feng</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of immunomodulatory therapy on COVID-19 vaccine response in patients with autoimmune inflammatory rheumatic diseases</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><fpage>274</fpage><pub-id pub-id-type="doi">10.3390/vaccines12030274</pub-id><pub-id pub-id-type="pmid">38543908</pub-id><pub-id pub-id-type="pmcid">PMC10974321</pub-id></element-citation><mixed-citation id="mc-CR224" publication-type="journal">Yap RXL, Lai YW, Wei C, Ng JJW, Xu D, Feng S, et al. Impact of immunomodulatory therapy on COVID-19 vaccine response in patients with autoimmune inflammatory rheumatic diseases. Vaccines. 2024;12:274. 10.3390/vaccines12030274.<pub-id pub-id-type="pmid">38543908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines12030274</pub-id><pub-id pub-id-type="pmcid">PMC10974321</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225.</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Setlai</surname><given-names>BP</given-names></name><name name-style="western"><surname>Hull</surname><given-names>R</given-names></name><name name-style="western"><surname>Bida</surname><given-names>M</given-names></name><name name-style="western"><surname>Durandt</surname><given-names>C</given-names></name><name name-style="western"><surname>Mulaudzi</surname><given-names>TV</given-names></name><name name-style="western"><surname>Chatziioannou</surname><given-names>A</given-names></name><name name-style="western"><surname>Dlamini</surname><given-names>Z</given-names></name></person-group><article-title>Immunosuppressive signaling pathways as targeted cancer therapies</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><fpage>682</fpage><pub-id pub-id-type="doi">10.3390/biomedicines10030682</pub-id><pub-id pub-id-type="pmid">35327484</pub-id><pub-id pub-id-type="pmcid">PMC8945019</pub-id></element-citation><mixed-citation id="mc-CR225" publication-type="journal">Setlai BP, Hull R, Bida M, Durandt C, Mulaudzi TV, Chatziioannou A, Dlamini Z. Immunosuppressive signaling pathways as targeted cancer therapies. Biomedicines. 2022;10:682. 10.3390/biomedicines10030682.<pub-id pub-id-type="pmid">35327484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10030682</pub-id><pub-id pub-id-type="pmcid">PMC8945019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226.</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adam</surname><given-names>L</given-names></name><name name-style="western"><surname>Rosenbaum</surname><given-names>P</given-names></name><name name-style="western"><surname>Bonduelle</surname><given-names>O</given-names></name><name name-style="western"><surname>Combadi&#232;re</surname><given-names>B</given-names></name></person-group><article-title>Strategies for immunomonitoring after vaccination and during infection</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>365</fpage><pub-id pub-id-type="doi">10.3390/vaccines9040365</pub-id><pub-id pub-id-type="pmid">33918841</pub-id><pub-id pub-id-type="pmcid">PMC8070333</pub-id></element-citation><mixed-citation id="mc-CR226" publication-type="journal">Adam L, Rosenbaum P, Bonduelle O, Combadi&#232;re B. Strategies for immunomonitoring after vaccination and during infection. Vaccines. 2021;9:365. 10.3390/vaccines9040365.<pub-id pub-id-type="pmid">33918841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9040365</pub-id><pub-id pub-id-type="pmcid">PMC8070333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227.</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>R</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>E</given-names></name><name name-style="western"><surname>Wright</surname><given-names>M</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>J</given-names></name><name name-style="western"><surname>Oliphant</surname><given-names>C</given-names></name><name name-style="western"><surname>Cleveland</surname><given-names>K</given-names></name><name name-style="western"><surname>Nies</surname><given-names>MA</given-names></name></person-group><article-title>Factors contributing to vaccine hesitancy and reduced vaccine confidence in rural underserved populations</article-title><source>Humanit Soc Sci Commun</source><year>2022</year><volume>9</volume><fpage>416</fpage><pub-id pub-id-type="doi">10.1057/s41599-022-01439-3</pub-id><pub-id pub-id-type="pmid">36466708</pub-id><pub-id pub-id-type="pmcid">PMC9702767</pub-id></element-citation><mixed-citation id="mc-CR227" publication-type="journal">Robinson R, Nguyen E, Wright M, Holmes J, Oliphant C, Cleveland K, Nies MA. Factors contributing to vaccine hesitancy and reduced vaccine confidence in rural underserved populations. Humanit Soc Sci Commun. 2022;9:416. 10.1057/s41599-022-01439-3.<pub-id pub-id-type="pmid">36466708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1057/s41599-022-01439-3</pub-id><pub-id pub-id-type="pmcid">PMC9702767</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR228"><label>228.</label><citation-alternatives><element-citation id="ec-CR228" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Dubey</surname><given-names>V</given-names></name></person-group><article-title>Addressing vaccine hesitancy: Clinical guidance for primary care physicians working with parents</article-title><source>Can Fam Physician Med Fam Can</source><year>2019</year><volume>65</volume><fpage>175</fpage><lpage>181</lpage><pub-id pub-id-type="pmcid">PMC6515949</pub-id><pub-id pub-id-type="pmid">30867173</pub-id></element-citation><mixed-citation id="mc-CR228" publication-type="journal">Shen SC, Dubey V. Addressing vaccine hesitancy: Clinical guidance for primary care physicians working with parents. Can Fam Physician Med Fam Can. 2019;65:175&#8211;81.<pub-id pub-id-type="pmcid">PMC6515949</pub-id><pub-id pub-id-type="pmid">30867173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR229"><label>229.</label><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montuori</surname><given-names>P</given-names></name><name name-style="western"><surname>Gentile</surname><given-names>I</given-names></name><name name-style="western"><surname>Fiorilla</surname><given-names>C</given-names></name><name name-style="western"><surname>Sorrentino</surname><given-names>M</given-names></name><name name-style="western"><surname>Schiavone</surname><given-names>B</given-names></name><name name-style="western"><surname>Fattore</surname><given-names>V</given-names></name><etal/></person-group><article-title>Understanding factors contributing to vaccine hesitancy in a large metropolitan area</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>1558</fpage><pub-id pub-id-type="doi">10.3390/vaccines11101558</pub-id><pub-id pub-id-type="pmid">37896961</pub-id><pub-id pub-id-type="pmcid">PMC10610669</pub-id></element-citation><mixed-citation id="mc-CR229" publication-type="journal">Montuori P, Gentile I, Fiorilla C, Sorrentino M, Schiavone B, Fattore V, et al. Understanding factors contributing to vaccine hesitancy in a large metropolitan area. Vaccines. 2023;11:1558. 10.3390/vaccines11101558.<pub-id pub-id-type="pmid">37896961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11101558</pub-id><pub-id pub-id-type="pmcid">PMC10610669</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR230"><label>230.</label><citation-alternatives><element-citation id="ec-CR230" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nuwarda</surname><given-names>RF</given-names></name><name name-style="western"><surname>Ramzan</surname><given-names>I</given-names></name><name name-style="western"><surname>Weekes</surname><given-names>L</given-names></name><name name-style="western"><surname>Kayser</surname><given-names>V</given-names></name></person-group><article-title>Vaccine hesitancy: contemporary issues and historical background</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><fpage>1595</fpage><pub-id pub-id-type="doi">10.3390/vaccines10101595</pub-id><pub-id pub-id-type="pmid">36298459</pub-id><pub-id pub-id-type="pmcid">PMC9612044</pub-id></element-citation><mixed-citation id="mc-CR230" publication-type="journal">Nuwarda RF, Ramzan I, Weekes L, Kayser V. Vaccine hesitancy: contemporary issues and historical background. Vaccines. 2022;10:1595. 10.3390/vaccines10101595.<pub-id pub-id-type="pmid">36298459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines10101595</pub-id><pub-id pub-id-type="pmcid">PMC9612044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR231"><label>231.</label><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>NE</given-names></name></person-group><article-title>Vaccine hesitancy: definition, scope and determinants</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4161</fpage><lpage>4164</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.036</pub-id><pub-id pub-id-type="pmid">25896383</pub-id></element-citation><mixed-citation id="mc-CR231" publication-type="journal">MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33:4161&#8211;4. 10.1016/j.vaccine.2015.04.036.<pub-id pub-id-type="pmid">25896383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.04.036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR232"><label>232.</label><citation-alternatives><element-citation id="ec-CR232" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trivedi</surname><given-names>D</given-names></name></person-group><article-title>Cochrane review summary: face-to-face interventions for informing or educating parents about early childhood vaccination</article-title><source>Prim Health Care Res Dev</source><year>2014</year><volume>15</volume><fpage>339</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1017/S1463423614000322</pub-id><pub-id pub-id-type="pmid">25146256</pub-id></element-citation><mixed-citation id="mc-CR232" publication-type="journal">Trivedi D. Cochrane review summary: face-to-face interventions for informing or educating parents about early childhood vaccination. Prim Health Care Res Dev. 2014;15:339&#8211;41. 10.1017/S1463423614000322.<pub-id pub-id-type="pmid">25146256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1463423614000322</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR233"><label>233.</label><citation-alternatives><element-citation id="ec-CR233" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jalilian</surname><given-names>H</given-names></name><name name-style="western"><surname>Amraei</surname><given-names>M</given-names></name><name name-style="western"><surname>Javanshir</surname><given-names>E</given-names></name><name name-style="western"><surname>Jamebozorgi</surname><given-names>K</given-names></name><name name-style="western"><surname>Faraji-Khiavi</surname><given-names>F</given-names></name></person-group><article-title>Ethical considerations of the vaccine development process and vaccination: a scoping review</article-title><source>BMC Health Serv Res</source><year>2023</year><volume>23</volume><fpage>255</fpage><pub-id pub-id-type="doi">10.1186/s12913-023-09237-6</pub-id><pub-id pub-id-type="pmid">36918888</pub-id><pub-id pub-id-type="pmcid">PMC10013982</pub-id></element-citation><mixed-citation id="mc-CR233" publication-type="journal">Jalilian H, Amraei M, Javanshir E, Jamebozorgi K, Faraji-Khiavi F. Ethical considerations of the vaccine development process and vaccination: a scoping review. BMC Health Serv Res. 2023;23:255. 10.1186/s12913-023-09237-6.<pub-id pub-id-type="pmid">36918888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12913-023-09237-6</pub-id><pub-id pub-id-type="pmcid">PMC10013982</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR234"><label>234.</label><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>V</given-names></name><name name-style="western"><surname>Aranha</surname><given-names>V</given-names></name><name name-style="western"><surname>Rajgarhia</surname><given-names>R</given-names></name><name name-style="western"><surname>Royal</surname><given-names>A</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>K</given-names></name></person-group><article-title>Expanded principles of ethics and its implementation during COVID-19 vaccine trials: a scoping evidence based research synthesis</article-title><source>Hum Vaccines Immunother</source><year>2021</year><volume>17</volume><fpage>3843</fpage><lpage>3849</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.1947101</pub-id><pub-id pub-id-type="pmcid">PMC8827634</pub-id><pub-id pub-id-type="pmid">34264174</pub-id></element-citation><mixed-citation id="mc-CR234" publication-type="journal">Kumar V, Aranha V, Rajgarhia R, Royal A, Mehta K. Expanded principles of ethics and its implementation during COVID-19 vaccine trials: a scoping evidence based research synthesis. Hum Vaccines Immunother. 2021;17:3843&#8211;9. 10.1080/21645515.2021.1947101.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2021.1947101</pub-id><pub-id pub-id-type="pmcid">PMC8827634</pub-id><pub-id pub-id-type="pmid">34264174</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR235"><label>235.</label><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borowicz</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Day</surname><given-names>G</given-names></name><name name-style="western"><surname>Pinto da Costa</surname><given-names>M</given-names></name></person-group><article-title>Vaccine equity in COVID-19: a meta-narrative review</article-title><source>BMJ Glob Health</source><year>2022</year><volume>7</volume><fpage>e009876</fpage><pub-id pub-id-type="doi">10.1136/bmjgh-2022-009876</pub-id><pub-id pub-id-type="pmid">36524409</pub-id><pub-id pub-id-type="pmcid">PMC9748514</pub-id></element-citation><mixed-citation id="mc-CR235" publication-type="journal">Borowicz J, Zhang Z, Day G, Pinto da Costa M. Vaccine equity in COVID-19: a meta-narrative review. BMJ Glob Health. 2022;7:e009876. 10.1136/bmjgh-2022-009876.<pub-id pub-id-type="pmid">36524409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjgh-2022-009876</pub-id><pub-id pub-id-type="pmcid">PMC9748514</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR236"><label>236.</label><citation-alternatives><element-citation id="ec-CR236" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adejumo</surname><given-names>OA</given-names></name><name name-style="western"><surname>Adejumo</surname><given-names>OA</given-names></name></person-group><article-title>Recalling the universal health coverage vision and equity in the COVID-19 vaccine distribution plan</article-title><source>Pan Afr Med J</source><year>2021</year><volume>39</volume><fpage>197</fpage><pub-id pub-id-type="doi">10.11604/pamj.2021.39.197.29041</pub-id><pub-id pub-id-type="pmid">34603578</pub-id><pub-id pub-id-type="pmcid">PMC8464202</pub-id></element-citation><mixed-citation id="mc-CR236" publication-type="journal">Adejumo OA, Adejumo OA. Recalling the universal health coverage vision and equity in the COVID-19 vaccine distribution plan. Pan Afr Med J. 2021;39:197. 10.11604/pamj.2021.39.197.29041.<pub-id pub-id-type="pmid">34603578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.11604/pamj.2021.39.197.29041</pub-id><pub-id pub-id-type="pmcid">PMC8464202</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR237"><label>237.</label><citation-alternatives><element-citation id="ec-CR237" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greco</surname><given-names>DB</given-names></name></person-group><article-title>Ethical limits to placebo use and access to Covid-19 vaccines as a human right</article-title><source>Indian J Med Ethics</source><year>2021</year><volume>VI</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.20529/IJME.2021.027</pub-id><pub-id pub-id-type="pmid">33908350</pub-id></element-citation><mixed-citation id="mc-CR237" publication-type="journal">Greco DB. Ethical limits to placebo use and access to Covid-19 vaccines as a human right. Indian J Med Ethics. 2021;VI:1&#8211;14. 10.20529/IJME.2021.027.<pub-id pub-id-type="pmid">33908350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20529/IJME.2021.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR238"><label>238.</label><citation-alternatives><element-citation id="ec-CR238" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alqahtani</surname><given-names>M</given-names></name><name name-style="western"><surname>Mallah</surname><given-names>SI</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>N</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>S</given-names></name></person-group><article-title>Vaccine trials during a pandemic: potential approaches to ethical dilemmas</article-title><source>Trials</source><year>2021</year><volume>22</volume><fpage>628</fpage><pub-id pub-id-type="doi">10.1186/s13063-021-05597-8</pub-id><pub-id pub-id-type="pmid">34526086</pub-id><pub-id pub-id-type="pmcid">PMC8443109</pub-id></element-citation><mixed-citation id="mc-CR238" publication-type="journal">Alqahtani M, Mallah SI, Stevenson N, Doherty S. Vaccine trials during a pandemic: potential approaches to ethical dilemmas. Trials. 2021;22:628. 10.1186/s13063-021-05597-8.<pub-id pub-id-type="pmid">34526086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13063-021-05597-8</pub-id><pub-id pub-id-type="pmcid">PMC8443109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR239"><label>239.</label><citation-alternatives><element-citation id="ec-CR239" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wibawa</surname><given-names>T</given-names></name></person-group><article-title>COVID-19 vaccine research and development: ethical issues</article-title><source>Trop Med Int Health</source><year>2021</year><volume>26</volume><fpage>14</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1111/tmi.13503</pub-id><pub-id pub-id-type="pmid">33012020</pub-id><pub-id pub-id-type="pmcid">PMC7675299</pub-id></element-citation><mixed-citation id="mc-CR239" publication-type="journal">Wibawa T. COVID-19 vaccine research and development: ethical issues. Trop Med Int Health. 2021;26:14&#8211;9. 10.1111/tmi.13503.<pub-id pub-id-type="pmid">33012020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/tmi.13503</pub-id><pub-id pub-id-type="pmcid">PMC7675299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR240"><label>240.</label><citation-alternatives><element-citation id="ec-CR240" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Pardeshi</surname><given-names>G</given-names></name></person-group><article-title>COVID-19 vaccination in India: an ethical perspective</article-title><source>Diabetes Metab Syndr Clin Res Rev</source><year>2021</year><volume>15</volume><fpage>102314</fpage><pub-id pub-id-type="doi">10.1016/j.dsx.2021.102314</pub-id><pub-id pub-id-type="pmcid">PMC8516656</pub-id><pub-id pub-id-type="pmid">34678577</pub-id></element-citation><mixed-citation id="mc-CR240" publication-type="journal">Sharma P, Pardeshi G. COVID-19 vaccination in India: an ethical perspective. Diabetes Metab Syndr Clin Res Rev. 2021;15:102314. 10.1016/j.dsx.2021.102314.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dsx.2021.102314</pub-id><pub-id pub-id-type="pmcid">PMC8516656</pub-id><pub-id pub-id-type="pmid">34678577</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR241"><label>241.</label><citation-alternatives><element-citation id="ec-CR241" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giubilini</surname><given-names>A</given-names></name></person-group><article-title>Vaccination ethics</article-title><source>Br Med Bull</source><year>2021</year><volume>137</volume><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1093/bmb/ldaa036</pub-id><pub-id pub-id-type="pmid">33367873</pub-id><pub-id pub-id-type="pmcid">PMC7799313</pub-id></element-citation><mixed-citation id="mc-CR241" publication-type="journal">Giubilini A. Vaccination ethics. Br Med Bull. 2021;137:4&#8211;12. 10.1093/bmb/ldaa036.<pub-id pub-id-type="pmid">33367873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bmb/ldaa036</pub-id><pub-id pub-id-type="pmcid">PMC7799313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR242"><label>242.</label><citation-alternatives><element-citation id="ec-CR242" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McClung</surname><given-names>N</given-names></name><name name-style="western"><surname>Chamberland</surname><given-names>M</given-names></name><name name-style="western"><surname>Kinlaw</surname><given-names>K</given-names></name><name name-style="western"><surname>Bowen Matthew</surname><given-names>D</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M</given-names></name><name name-style="western"><surname>Bell</surname><given-names>BP</given-names></name><etal/></person-group><article-title>The advisory committee on immunization practices&#8217; ethical principles for allocating initial supplies of COVID-19 vaccine - United States, 2020</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2020</year><volume>69</volume><fpage>1782</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6947e3</pub-id><pub-id pub-id-type="pmid">33237895</pub-id><pub-id pub-id-type="pmcid">PMC7727606</pub-id></element-citation><mixed-citation id="mc-CR242" publication-type="journal">McClung N, Chamberland M, Kinlaw K, Bowen Matthew D, Wallace M, Bell BP, et al. The advisory committee on immunization practices&#8217; ethical principles for allocating initial supplies of COVID-19 vaccine - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1782&#8211;6. 10.15585/mmwr.mm6947e3.<pub-id pub-id-type="pmid">33237895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6947e3</pub-id><pub-id pub-id-type="pmcid">PMC7727606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR243"><label>243.</label><mixed-citation publication-type="other">The UNESCO Universal Declaration on Bioethics and Human Rights: Perspectives from Kenya and South Africa - PMC. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2226192/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2226192/</ext-link>. Accessed 12 Sept 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10728-007-0055-7</pub-id><pub-id pub-id-type="pmcid">PMC2226192</pub-id><pub-id pub-id-type="pmid">18240025</pub-id></mixed-citation></ref><ref id="CR244"><label>244.</label><citation-alternatives><element-citation id="ec-CR244" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carson</surname><given-names>SL</given-names></name><name name-style="western"><surname>Casillas</surname><given-names>A</given-names></name><name name-style="western"><surname>Castellon-Lopez</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mansfield</surname><given-names>LN</given-names></name><name name-style="western"><surname>Morris</surname><given-names>D</given-names></name><name name-style="western"><surname>Barron</surname><given-names>J</given-names></name><etal/></person-group><article-title>COVID-19 vaccine decision-making factors in racial and ethnic minority communities in Los Angeles</article-title><source>California JAMA Netw Open</source><year>2021</year><volume>4</volume><fpage>e2127582</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.27582</pub-id><pub-id pub-id-type="pmid">34591103</pub-id><pub-id pub-id-type="pmcid">PMC8485164</pub-id></element-citation><mixed-citation id="mc-CR244" publication-type="journal">Carson SL, Casillas A, Castellon-Lopez Y, Mansfield LN, Morris D, Barron J, et al. COVID-19 vaccine decision-making factors in racial and ethnic minority communities in Los Angeles. California JAMA Netw Open. 2021;4:e2127582. 10.1001/jamanetworkopen.2021.27582.<pub-id pub-id-type="pmid">34591103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.27582</pub-id><pub-id pub-id-type="pmcid">PMC8485164</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR245"><label>245.</label><citation-alternatives><element-citation id="ec-CR245" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin-Fumad&#243;</surname><given-names>C</given-names></name><name name-style="western"><surname>Aragon&#232;s</surname><given-names>L</given-names></name><name name-style="western"><surname>Esquerda Areste</surname><given-names>M</given-names></name><name name-style="western"><surname>Arimany-Manso</surname><given-names>J</given-names></name></person-group><article-title>Medico-legal, ethical and deontological considerations of vaccination against COVID-19 in healthcare professionals</article-title><source>Med Clin Engl Ed</source><year>2021</year><volume>157</volume><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.medcle.2021.04.004</pub-id><pub-id pub-id-type="pmid">34151023</pub-id><pub-id pub-id-type="pmcid">PMC8196330</pub-id></element-citation><mixed-citation id="mc-CR245" publication-type="journal">Martin-Fumad&#243; C, Aragon&#232;s L, Esquerda Areste M, Arimany-Manso J. Medico-legal, ethical and deontological considerations of vaccination against COVID-19 in healthcare professionals. Med Clin Engl Ed. 2021;157:79&#8211;84. 10.1016/j.medcle.2021.04.004.<pub-id pub-id-type="pmid">34151023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.medcle.2021.04.004</pub-id><pub-id pub-id-type="pmcid">PMC8196330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR246"><label>246.</label><citation-alternatives><element-citation id="ec-CR246" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weerarathna</surname><given-names>IN</given-names></name><name name-style="western"><surname>Luharia</surname><given-names>A</given-names></name><name name-style="western"><surname>Tivaskar</surname><given-names>S</given-names></name><name name-style="western"><surname>Nankong</surname><given-names>FA</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>D</given-names></name></person-group><article-title>Emerging applications of biomedical science in pandemic prevention and control: a review</article-title><source>Cureus</source><year>2023</year><volume>15</volume><fpage>e44075</fpage><pub-id pub-id-type="doi">10.7759/cureus.44075</pub-id><pub-id pub-id-type="pmid">37750154</pub-id><pub-id pub-id-type="pmcid">PMC10518042</pub-id></element-citation><mixed-citation id="mc-CR246" publication-type="journal">Weerarathna IN, Luharia A, Tivaskar S, Nankong FA, Raymond D. Emerging applications of biomedical science in pandemic prevention and control: a review. Cureus. 2023;15:e44075. 10.7759/cureus.44075.<pub-id pub-id-type="pmid">37750154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.44075</pub-id><pub-id pub-id-type="pmcid">PMC10518042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR247"><label>247.</label><citation-alternatives><element-citation id="ec-CR247" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsheikh</surname><given-names>R</given-names></name><name name-style="western"><surname>Makram</surname><given-names>AM</given-names></name><name name-style="western"><surname>Huy</surname><given-names>NT</given-names></name></person-group><article-title>Therapeutic cancer vaccines and their future implications</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>660</fpage><pub-id pub-id-type="doi">10.3390/vaccines11030660</pub-id><pub-id pub-id-type="pmid">36992245</pub-id><pub-id pub-id-type="pmcid">PMC10052542</pub-id></element-citation><mixed-citation id="mc-CR247" publication-type="journal">Elsheikh R, Makram AM, Huy NT. Therapeutic cancer vaccines and their future implications. Vaccines. 2023;11:660. 10.3390/vaccines11030660.<pub-id pub-id-type="pmid">36992245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11030660</pub-id><pub-id pub-id-type="pmcid">PMC10052542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR248"><label>248.</label><citation-alternatives><element-citation id="ec-CR248" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Qian</surname><given-names>C</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N</given-names></name></person-group><article-title>Current progress in the development of prophylactic and therapeutic vaccines</article-title><source>Sci China Life Sci</source><year>2023</year><volume>66</volume><fpage>679</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1007/s11427-022-2230-4</pub-id><pub-id pub-id-type="pmid">36469218</pub-id><pub-id pub-id-type="pmcid">PMC9734355</pub-id></element-citation><mixed-citation id="mc-CR248" publication-type="journal">Li T, Qian C, Gu Y, Zhang J, Li S, Xia N. Current progress in the development of prophylactic and therapeutic vaccines. Sci China Life Sci. 2023;66:679&#8211;710. 10.1007/s11427-022-2230-4.<pub-id pub-id-type="pmid">36469218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11427-022-2230-4</pub-id><pub-id pub-id-type="pmcid">PMC9734355</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR249"><label>249.</label><citation-alternatives><element-citation id="ec-CR249" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zieneldien</surname><given-names>T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>C</given-names></name></person-group><article-title>COVID-19 vaccines: current conditions and future prospects</article-title><source>Biology</source><year>2021</year><volume>10</volume><fpage>960</fpage><pub-id pub-id-type="doi">10.3390/biology10100960</pub-id><pub-id pub-id-type="pmid">34681059</pub-id><pub-id pub-id-type="pmcid">PMC8533517</pub-id></element-citation><mixed-citation id="mc-CR249" publication-type="journal">Zieneldien T, Kim J, Cao J, Cao C. COVID-19 vaccines: current conditions and future prospects. Biology. 2021;10:960. 10.3390/biology10100960.<pub-id pub-id-type="pmid">34681059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biology10100960</pub-id><pub-id pub-id-type="pmcid">PMC8533517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR250"><label>250.</label><citation-alternatives><element-citation id="ec-CR250" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>SA</given-names></name></person-group><article-title>Vaccines: past, present and future</article-title><source>Nat Med</source><year>2005</year><volume>11</volume><issue>4 Suppl</issue><fpage>S5</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/nm1209</pub-id><pub-id pub-id-type="pmid">15812490</pub-id><pub-id pub-id-type="pmcid">PMC7095920</pub-id></element-citation><mixed-citation id="mc-CR250" publication-type="journal">Plotkin SA. Vaccines: past, present and future. Nat Med. 2005;11(4 Suppl):S5&#8211;11. 10.1038/nm1209.<pub-id pub-id-type="pmid">15812490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1209</pub-id><pub-id pub-id-type="pmcid">PMC7095920</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR251"><label>251.</label><citation-alternatives><element-citation id="ec-CR251" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Moamly</surname><given-names>AA</given-names></name><name name-style="western"><surname>El-Sweify</surname><given-names>MA</given-names></name></person-group><article-title>Malaria vaccines: the 60-year journey of hope and final success&#8212;lessons learned and future prospects</article-title><source>Trop Med Health</source><year>2023</year><volume>51</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s41182-023-00516-w</pub-id><pub-id pub-id-type="pmid">37198702</pub-id><pub-id pub-id-type="pmcid">PMC10189698</pub-id></element-citation><mixed-citation id="mc-CR251" publication-type="journal">El-Moamly AA, El-Sweify MA. Malaria vaccines: the 60-year journey of hope and final success&#8212;lessons learned and future prospects. Trop Med Health. 2023;51:29. 10.1186/s41182-023-00516-w.<pub-id pub-id-type="pmid">37198702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41182-023-00516-w</pub-id><pub-id pub-id-type="pmcid">PMC10189698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR252"><label>252.</label><citation-alternatives><element-citation id="ec-CR252" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reuschenbach</surname><given-names>M</given-names></name><name name-style="western"><surname>Doorbar</surname><given-names>J</given-names></name><name name-style="western"><surname>Del Pino</surname><given-names>M</given-names></name><name name-style="western"><surname>Joura</surname><given-names>EA</given-names></name><name name-style="western"><surname>Walker</surname><given-names>C</given-names></name><name name-style="western"><surname>Drury</surname><given-names>R</given-names></name><etal/></person-group><article-title>Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>6194</fpage><lpage>6205</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.08.047</pub-id><pub-id pub-id-type="pmid">37704498</pub-id></element-citation><mixed-citation id="mc-CR252" publication-type="journal">Reuschenbach M, Doorbar J, Del Pino M, Joura EA, Walker C, Drury R, et al. Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer. Vaccine. 2023;41:6194&#8211;205. 10.1016/j.vaccine.2023.08.047.<pub-id pub-id-type="pmid">37704498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2023.08.047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR253"><label>253.</label><citation-alternatives><element-citation id="ec-CR253" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weerarathna</surname><given-names>IN</given-names></name><name name-style="western"><surname>Kamble</surname><given-names>AR</given-names></name><name name-style="western"><surname>Luharia</surname><given-names>A</given-names></name></person-group><article-title>Artificial intelligence applications for biomedical cancer research: a review</article-title><source>Cureus</source><year>2023</year><volume>15</volume><fpage>e48307</fpage><pub-id pub-id-type="doi">10.7759/cureus.48307</pub-id><pub-id pub-id-type="pmid">38058345</pub-id><pub-id pub-id-type="pmcid">PMC10697339</pub-id></element-citation><mixed-citation id="mc-CR253" publication-type="journal">Weerarathna IN, Kamble AR, Luharia A. Artificial intelligence applications for biomedical cancer research: a review. Cureus. 2023;15:e48307. 10.7759/cureus.48307.<pub-id pub-id-type="pmid">38058345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.48307</pub-id><pub-id pub-id-type="pmcid">PMC10697339</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>